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Abstract
The protein signaling activities of the glycerolipid diacylglycerol (DAG) form the impetus for
the projects described herein. DAG’s governance of cellular functions involves activation of
peripheral membrane proteins (PMPs) at bilayer surfaces, which includes the activation of protein
kinase C (PKC) to regulate oncogenesis. In addition to enzymatic signal transduction, DAG
influences membrane mechanics and is a central lipid metabolite. Relatively little is known about
DAG when compared to more common signaling lipids such as phosphatidylinositol
polyphosphates (PIPns). This is due in part to the surreptitious nature of PMP operation and the
complexity of natural bilayers. We developed a liposomal platform to identify PMP binding as a
function of specific lipids. Synthetic, photocrosslinking lipids with clickable tags are incorporated
into liposomes to capture and enrich proteins. Affinity-based protein profiling (AfBPP)
experiments initially demonstrated proteome-wide increases in affinity when using DAG or
phosphatidic acid (PA) as chase lipids. With the aid of collaborators at The Scripps Research
Institute (TSRI), we optimized our AfBPP protocol to label select proteins as a function of
liposomal DAG content when a generic lipid probe was also present in the membrane. The generic
probe strategy varies natural lipid content with consistent probe concentration between liposomal
treatments, this is called the lipomimetic approach. Lipid specific probes have also been applied to
liposomal AfBPP, which is termed the lipospecific approach.
In a separate project, we tested to see if DAG could potentiate the cell-association of a liposomal
delivery system (LDS). LDSs are a rapidly expanding field; most existing nanodrugs are
liposomal. Strategies for increasing LDS efficacies often undermine clinical translatability.
Incorporating natural signaling lipids into nanodrugs architectures is a clinically viable targeting
strategy. A polyethylene glycol (PEG) decorated (PEGylated) liposome bearing a cell penetrating
peptide (CPP) was doped with DAG and/or PS and significant, dose-dependent increases in
association to target cells were observed. We also advanced LDSs with new technologies for
controlling vesicle release and fusion. Liposomes have limitless utility as theranostic tools and
platforms for biochemical investigations. Herein, we bring liposomal technologies closer to their
scientific and clinical potentials.
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PREAMBLE
Utility often precedes elucidation. Antibiotics, gunpowder, willow bark and countless more
natural phenomena were harnessed by humanity before we unraveled the mechanisms of their
actions. Upon discovering biochemical relationships, we may seek to explicate or exploit.
Explication is crucial and often leads to further discovery. Exploitation of biological phenomena
can happen at any point and should not wait for explanations to be defined. Prescient minds see
opportunity in the inexplicable; Cézanne, Whitman and Escoffier emboldened their work by
intuiting yet-to-be-discovered laws of vision, cognition and sense.1 These three seminal examples
are mirrored by modern-day scientists that exploit molecular proclivities to enable new
technologies before said proclivities are defined fully.
Regarding lipid second messengers, much is known but little is fully understood. They are
critical, ubiquitous cellular operators with unassailable abilities to modulate supramolecular
membrane activities. Lipid mechanics and signal transduction can be difficult to characterize in
their natural setting and are under-utilized in applied sciences such as medicine. Here, liposomes
were employed as a biomimetic medium to study protein-membrane binding interactions and
identify novel DAG binding proteins. Prior to achieving our goal, we applied experimental
observations to harness DAG’s import and increase the efficacy of a new liposomal nanodrug.
Eventually, we created a selective and repeatable liposomal platform for labeling proteins in the
presence of DAG. We are now working to discover new potential drug targets for a litany of
diseases including cancer. Although our understanding of DAG is far from complete, it may be
harnessed for immediate increases in the efficacy of liposomal delivery systems (LDSs).
Increasing LDS efficacies and studying protein-recruitment by lipid secondary messengers are
the two focal points of this dissertation. We will begin with the latter, introducing relevant
background in Chapter 1 and describing our novel liposomal chemical biology platforms in
Chapter 2. The discussion shifts towards liposomal localization in Chapter 3 with a simple, natural
solution to the targeting of liposomal delivery systems using DAG and PS. Chapter 4 presents
more complex strategies to achieve the controlled release of liposomal cargo. The work described
in the later chapters was aided by the literature review and experimental observations that precede
them.
1

CHAPTER 1: INTRODUCTION
1.1 Glycerolipids
Lipids are comprised of a diverse group of biological molecules with an array of cellular
functions. There are thousands of different lipids2-3 including mono-/di-/triglycerides, sterols,
hydrophobic vitamins and other fat-soluble biological molecules. Lipid functions may be as
fundamental as energy storage or as complex as governing cell signal transduction and function.
Glycerophospholipids, or ‘phospholipids,’ are the most abundant phosphatides in organisms and
the most recognizable group of lipids. Herein, the focus will be on the amphiphilic glycerolipid
diacylglycerol (DAG) which is the non-phosphorylated version of any of the six groups of
phospholipids: phosphatidylglycerol (PG), phosphatidylserine (PS), phosphatidic acid (PA),
phosphatidylethanolamine (PE), phosphatidylcholine (PC) and sphingomyelin (SM).4

Form and function of glycero(phospho)lipids
Lipids, namely glycerolipids and phospholipids but also cholesterol and other amphiphilic
signaling molecules such as glycolipids and hormones, gain much of their utility from their shape.
Within each of the groups of glycerophospholipids in Figure 1.1, different species are determined
by the length and saturation of hydrocarbon tails which impacts the geometry of that lipid. Unless
otherwise noted, “lipids” will henceforth be referring to one of these groups in Figure 1.1. In the
case of phospholipids, their geometry is categorized by the cone angle dictated by the relative sizes

Figure 1.1: Seven common lipids with their chemical structures. Hydrocarbon tails vary in
nature in terms of length and saturation and are represented here by truncated squiggly lines.
2

of headgroups to lipid tails. Cone angle dictates the type of self-assembly the lipid undergoes.5
Figure 1.2 on the following page presents some common lipids in this geometric context
alongside different supramolecular assemblies that are formed depending on the structure of the
lipid. In this way, form determines function as illustrated by preferred shapes of self-assembly.
PC, for example, assembles into stable bilayers and is the most abundant mammalian lipid;
eukaryotic cell membranes contain greater than 50% PC.6
Self-assembly results from the shared hydrophobicity of the tails gathering in a manner that
leaves only the hydrophilic headgroup exposed to the aqueous media. Hydrogen bonding between
polar headgroups and aqueous media outside and within the vesicles adds stability. Shared
hydrophobicity brings the lipid tails together and van der Walls forces add rigidity to the lipid
architecture.
Phospholipids and DAG have a glycerol backbone with acyl tails on the sn-1 and sn-2 carbons
(see Figure 1.2)7 that may vary in saturation and length depending on the fatty acids that are
incorporated during lipid biosynthesis. If one of these acyl tails is missing, the lipid is in its ‘lyso’
form. The headgroup is found on the sn-3 carbon. Three-dimensional illustration of liposomes,
micelles and cellular bilayers are shown in Figure 1.38.
Based on supramolecular assembly properties, lipids are commonly classified as either bilayer
or nonbilayer lipids. Bilayer lipids such as PC possess the appropriate geometry for residing within
the curvature of bilayer membranes such as those found in cellular membranes and liposomes.
Nonbilayer lipids comprise two groups: type 1 nonbilayer lipids include lyso lipids that induce
positive (outward) stress on the membrane curvature, while type 2 nonbilayer lipids include DAG
and PE, which have larger cone angles due to smaller headgroups, induce negative (inward) stress
to phospholipid bilayers.
PE has a shape more like PC and can occupy up to 70% of membranes while DAG is missing the
phosphate modality entirely and the relatively tiny hydroxyl head group gives it very strong
nonbilayer properties. Thus, DAG occupies only 1-2% of healthy membranes but can be found at
concentrations as high as 10% in diseased cells such as cancer.9 This is likely related to the rapid
division of cancerous cells as well as the aberrant expression of DAG-binding proteins involved
in oncogenesis.
3

Figure 1.2: Phospholipid cone angles and self-assembled structures. PC is shown with
glycerol carbons labeled for reference. PE is an example of a type 2 nonbilayer lipid, like DAG,
due to a smaller headgroup. LPC is a type 1 nonbilayer lipid.7

4

Figure 1.3: Self-assembled structures of phospholipids in aqueous media. Image is public
domain, credit: Mariana Ruiz8

DAG, a focal point of this dissertation, will continue to serve as our exemplar lipid. Much of
DAG’s renown is for being the precursor for other phospholipids.10 Lipid synthesis, or
topogenesis, has been studied extensively and DAG is key for phospholipid production via the
Kennedy pathway.11 In regard to signal transduction, there is rapidly accumulating evidence for
lipid governance of pathological cellular states.6, 12-15 Still, DAG and many other lipids warrant
more investigation than they currently receive. Studying lipid second messengers such as DAG
may eventually help answer important questions regarding tissue-specific lipid dysregulation,
something that is studied indirectly by the work presented in Chapter 3 that explores the potential
of signaling lipids to modulate liposomal delivery systems (LDSs).
In addition to variable lipidomes, cells are also distinguished by the proteins they express to
achieve their unique functions. It would be an oversimplification to assert that varying abundances
of associated signaling lipids are always the product of protein expression. However, it is also
presumptuous to assume that lipids are the driving force behind protein presentation. For example,
certain proteins exist to biologically engineer DAG (synthases), others exist to metabolize it
(kinases), while others yet are activated by it to regulate cellular function. Many of these proteins
5

operate in coordination, with abundances that may be directly or indirectly correlated to one
another and their lipid activators. Lipid signaling operations are therefore too diverse and dynamic
to qualify broadly and must be identified individually. As this chapter progresses, it will become
clear that more research is needed to understand DAG’s role in the onset and progression of
cancer,16 Alzheimer’s and dementia (AD),17 hypertension18 and other diseases.
As stated, the dysregulation of DAG is a combinatorial consequence of it being an intermediary
in the synthesis of other upregulated lipids, a signaling lipid in oncosuppressive or oncogenic
cascades, and its strong nonbilayer properties due to a cone angle that may help promote fission in
rapidly dividing cells and extravesicular cellular communications.19-22 It is impossible to separate
the metabolic and cell-signaling significance of lipids from their geometries as the two are closely
intertwined, thus illustrating the complexities inherent to experimentation geared at studying
species such as DAG.
DAG can be incorporated into stable liposomes at least as high as 25% when the other 75% is
composed of a 4:1 ratios of PC:PS.23 At high percentages such as this, however, DAG can induce
liquid-disordered (Ld) nonbilayer membrane perturbations in the presence of calcium (Ca2+)
cations. Interestingly, increasing DAG and Ca2+ concentrations also potentiates the activity of
certain PKC enzymes (in the presence of PS), but only up to 2.5 mM Ca2+, after which the cation
has a deleterious effect on enzyme activity. In the case of PKC, Ca2+ sensitivity hinges upon a
specific C2 binding domain and this is discussed in the upcoming section on the PKC C 1 binding
domain.
The fatty acid composition of the acyl tails at the sn-2 or sn-3 positions of lipid species has an
impact on membrane partitioning and cone angle, can vary in any of the glycerolipids, and is of
importance when determining a lipid’s bilayer properties. Commonly observed tails include oleic
acid and palmitoleic acid, which are 18 and 16 carbons long respectively and are unsaturated
meaning they each have at least one double bond. This is denoted using C:D nomenclature where
C is number of carbons and D is the number of double bounds. To reference the position of the
double bond one would use ‘n-x’ notation where x is the number of carbons from the chain’s
terminal methyl group at which the first double bond is found. The ‘n’ is often exchanged for
‘omega’ in nutritional literature when discussing fatty acids.
When there is more than one double bond, the location of each double bond is given as Δx where
6

x is the first carbon of each alkene using traditional numbering, which counts from the carbonyl
carbon. Arachidonic acid in Figure 1.4 would be notated as follows, (20:4 (n-6) cis, cis, cis, cis,
Δ5, Δ8, Δ11, Δ13). All the fatty acids mentioned thus far are cis, which is the predominant natural
orientation for fatty acid double bonds. The trans versions have different trivial names, for
example oleic acid becomes elaidic acid when the configuration of the double bond is instead
trans.
Not surprisingly, fatty acids are incorporated into lipid structures at varying concentrations in
correlation with cellular dysfunction. An analysis of total phospholipid content of the arterial
tissues of heart attack victims showed significant increases in palmitic acid (16:0) and linoleic acid
(18:2 (n-6)) with significant decreases of arachidonic acid (20:4 (n-6)) and all other major
polyunsaturated fatty acids of n-3 and n-6.24 DAG is no exception and among the 50+ types of
diglycerides25 found in biology there is evidence that the fatty acids composing their acyl tails are
crucial to determining signaling activity,26 including PKC activation.27

Figure 1.4: Four common fatty acids with their trivial names: palmitic acid, oleic acid,
arachidonic acid and palmitoleic acid.
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The causes and/or consequences of aberrant lipid expression of course vary with the type of
cell, more precisely with the state of the cell, and even more precisely with each specific protein
effector. Proteins justifiably remain the focal points of studies regarding cellular pathologies as
well as biomedical endeavors to selectively target diseased tissues. Our entry point into exploring
cellular function is lipid-centric, but discovering novel DAG-binding proteins is still the goal of
the experimentation introduced in Chapter 2. As background for said experimentation, we will
introduce membrane proteins and then overview of glycerophospholipid-PMP cell signaling
relationships with a focus on DAG and the closely related lipids PA, PS and SM.

Membrane proteins
Each living membrane contains a proteome unique cellular function, tissue type, and state. The
most abundant class of proteins are the membrane proteins, which have diverse sizes, shapes and
functions.28 Integral, or ‘intrinsic’, membrane proteins are deeply embedded into or through the
membrane bilayer. Integral proteins that do not span from the outer to inner leaflet of the bilayer
are less common and usually have lipophilic side chains to anchor them in the phospholipid bilayer,
while their hydrophilic peptides remain exposed. Some integral proteins have fatty acid
appendages to serve as their anchors. Most integral proteins span from the outer to inner leaflet of
the bilayer and are referred to as transmembrane proteins. The integrated portions of
transmembrane proteins are composed of α-helices or ß-strands. Peripheral membrane proteins
(PMP)—or extrinsic proteins—do not interact directly with the hydrophobic region of the bilayer,
and exhibit disparate means of membrane association.

Peripheral membrane proteins
PMPs operate transiently and reversibly. Their movement and docking can rely on any
combination of electrostatics,29 specific interactions with hydrophilic lipid headgroups,12
indirect/nonspecific lipophilic interactions,30 and protein-protein interactions (PPIs).31 PPIs are
typically between extrinsic and intrinsic proteins. PMP binding to a specific array of signaling
lipids is represented in the schematic cartoon in Figure 1.5. When PMPs bind the bilayers in this
manner it is accompanied by a change in their conformation and modulates protein function. Such
reversible protein activations can be described as amphitropic regulation.32
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Figure 1.5: A cartoon schematic of a liquid ordered (Lo) nanodomain accommodating a
PMP at the hydrophilic face of a bilayer membrane. Signaling lipids encourage membrane
perturbation and recruit peripheral proteins. The pink lipids represent DAG or lyso-DAG and
the yellow structures are cholesterol molecules. The blue/green shape represents a water-soluble
protein with affinity for DAG and PS, such as a phorbol ester binding protein like PKC.

Amphitropic enzymes include protein kinase C (PKC) and other proteins reviewed later for
their relevance to DAG. Some PMPs, such as extracellular matrix proteins, are located on the
exoplasmic outer leaflet. DAG works with extracellular PMPs to shuttle signaling molecules and
vesicles to enable in neuronal and immune cascades.20, 33-34 DAG is also involved in endosomal
activity within the cytosol, and it is crucial to transport at the Golgi apparatus.22 Other PMPs, such
as PKC and other signal transduction enzymes, operate internally and are thus localized at the
cytosolic leaflet. PMPs have function beyond cell signaling; cytoskeletal PMPs, for example, are
important structural components of erythrocyte cells.
PMP association is lipid specific.12 The complexity of interactions and functions among PMPs
make them dynamic macromolecules that are challenging to study in a natural context. The
translocation of PMPs varies from Brownian to actively controlled motion.35 Cellular and
biophysical investigation of PMPs such as PKC and phospholipases have helped develop our
understanding of protein-membrane interactions although there is still much more to be learned.
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Phospholipases are an important subset of amphitropic PMPs. These enzymes are ubiquitous
biological molecules that act by cleaving the phosphate or ester bonds of phospholipid
headgroups.36 Phospholipase activity has been experimentally tied to plant defense,37 bacterial
virulence,38 cancer15,

39

and much more. Several phospholipases related to DAG—and other

PMPs—are presented later in this chapter.
The packing of bilayer lipids, in natural membranes or artificial vesicles, is perturbed by the
presence of nonbilayer lipids. Geometric changes in lipid arrangement are mechanical yet have
evolved complex biological purposes including membrane recruitment of PMPs and vesicular
communication. PMPs are stimulated extrinsically to translocate about the membrane for further
activation by lipid second messengers. Areas of protein translocation are liquid ordered (Lo)
domains enriched with specific membrane constituents such as cholesterol and signaling lipids.40
These domains are colloquially termed ‘rafts’ and are discussed in the Nanodomains section later
in this chapter. Signal transduction depends on these unique membrane perturbations; proteinspecific arrays of bulk lipids and lipid second messengers create ideal conditions for
glycerophospholipid headgroup interactions with activated proteins. A lipid-specific nanodomain
is represented by the cartoon schematic in Figure 1.5. This simplified depiction of ‘rafting’ is
expanded in Figure 1.8 to include an integral membrane protein and a more transient PMP. Figure
1.6 includes several of the other membrane components omitted from Figures 1.5 and 1.9, such as
glycolipids and glycoproteins.

1.2: Cellular functions of DAG and related lipids
Nearly a century ago, it was posited that there is a fatty lipoid coating two molecules thick
surrounding our cells.41 Half a century later, the phospholipid bilayer hypothesis was confirmed42
and the fluid mosaic model for cellular membranes was proposed.43 Once it was confirmed that
phospholipid self-assembly into cellular membranes forms the building blocks of life, lipids came
under more scrutiny as cellular operators. The variety of lipids per cell and their differing
supramolecular behaviors is evidence enough to suggest that cellular importance of lipids extends
beyond providing structure. Before long, researchers were uncovering lipid propensities to interact
with metal cations and proteins to achieve isothermal regulation of cellular activities.5 This led to
10

the discovery of enzymatic and electrostatic protein interactions of nonbilayer lipids, in addition
to their mechanical roles, underscoring the importance of lipid secondary messengers and their
fatty acid intermediaries.6, 12, 44-48
It is widely agreed upon now that in addition to forming cells, signaling lipids also act as
metabolites and secondary messengers through protein translocation and activation. Presently, our
understanding of the plasma membrane is more nuanced than it was decades ago, but still very
much incomplete. What can be said for certain is that proteins and lipids work in synchronization
to protect our cells and organelles, dictate cellular function, and regulate ionic gradients between
the cytosol and extracellular matrix. Roughly one quarter of our proteome is comprised of
membrane proteins and their tight interactions with lipids within cell bilayers is crucial for
maintaining structure and the electrochemical potential that allows for adenosine triphosphate
(ATP) synthesis.49 The cell membrane is a natural phenomenon fundamental to life itself and PC—
with its ideal cone angle—deserves credit for driving the self-assembly of our cells.
It is the nonbilayer glycerolipids found within the plasma membrane that are the focus of this
dissertation due to innumerable biological functions they control. Such glycerolipid second
messengers are generated passively upon stimulation of receptor tyrosine kinases (RTK) or seventransmembrane receptors. The latter are now more commonly known as G protein-coupled
receptors (GPCRs) and comprise the most commonly targeted group of proteins for therapeutic
applications.50
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Figure 1.6: An illustration of the plasma membrane.
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The case for low abundance glycerolipids as mediators in several cellular pathologies is clearly
very strong. It is no surprise that signaling lipids such as DAG are already under investigation for
the roles in cancer and other diseases.

DAG and PKC
Much of what is known of DAG’s cellular importance regards activation of protein kinases
known as phorbol ester receptors that share a conserved binding domain colloquially known as the
C1 domain. Protein kinase C (PKC) enzymes are a type of phorbol ester binding protein and were
the first to be discovered and investigated for DAG-mediated subcellular signaling activity.
Phorbol esters are naturally occurring plant-derived compounds that have a protein recognition
profile similar to DAG.51 PKCs have garnered the most notoriety among DAG’s protein targets
thanks to a host of crucial physiological roles. We will discuss these roles in depth after briefly
reviewing PKC structure.
The C1 domain
PKCs contain two C1 binding domains (A and B) that operate in tandem and often have DAG
affinities that vary among different PKC isozymes.52 As determined by nuclear magnetic
resonance (NMR), the C1 domains consist of two β sheets and an abbreviated C-terminal α-helix,
and chelate with two Zinc (Zn2+) ions through a pair of similar motifs each composed of three
cysteines and a histidine.53 The C1 domains of non-PKC phorbol ester proteins are analogous to
the C1 domain of the PKC isozymes, however certain phorbol ester binding proteins have a
disparate dormant structure that demands more drastic conformational change for activation. This
suggests that significantly higher amounts of DAG are required for activation of these proteins
(such as mammalian uncoordinated protein-13 or ‘Munc13,’ discussed later) than with PKC.52
There are no fewer than six other species of phorbol ester receptors for DAG capable of
instigating cell signaling cascades on DAG’s behalf.54 Phorbol esters are typically poisonous
plant-derived carcinogens that maintain affinity for the C1 binding domain and lock PKC in active
forms.55 Although, some naturally derived phorbol esters have demonstrated promising therapeutic
capacities.56 The C1 domain of DAG-binding proteins is buried until proteins are promoted to their
active form by signaling molecules such as growth factors or hormones. PS is crucial at this point,
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as it frees the C1-A domain to bind DAG by first untethering it from a C2 domain conserved among
many PKC isozymes.57 The C2 domain binds anionic phospholipids in a calcium-dependent
manner, making calcium a key cofactor for the membrane-binding of certain PKC isozymes.
PKC - structure
C1 and C2 domains are located at the amino (N) termini of PKC enzymes where the structures of
the regulatory domains determine the family of PKC.58 Conventional PKC (cPKC) isozymes have
both C1 and C2 domains including C1 A and B. Novel PKC (nPKC) isozymes differ at the C2
domain where an acidic residue is missing, thus removing the calcium requirement for anionic
phospholipid binding. nPKC and cPKC isozymes also vary their respective order of presentation
of residue domains, as shown in Figure 1.7 based on information found in Susan Steinberg’s
review of PKC structure.58 Atypical PKCs (aPKCs) lack the C2 domain entirely and have a
disparate C1 domain with a less-complex, cysteine-rich binding pocket. aPKC C1 domains do not
bind DAG, instead they are attracted to PIP3 or ceramide and participate in protein-protein binding
interactions. DAG activates at least eight different cPKC and nPKC isozymes. cPKC is divided
into cPKCα, β1, β2 and γ. nPKC subdivides into nPKCϵ, η, and θ.54
In addition to the C1 domain, many other lipid-specific protein domains have been discovered
across the peripheral membrane proteome.12 Although the structural impetuses for PMP binding
pocket recognition of membrane operators such as DAG and the PIPns are well-understood,59
precise mechanisms are not known for protein translocation to membrane areas rich in signaling
lipids. Here, it is important to note that lipid positioning in the membrane is not static and the

cPKC:
nPKC:

C2

C1A|C1B
C2-like

C1A|C1B

kinase domain

kinase domain

Figure 1.7: Conventional and novel PKC regulatory domains. Gray boxes represent hinge
regions between regulatory domains and from regulatory domains to the conserved kinase
58
domain. Kinase domain variation determines specific species within each family.
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collocation of signaling lipids into concentrated membrane nanodomains has been uncovered as a
crucial method of lipid-instigated protein translocation. This phenomenon has been dubbed
‘rafting’ and will be discussed in its own section after we complete our review of DAG and related
lipid second messengers.
PKC-activity (non-cancer-related)
PKCs and their ilk are most often investigated with respect to oncological transformations14, 16
but it is crucial for normal cell physiology and other diseases. For instance, PKC is also underexpressed in erythrocyte membranes of hypertensive patients18 suggesting that PKC and DAG are
important for maintaining healthy cardiac function. Just as PKC has many roles beyond regulating
carcinogenesis, so too does DAG.
In addition to fighting oncogenesis and cardiac hypertrophy, DAG’s activation of PKC impacts
mammalian physiology in numerous other ways. PKC is crucial for cell growth, learning,
memory60 and immune response.61 PKC isozymes also instigate profoundly important cellular
events such as transcription62 or receptor desensitization,63 as well as participating in proteinprotein crosstalk to influence a litany of other cellular functions.54, 64 PKCs also control contraction
of smooth muscle cells to allow healthy tissue function at various points in mammalian digestive
tracks.65-66

DAG function
If we cultivate a better understanding of DAG and other signaling lipids we may advance
medicinal chemistry on many fronts. Proteins are widely studied as means to therapeutic ends, yet
lipids do not receive nearly as much attention despite a similar level of diversities.67 These
macromolecules work together to govern cellular behavior and it is the general aim of this
dissertation to investigate such behavior from a lipidic perspective. Lipid activity is tightly
controlled in biological systems and this specificity could open new avenues for research
applications and targeted therapeutics.
DAG’s oncological significance will be discussed at length in its own subsequent section. First,
some of DAG’s other functions are introduced before briefly describing the activities of closely
related lipids. Lipid second messengers like DAG regulate virtually everything that goes on in the
cell. DAG facilitates membrane trafficking at the Golgi complex 22 and is a pivotal part of cell
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signaling cascades and lipid metabolisms related to cell proliferation,19 hypertension,18 immune
response34 and neuronal signaling.21 There are many proteins that are activated by DAG or produce
DAG via a related lipid effector. For ease-of-reference, these proteins will continue to be
highlighted in blue to the right of the page as they appear in the text. The ultimate goal of the work
described in Chapter 2 is to identify new proteins or classes of proteins that participate in DAG
signaling activities.
DGK – non-cancer-related activity
The most common metabolic fate of DAG is phosphorylation into PA by diacylglycerol kinases
(DGKs). DAG can also be metabolized through an acyl tail removal by DAG lipase or addition of
choline/ethanolamine headgroups into PC/PE, however DGK’s generation of PA is the most
common metabolic pathway for DAG in signaling cascades.21 DGK isoforms have myriad
functions. For example, DGK-α activates the movement and multiplication of endothelial cells
stimulated by vascular endothelial growth factor, leading to angiogenesis.68 Each of the ten DGK
isozymes discovered so far have distinct localization throughout the body but have the conserved
trait of protein-protein crosstalk to activate other DAG and PA binding proteins, such as PKC. Not
surprisingly, DGKs contain C1 and C2 domains homologous to those found in PKC.
Like PKCs, DGKs are most widely investigated regarding cancer and will be touched upon
again in the DAG & Cancer section. The physiological roles outside of cancer of the PKCs have
received significantly more attention than those of the DGKs and are well-characterized in
comparison. However, the physiological roles of DGK are still being uncovered. In addition to
oncogenesis, DGKs have been tied to neural cascades and immune response.

DAG and Immune response
Lymphocytes, or ‘T cells’ communicate synaptically to effect immune response and DAG
seems to be crucial for signal transduction via synaptic vesicles. Thus, the immunological synapse
(IS) is another arena where DAG localization and the coordinated responses of DAG binding
proteins are key for cellular communication.34 Precise mechanisms of DAG-mediated IS signaling
are still being unraveled. Evidence suggests that both the construction and metabolism of DAG
are tightly controlled to achieve immunological signal transduction.69 Recent evidence suggests
that DAG maintains polarity of the microtubule organizing centers (MTOCs) of lymphocytes such
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that they may exact antigen-determined responses appropriately.34
DAG and Alzheimer’s Disease
Elevated signaling lipid content, including DAG, has been discovered in select regions of brains
afflicted with Alzheimer’s disease (AD). Studies have shown no discernable lipidomic alteration
in the cerebellum of AD brains while other regions had site-specific elevations of certain signaling
lipids.70 DAG levels were found to be significantly higher in the prefrontal cortexes of AD brains
than in the same regions of healthy brains.
Additionally, elevated DAG content was recently detected in the frontal cortex and plasma of
MCI (mild cognitive impairment) subjects. A substantial number of AD patients experience MCI
as a prodromal phase prior to disease onset.17 Although DAG is not elevated in the cerebellum of
AD brains, it is still a crucial lipid effector in this region through its modulation of Munc13-3,
which is virtually absent in the body apart from the cerebellum.33
munc13
DAG activation of mammalian uncoordinated protein-13 (munc13) occurs in parallel to PKC
activities. Munc13 has been investigated for its DAG-responsive regulation of synaptic
transmissions, learning and motor function, and insulin release.71 The munc-13 kinases are a
family of C1-containing phorbol ester receptors involved in neurotransmitter release from synaptic
vesicles. There are three members in this family, munc13-1/2/3. Munc13-3 is cerebellum-specific
and seems to play a role in learning and memory in mice.33 Munc13-1 on the other hand, is an
ever-present pre-synaptic protein in the neurons of rodent central nervous systems. Munc13-1 is
also required for sustained release of insulin in mice.71 It has also been demonstrated in mice that
genetic alterations in munc13-2 expression have an array of implications for brain pathologies.72
All three of members of the munc13 family are promising targets for developing new
neurotherapeutics. Munc13s also contain the C2 phorbol ester binding domain conserved among
some but not all phorbol ester binding proteins.
DAG, along with its related species and transferases, has also been implicated in the
progression of nonalcoholic fatty liver diseases (NFLD), including cirrhosis.73 DAG has even been
shown to increase the pigmentation of guinea pig skin in vivo and the melanin content of human
melanocytes in vitro.74 DAG is not only ubiquitous but also omnipotent in its regulation of
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biological processes. It could be argued that virtually every phospholipid is related to DAG. To
manage the scope of this introduction, the discussion that follows will be limited to DAG’s siblings
PA and SM and its PKC binding cofactor PS.

PA

PAP

DAG’s activation of protein kinase C (PKC) involves the exchange of a phosphate group to
form PA, a crucial signaling lipid that also warrants further investigation.9 PA is similarly formed
when DAG activates DGKα. DAG molecules are reformed from PA by phosphatidic acid
phosphatase (PAP) and are then used in de novo lipid syntheses of triacylglycerol (TAG) as well
as PE and PC through the Kennedy pathway via cytidine diphosphate(CDP)-DAG.75 PAP enzymes
also provide DAG for PKC activation and seem to be key regulators of mammalian lipidomics and
thus cell physiology in general.
PLD and SPHK
PA is also generated by phospholipase D (PLD), a common enzyme whose main substrate is
PC. PLD pumps out PA for cell signaling purposes in a variety of species including viruses, fungi,
plants, and animals. PLD isozymes have been widely explored as targets for cancer therapeutics.15
In plants, PLD is critical in cellular responses to environmental stress.37 PA is well-studied in
plants where it occupies less than 1% of total phospholipid content but seems to be a key first
responder for flora by regulating sphingosine kinases (SPHKs), PLD and other enzymes in
response to biotic or abiotic stress.76 SPHKs are also present in human biology and are a subset of
DGKs.77 SPHKs (1 & 2) have complementary and/or opposing roles in simpler organisms
including modulation of cell proliferation and the mediations of cellular responses to a variety of
stimuli.78 SPHKs are considered cytosolic proteins but as their location is dictated by membrane
constituents such as PA they may be thought of as PMPs. SPHKs were at first thought to be
redundant in mammalian tissues but subtle differences have been uncovered that suggest that
SPHK1 and 2 may make promising drug targets for the selective inhibition or promotion of cellular
processes.
RAF-1
PA activates the rapidly accelerated fibrosarcoma kinase-1 (RAF-1) in mammalian cells
through binding at a specific amino acid sequence in the enzyme’s kinase domain.79 RAF-1 also
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contains a unique binding domain for PS.80 RAF-1 participates in the mitogen-activated protein
kinase (MAPK) cascade. BRAF and KRAS are genes that encode for RAF proteins and are mutated
in 40% and 10% of colorectal cancers (CRCs), respectively,81 and combined they are mutated in
30% of all tumors and 40% of melanomas.82 RAF inhibitors are promising anticancer agents and
they act through specific inhibition of the MAPK cascade to stymie tumor growth. RAF-1 is
homologous to the plant constitutive triple response 1 (CTR1) kinase which is a copper-regulator
modulated by PA in response to biotic or abiotic stress.83
SHP-1
Protein effectors such as DAG and PA often set off signaling cascades leading to oncogenesis,
mitosis, cell differentiation and proliferation. Another example of this is PA’s targeted activation
of Src homology region 2 domain-containing phosphatase-1 (SHP-1) of the protein tyrosine
phosphatase (PTP) family. In cancerous tissues, SHP-1 is overexpressed in epithelial cells and
underexpressed in hemopoietic cells.84 PA also regulates PIPn receptor enzymes and PTPs
including SHP-1, which are crucial for many cellular functions including oncogenesis.
GAPs/mTOR/PP2A/PP1
PA is also an effector for guanosine triphosphate (GTP)ase-activity accelerating proteins
(GAPs) which are crucial in regulating cellular pathways including carcinogenesis.85 PA activates
the mammalian target of rapamycin86 (mTOR) which controls cell cycle progression/growth and
switches cellular metabolisms from catabolic to anabolic.87 PA is also known to regulate
phosphatase-2A (PP2A) and phosphatase-1 (PP1) to control apoptosis, cell growth and glucose
metabolisms with correlated influences on disease prevention or onset with regards to AD, human
immunodeficiency virus (HIV) and herpes simplex virus (HSV).88-91
ABI1/PP2C
PA has also been implicated in the nuclear translocation of proteins that lack the canonical
nuclear localization signal (NLS) motif.92 An example of this is PA’s governance of abscisic acid
insensitive protein 1 aka Abelson interactor 1 (ABI1). ABI1’s specific activation by PA also
completes a signaling cycle involving PLD and phosphatase-2C (PP2C) that is crucial for
regulating many cellular functions.93
Lysophosphatidic acid (LPA) is a critical signaling lipid as well. LPA has demonstrated
increased control over cellular activity during tumor metastasis in pancreatic cancer.13 LPA may
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also help rapidly dividing cells evade apoptosis and have a protective role in neurogenesis.94

PS
DAG is also thought to work in conjunction with PS, a vital lipid that is typically found on the
inner leaflet of cellular bilayers but flips to the outer leaflet in pathological cells.47 The concomitant
binding of multiple lipids of the same or different species adds significant complexity to the task
of characterizing PMPs, which translocate to different areas of the membrane based on the
affinities of their binding pockets and associated lipid constituents. PS, along with the PIPn lipids,
have been studied to a greater extent95-100 than DAG or PA, and a thorough review of either lipid
would be ancillary to this dissertation.
Annexin
PS’s electrostatic untethering of C1 domains that allows DAG to recruit and activate cPKCs is
most relevant to the phenomena we seek to study.57 Also relevant is PS’s anionic character, which
contributes to its biological functions. The most common example of this is the recruitment of
annexins by PS-containing membranes. Annexins are a family of proteins with strong membrane
affinities and a variety of roles from membrane transport to apoptosis.101 Not surprisingly, calcium
bridges facilitate PS-annexin associations just as they do when C2 domains bind to PS. The known
interaction of PS and annexin protein A5 was utilized in proof-of-concept experiments in the
development of the liposomal protein screening assays described in Chapter 2. Annexins have
many protein-protein and protein-phospholipid interactions and, interestingly, these include
several annexin-PKC interactions, including annexin A5’s negative regulation of PKC.102
Annexins also regulate the EGRF/Ras signaling pathway.

SM

SMS/Akt

DAG is also formed by the enzymatic exchange of a choline headgroup from PC to ceramide
by sphingomyelin synthase (SMS) to form SM and DAG. SM and DAG levels are correlated in
cancerous tissues with low concentrations of SM implicating a poor prognosis.103 SM is associated
with inhibition of cancer pathways such as rat sarcoma (RAS) protooncogene protein P21-mitogen
activated protein kinases (MAPK, also known as extracellular signal-regulated kinase (ERK))
pathway. In addition to inhibiting the RAS-MAPK/ERK oncogenic pathway, SM stymies PIP3
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activation of protein kinase B (PKB or ‘Akt’) as well. Akt controls crucial cellular functions
including cell proliferation and migration. The promising new glioma drug minerval (2hydroxyoleic acid, 2OHOA) has been shown to increase both SM and DAG concentrations with a
concurrent reduction in PE as part of its mechanism of antitumor activity.
An exhaustive review of SM is beyond the scope of this dissertation because it is never
investigated by any of the experimentation described herein. However, SM is a key cog in DAG
metabolisms and in membrane nanodomains. For these reasons, SM deserves mentioning and
should be considered one of the most important costars in the cellular cinema that is DAG activity.
SM also serves as a facile transition to our discussion of DAG and cancer, particularly because the
RAS-MAPK/ERK pathway that DAG and SM cooperatively govern has been investigated for
decades as a cellular switchboard for carcinogenesis.

DAG & cancer
DAG activity is amplified in cancerous cells16 and it is thought this is because DAG is an
effector of cancer-associated proteins such as the PKCs. Only recently, however, was it discovered
that cPKCs act as tumor-suppressors,14 thus inverting the assumption that DAG’s activation of
PKC was involved in promoting cancer. Figure 1.8—which contains information published in a
review of DGK involvement in T-cell activity,104 as well as other lipid-protein relationships
reviewed in this chapter—illustrates how convoluted DAG is in terms of cell signaling and
metabolic pathways. Clearly, more investigation of DAG’s second messenger activity is necessary
and will unveil new angles for cancer therapeutics. What follows is a brief discussion of DAG
signaling activity in relation to cancer, at least what is known. We begin where we left off in the
previous section with DAG’s instigation of the RAS-MAPK pathway.
RAS-MAPK/ERK
RAS refers to a super family of small guanosine triphosphatase (GTPase) proteins, one member
of which was mentioned earlier with regards to SM’s signaling activity. RAS are established
MAPK/ERK triggers and have been widely explored as targets of cancer therapies.105 RAS and
other GTPase proteins are instrumental in the signal transduction of secondary messenger
pathways that catalyze the removal of a phosphate into guanosine diphosphate (GDP). GTP is also
a major source of cellular energy for the construction of macromolecules.
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Figure 1.8: A DAG-centric map of relevant cell signaling pathways. The complex nature of
DAG’s cellular functions is illustrated. Other PA protein targets include RAF1, PIP5K, SHP1,
ABI1, CTR1, SPHK1 and SPHK2.
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There are many families of small GTPase proteins and they have roles in adhesion, motility,
survival, cytoskeletal stability and cellular growth.106 Flawed RAS GTPase activity leads healthy
cells to become malignant cancers.
Early investigations found permanently active RAS in a variety of tumor types including 90%
of pancreatic, 50% of colon and 30% of lung adenocarcinomas, 50% of thyroid tumors and 30%
of acute myeloid leukemia.107 RAS-GRP1 (glucose regulated protein 1) relies upon its activation
by DAG for specific activation of MAPK/ERK kinases related to gene expression.108 To envision
how crucial this particular cell signaling cascade is, imagine the inactive RAS-GDP to be a switch
in the off position. If it remains off, the cell will die. RAS-GTP however represents the on switch
and when it is left on cells become invasive cancerous species.
PLC
Phospholipase C (PLC) converts PIP3 into DAG and increases intracellular calcium cation
(Ca2+) concentrations. PLC is first in line to respond to RTKs and GPCRs that have been stimulated
to promote lipid metabolisms, making them chief DAG producers for intracellular signaling
purposes. Increased Ca2+ is also a hallmark of PKC activation, addressed earlier, and is a crucial
factor in the signaling cascades set off by DAG and other signaling lipids. PLC is a vital operator
in healthy cells and plays a significant role in cancer onset and proliferation.39 There are 13
isozymes in the PLC family that are further divided into 6 subsets. PLCϵ is perhaps the most hotly
investigated for its carcinogenic behavior and has been implicated in intestine, skin, prostate,
gallbladder, bladder, lung, head and neck, colorectal, esophageal and gastric cancers.
PKD
Protein kinase D (PKD) is another highly studied DAG-binding protein and is a partner protein
to PKC in cell signaling cascades crucial to a litany of functions. PKD has irons in biological fires
ranging from gene expression and lymphocyte biology to cardiac hypertrophy and tumor
metastasis.64, 109 DAG is an effector of PKD isozymes 1,2 and 3 with PKD1 inhibiting invasive
cellular behaviors while PKD2 and PKD3 seem to drive them. The ubiquity of PKD upregulation
in malignant tumors makes it an intriguing target for new cancer therapies.
Chimaerins
Chimaerins are another family of proteins that bind DAG via a C1 domain.110 Chimaerins are
important in brain health and development, much like the munc13 family of proteins. Chimaerins
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have also been associated with breast cancer and duodenal adenocarcinomas.111 β2-chimaerin’s
observed activity in cancer progression could be oncosuppressive as it contains a GAP domain at
its C terminus capable of RAC inhibition. RAC proteins are a subset of the RHO family of GTPase
proteins to which RAS also belongs. RAC are involved in glucose transport and best known for
being highly engaged in carcinogenic cell progression.112-113
DGK
Diacylglycerol kinases (DGK) were introduced earlier as they are the most common route for
phosphorylating DAG into PA. DGK’s have been implicated in modulating cellular activity
including but not limited to carcinogenesis, immune response, and neuronal signaling cascades.21
DAG’s governance of diacylglycerol kinases (DGK) such as DGK-α activates the movement and
multiplication of endothelial cells stimulated by vascular endothelial growth factor, leading to
angiogenesis.68 Like PKC, DGKs are most widely investigated for their cancer-related activity.
There are at least ten different isozymes of DGK, and diacylglycerol kinase alpha (DGK-α) is
perhaps the most strongly linked to cancer and is implicated in the onset and proliferation of brain
gliomas, melanoma, lung cancer and other carcinomas.114 DGK-α activity is governed by DAG
and PA but therapeutic investigation has focused principally on the kinase itself, not the lipids.
DGK-α is indeed a very promising drug target as it is expressed in carcinogenic melanocytes but
not healthy melanocytes, and the inhibition of DGK-α induces apoptosis in tumorigenic cells by
blocking its ability to instigate nuclear factor kappa B (NF-kappaB).115 DGK-α’s lipid effectors,
however, deserve attention for their potential to modulate carcinogenesis.
DAG and PA are certainly not the only lipids involved in oncology. Metastasizing cancer cells
require increased nonbilayer lipid content (mainly PE) for proliferation. Tumorous tissues and
other diseased cells exhibit higher fatty acid concentration as a result of the requisite lipid synthase
activity for proliferation.19 The initial impetus for the investigation of nonbilayer lipids such as
DAG involved their mechanical influence on fusion and fission. However, the alteration of fatty
acid content in the tissue surrounding carcinomas has been shown to occur prior to metastasis in
breast cancer patients, suggesting that lipid regulation may be causal as well as reactionary in terms
of oncogenesis and/or oncosuppression.116 This is further evidenced by DAG’s importance as a
lipid metabolite as it is an ideal intermediary in the enzymatic construction of other phospholipids,
as can be observed in Figure 1.1. Several lipid synthases produce and convert DAG from/into other
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lipids. In this way, the metabolic processes involving DAG blur with DAG’s activity as a lipid
secondary messenger.
The DAG-PA/PKC phosphorylation activation pathway already mentioned is the canonical
example of this. However, DAG’s peripheral membrane protein (PMP) targets range far beyond
PKC. DAG’s multiplicity of action and crosstalk between its pathways have made it difficult to
pin down its cellular roles and capitalize on its activities therapeutically, as can be observed from
the decades-long endeavors to harness PKC inhibition and/or activation (depending on the isozyme
and cancer type) to inhibit tumor metastasis.117-118
PKC – cancer-related activity
Overtime, PKC inhibition proved to be an intractable target for cancer treatment. Individual
PKC isozymes have now been identified as definite tumor-suppressors.119 Newton, Brognard and
coworkers recently investigated several PKC mutations in cancer cells and concluded that PKC
isozymes are, overall, not oncogenic.14 Inhibition of PKC affords cancer the opportunity to
proliferate and thus over-expression may be a non-oncogenic cellular response to carcinogenesis.
Thus, cancer treatment strategies involving PKC should activate the enzyme to restore the
antitumor capacities of healthy cells. Moreover, it raises questions as to what the under-expression
of PKC in hypertensive patients18 means for PKC’s role in maintaining cardiac health.
Clearly, our understanding of DAG’s carcinogenic activity is nascent. With each passing year,
however, more experimental data supports lipid dysregulation as a global feature of cancers.48
Furthermore, cancerous cells depend on their unique lipidome to survive the harsh tumor
environments that they perpetuate, and understanding the roles of lipids in cancer may open new
avenues for treatment.120 DAG, then, stands as a key player in oncology. When considering DAG,
it is important to bear in mind the complexity of the membrane context in which it operates. To
this end, we will next discuss the concept of membrane nanodomains.

Nanodomains: to raft or not to raft
The original concept of biological bilayers as homogenized assemblies of amphiphiles has
turned out to be far from the reality of membrane composition. In truth, our cell membranes are
dynamic and actively allocate cholesterol, sphingolipids and other signaling molecules into small
membrane regions in order to compartmentalize cellular functions.121 The accepted theory to
24

describe the plasma membrane is as a liquid disordered (Ld) heterogenous mixture of lipids,
proteins and other molecules that may or may not sequester certain membrane components into
many nanoscopic liquid ordered (Lo) domains based on intermolecular affinities. These Lo
domains are hypothesized to be crucial in lipid-mediated protein recruitment and single
transduction, but their very presence – in living cells – is still debated. Colocalization of signaling
molecules via Lo phase separation into membrane nanodomains has been dubbed ‘rafting’ and
these rafts have elevated concentrations of the low-abundance lipids discussed herein.122
In lab settings, rafts order themselves based on acyl tail saturation, move as a single structural
unit through the membrane, and may conglomerate with other rafts.123 All of these observations
are demonstrable in artificial membranes, with raft sizes reaching up to one micron in diameter.124
In live cells, however, nanodomains have yet to be observed at over 5 nm, 125 which implies
significantly more heterogeneity than the original natural theory of rafting allows for.
The simple answer for why raft-like events are observed in artificial systems but not their
biologically active counterparts is the presence of integral membrane proteins. 126 A computer
model showed that at 5-10% of total membrane area integral membrane proteins and protein

Figure 1.9: A cartoon of membrane rafting. Intrinsic (left) and extrinsic (middle, right)
proteins localize to membrane domains rich in signaling lipids and cholesterol (yellow). Ld
phase represented by PC and occasionally PS or PE. A transmembrane integral protein, left,
is present within a Lo nanodomain with cholesterol and specific signaling lipids (mono/diacyl).
Center, a Lo nanodomain is similarly formed with an activated peripheral membrane protein
(PMP) and its preferred array of signaling lipids including PS. Right, A more transient surface
PMP is shown with a smaller Lo nanodomain. Only the outer leaflet of the bilayer is
represented, several other molecules are omitted for clarity, proteins and lipids are not to scale.
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channels dramatically reduced the abilities of lipids to phase separate. Natural bilayers also contain
protein channels, globular proteins, peripheral membrane proteins and surface proteins.
The complex answer for why rafts are not observed in living systems is that they happen too
quickly, discretely and transiently for our current methods of detection to illustrate. However,
recent technological advances are allowing researchers to qualify the membranes of living systems.
Moving from laboratory recreations of membranes to actual organisms is a key step to unraveling
nanodomain behavior.

Nanodomain analyses
The fragility of cells and the vitality of rafting make nanodomains elusive targets of
experimental characterization. Cells are fragile and current optical microscope technology cannot
image them in vivo. Ex vivo work and exogenous labels are poor recreations of the nanodomain
behavior thought to occur in living organisms. Isotopic labeling techniques that label the cell and
its membrane with specific amounts of hydrogen and deuterium are most promising for in vivo
studies of nanodomains. Just this year, neutron scattering experiments in this vein were applied to
nanodomains of lamellar bacterial phospholipid membranes and confirmed the presence of ~40
nm raft-like lateral phases.127
Some of the early evidence for lipid rafts made use of spin-labeled electron paramagnetic
resonance (SL-EPR) to distinguish annular conglomerations of immobile lipid species stuck to the
intramembranous binding domains of proteins.128 These lipid species may include steroids or
phospholipids and are determined by the binding stoichiometries inherent to different proteins and
their preferred ligands.49 Up to 100 lipid molecules129 may be non-covalently adhered to a single
protein and perturbations in lipid ordering are observed at least 1-2 nm from the protein insertion
point.130 In lab settings raft radii are significantly larger.
The fluorescent dye Laurdan is sensitive to fluctuations in membrane packing and thus has been
used to investigate lipid raft existence and results suggest there are Lo domains moving coherently
among the Ld matrix of the plasma membranes of rabbit erythrocytes and hamster ovary cells. 131
Phasor analysis was used to garner evidence from an adapted fluorescent lifetime imaging
microscopy (FLIM) technique that suggested the membranes of intact, live cells are composed of
24% Ld domains and 76% sub-resolution Lo domains.132 Many of these studies converge upon the
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idea that there are no ‘free’ lipids and each and every membrane constituent is non-randomly
partitioned based on affinities for proteins and other bilayer molecules.
The crux of the raft debate as it stands today lies in the size of the purported “microdomain”.
“Nanodomain” is used instead of “microdomain” in this dissertation to reflect the updated
understanding of the concept. The initial estimation of raft sizes of 5-200 nm is now thought by
detractors to be an exaggeration. Indeed, far-field fluorescence nanoscopy by stimulated emission
depletion (STED) identified fleeting protein immobility of 10-20 ms in cholesterol rich membrane
subcomplexes of no more than 20 nm in diameter.133
Recently, a glycosylphosphatidylinositol (GPI) anchored green fluorescent protein (GFP) was
shown to have a Lo domain of only 1.6-2.5 nm.130 The results of this study suggest, abstractly, that
phase separation does not play a major role in protein recruitment and activation. The results also
provide more evidence that the abundance of integral membrane proteins in living membranes
precludes the separation of Lo and Ld phases that is so easily observed in synthetic membranes.
This study was limited in its ability to track Lo phases not related to GPI-GFP so it does not, as it
claims, disprove the concept of Lo rafting entirely. Rather, it underscores the true nature of rafts
as ubiquitous, nanoscale, transient membrane features.
Advanced techniques such as augmented inverse fluorescence correlation spectroscopy
(iFCS)134 and course-grained molecular dynamic simulations135 continue to be applied to rafting
in artificial membranes, but more work is needed in living membranes to adequately address the
nuances of natural nanodomains. Current techniques, including isotopic labeling neutron scattering
experiments and recently developed super-resolution optical microscopy40 have already confirmed
several nanodomain theories and will continue to expound upon what is known of this concept.

Implications of rafting
Nanoscale Lo raft domains remain the predominant hypothesis for how membrane constituents
recruit activated proteins to transmit cellular signals and how membrane proteins exert their will
on lipidic environments.40 Rafting is also suggested to be a mechanism of lipid governance towards
mercurial cellular behaviors such as drug resistant cancers.136 The concept of lipid rafts accounts
for multivalent/concomitant protein-lipid binding as well. Nanodomains are well-documented if
not well-understood and they should be investigated further as they contain information that may
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be exploited to bring more selectivity and efficacy to the treatment of diseases such as cancer and
HIV.137 Rafting, particularly increases of cholesterol in nanodomains, has been shown to play roles
in other diseased states including viral infections, hypertension and Alzheimer’s.138
In addition to lipid composition, the curvature of a membrane’s protein binding site is crucial
for recruitment of proteins for signal transduction.9 Perturbations in membrane curvature at
membrane nanodomains is yet another example of how rafts facilitate protein recruitment. A raft
region rich in DAG, for instance, would have significant negative stress, which likely plays a role
in providing ideal docking points for DAG-binding proteins. The presence of many signaling lipids
at membrane nanodomains reconciles with the multivalent binding that many proteins undergo
when docking to membranes. When the complexity of membrane operations is considered fully,
it becomes clear that recreating raft-like bilayer conditions is ideal for understanding lipid
behavior. One ideal medium emerges by which lipid-protein phenomena may be studied and
applied clinically: the liposome.

1.3: Relevant advances in chemical biology
The liposome
The same supramolecular properties that self-assemble phospholipids into cells allow for the
formation of liposomes. Hydrophobic hydrocarbon tails conglomerate to expose the polar
hydrophilic headgroups to aqueous media externally and within the liposomal core, as can be seen
in in the liposome cross section in Figure 1.3.
These highly tunable spherical bilayer vesicles have been applied everywhere from agriculture
to homeopathy and gone on to become the most common and effective nanoparticles used in drug
delivery and diagnostic imaging.7 The term ‘liposome’ was first used to describe lipoid droplets
observed as resultant biological microbodies in a variety of animals.139 A few years later in 1963,
Bangham and coworkers identified self-assembled phospholipid bilayers by electron
microscopy.140 Bangham was joined by Weissmann and coworkers who went on to posit in 1968
that phospholipid bilayers partitioned intra- and extracellular space.141 Two decades after
liposomes were discovered, the convergence of nanotechnology and biomedical sciences amplified
their clinical potential and the Food and Drug Administration (FDA) approved the liposomal
28

nanodrug Doxil™ in 1995, which has been administered successfully for delivery of doxorubicin
(dox).142 Cantharidin, 5-fluorouacil, cis-platin, combrestatin, docetaxel, irinotecan, mitoxantrone
and paclitaxel, among others, are commonly administered liposomally.143
Various approaches for the formation, manipulation and application of liposomes are introduced
and discussed in detail throughout this dissertation, we shall begin with a basic outline of liposome
formation. The first step almost always involves mixing lipid constituents from organic stock
solutions and then removing solvent to create homogenized lipid films. The most common
technique for liposome formation is called thin-film hydration and proceeds by hydrating the lipid
films in aqueous media with heating and mixing to promote self-assembly into giant multilamellar
bilayer vesicles. Next, freeze-thaw and/or sonication can be employed to disrupt multilamellarity
and size the liposomes down to large or small unilamellar vesicles (LUVs or SUVs). This may be
followed by extrusion to create vesicles of uniform diameter with a low polydispersity index (PDI),
size exclusion columns (SEC) or dialysis to remove un-encapsulated liposomal cargo (if present),
or centrifugation to separate LUV’s from SUV’s.
Ethanol injection and reverse phase evaporation (REV) are also common methods for liposome
formation and are presented in later chapters corresponding to their utility for the projects herein.
Ethanol injection proved most effective at encapsulating short interfacing ribonucleic acid
(siRNA)144 for liposomal nanodelivery of gene silencing agents and was used for liposomal
preparation in the DAG-potentiated cell association experiments described in Chapter 3. REV
liposomes gained notoriety for their enhanced encapsulation of aqueous cargo and this preparation
was explored for the click-promoted content mixing fusion assays described in Chapter 4.145
Liposomes may be characterized by many means. By far the most common and accessible
method for confirming uniform size of liposomes is dynamic light scattering (DLS). DLS
instruments can give average nanometer of vesicles with relative abundances at each diameter.
DLS experiments can also determine charge in the form of zeta potential. It is possible to snap
pictures of liposomes as well to confirm morphology. To this end, transmission electron
microscopy (TEM) as well as atomic force microscopy (AFM) can be used. We have used TEM
and scanning TEM (STEM) to image our liposomes in order to confirm morphology as well as
fusion events (Chapter 4). An example of a TEM liposome image is shown in Figure 1.0.
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Figure 1.10: TEM image of liposomes: a 1.5 mM [lipid] solution of liposomes composed of
75% PC, 24% PS and 2% of a bifunctional lipid probe. The liposomes are in 1x phosphate
buffered saline (PBS).

Lipophilic guests may be shuttled about within the membrane bilayer of liposomes. To achieve
this, the guest is included during the formation of the lipid film. Upon hydration, the lipophilic
guest will form into the bilayer up to a tolerated percentage. Lipophilic cargo or membrane
modifications may be added to liposomes after formation by a process called post-insertion.
Briefly, post-insertion requires forming the insertants into PE micelles, which are then incubated
with the pre-formed liposomes. The less-stable micelles, through electrostatics and natural lipidic
conglomeration, favor deforming and reforming into the larger, more stable liposomes.
Hydrophilic cargo is often introduced during hydration, in which case SEC or dialysis is
necessary after hydration to remove unencapsulated cargo. Encapsulation of aqueous drugs can
also be achieved after formation by creating concentration gradients of pH, manganese or
ammonium salt (citrate, phosphate, sulfate or acetate) between extra- and intraliposomal space:
drug molecules diffuse into the inner core of liposomes when they enter solution where a minor
change such as protonation or chelation prevents escape.146
Extrusion is important when uniform size is at the crux of the experimental platform or
liposomal application. Interestingly, extrusion can also be useful for ‘clean up’ of certain
unencapsulated organic molecules when these molecules are lipophilic bilayer components.
30

Bilayers will house lipophilic guests, such as the membrane-bound dye Nile Red, but if the guests
maintain some aqueous solubility they will exist extraliposomally. In the case of extraliposomal
Nile Red, it will stick to the plastic filter supports used during extrusion and visible changes in
sample color are observed post-extrusion in these cases. Encapsulated Nile Red is carried through
extrusion within the bilayer. Therefore, extrusion is advisable for many liposomal applications,
even when uniform size is not a concern. Extrusion techniques are discussed in more detail in
Chapter 2.
Extrusion to remove aqueous cargo147 not entrapped within liposomal core is also possible and
requires a clever approach where liposomes are first sized above a certain diameter, 100nm for
examples. Next, a smaller filter of 50nm can be used to push the liposomal solution up against a
wall that is impassible for intact vesicles. The passed-through solution contains un-entrapped
aqueous cargo and may be discarded. Clean buffer is passed back through the filter in the reverse
direction, pushing the vesicles off the filter and back into solution. This liposome extruder
purification (LEP) protocol may be repeated as many times as desired and the developers reported
>93% liposome recovery and contaminant removal in a single step.147
Liposomes have been used extensively to study fusion and other membrane recognition
events.148 The biocompatibility and biodegradability of liposomes make them attractive in food
science applications for the delivery of enzymes, nutrients and antimicrobials.149 Various
liposomal technologies have emerged over the last few decades and several relevant innovative
applications are described in the upcoming Liposomal Chemical Biology section. Liposomes are
also the obvious choice for testing and optimizing new technologies related to delivery of bioactive
compounds,150 which leads us into the vast field of liposomal delivery systems for the treatment
and diagnoses of several diseases, i.e. liposomal theranostics.

Liposomal Theranostics
Self-assembled liposomal drugs and diagnostic agents have emerged over the last two decades
as the preferred method for medicinal nanodelivery (‘nano’ used per the typical vesicle diameters
of ~50 to ~200 nanometers). Liposomal delivery systems (LDSs) are also known as liposomal
nanocarriers and they exemplify the rapidly expanding field of nanodelivery. For simplicity, ‘LDS’
will be used instead and LNC will only be used to refer to lipid nanocapsules. LNCs, incidentally,
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are one of several liposome subtypes developed for specific nanodrug applications—in this case,
LNCs have a long 18-month shelf life and favorable encapsulation efficiencies of aqueous
drugs.151 Small nucleic acid lipid particles SNALPs) comprise another subset of recentlydeveloped LDS subtype. These nanodrugs are typically cationic and fusogenic. An LDS can be
made fusogenic through a few different strategies, as will be described later in Figure 1.11 and
later chapters. SNALPS are ideal for the transport of nucleic acid cargo, called nanovectors, for
gene silencing applications.
The use of nanocarriers has allowed for significant advances in the passive targeting of tumors
and other inflammatory diseases owing to the enhanced permeability and retention (EPR) effect.152
Small drug molecules are indiscriminate, causing a wide array of side effects and creating doselimiting toxicity. The sites of tumors, bacterial infections and other types of neoplasms or vascular
injuries exhibit enlarged gaps in the surrounding endothelium. Liposomes can home drugs to target
sites by keeping them in circulation until they accumulate preferentially through these widened
endothelial gaps, as illustrated in Figure 1.11. This phenomenon is colloquially termed ‘passive
targeting’ to refer to the natural advantage of putting a small drug in a larger delivery vessel.
There are several non-liposomal nanodrug platforms including lipidic micelles or lipid-coated
inorganic nanoparticles, some nanoparticle delivery platforms are lipid-free such as purely
polymeric micelles or carbon nanotubes. All nanoparticular delivery strategies make use of passive
targeting (Figure 1.11) and will experience increases in efficacy as nebulous ‘active targeting’
strategies continue to be formed into nanoparticle architectures as a means for creating cellspecificity among nanoparticles. Active targeting refers to the homing of nanocarriers to target
sites using peptides or other molecules with affinity for cell surface receptors characteristic of
target tissues. EPR is not purely mechanical; to assert that it operates on the principle that ‘big
things cannot fit into small holes’ would be an oversimplification of how liposomes home to
neoplasms and inflammation. Enlarged endothelial gaps are a programed response to maladies
ranging from bacterial infections to cancers. There is a pre-existing biological infrastructure to
usher larger particles to these sites. Size, therefore, is not the only thing that leads to EPR.
Circulation time, charge and biocompatibility can be utilized to potentiate EPR.152 Furthermore,
there are nuanced molecular and chemical differences between inflamed and healthy tissues that
aid in this process. It is possible to go beyond EPR to target tissue microdomains where
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Figure 1.11: The enhanced permeability and retention (EPR) of nanocarriers at target
sites. Liposomes are shown accumulating at a tumor (green shape) through the leaky
vasculature (red) surrounding the diseased/inflamed tissue.

diseased/infected cells create unique environments. This is the forefront where passive targeting
becomes active targeting.
Active targeting is touched on at the end of this section and reviewed more thoroughly at the
onset of Chapter 3. The type of biological information we seek to uncover through the
experimentation described herein is applicable to the active targeting of LDSs. The controlled
release of cargo through ‘lipid switches’ or ‘lipid triggers’ is also a principle pursuit of Dr. Best
and our research group and a review of this emergent technology begins Chapter 4, where work is
presented that relates to the controlled release of LDS cargo.
Many promising drugs are cleared by our immune system before they can act. The prolonged
circulation time achieved with liposomal administration is yet another advantage of using a
nanodelivery system. Liposomes often make use of lipid-anchored polyethylene glycol (PEG)
coatings to avoid aggregation and evade being marked by opsonins for immune system
clearance.153 PEG, however, imparts dose-limiting toxicity to PEGylated LDSs as over-exposure
to PEGs leads to hand-foot syndrome (HFS). Non-PEGylated liposomes (NPL) make use of
propriety compositions and manufacturing techniques to prolong circulation time and have
emerged as more effective alternatives to existing PEGylated FDA-approved LDSs.154 Liposomes
have advanced therapy for cancer and several other diseases,155-158 but there are significant strides
yet to be made in terms of active targeting and the controlled release of cargo at target sites. To
date, there is but one FDA-approved nanodrug, Mepact®, that is actively targeted to its cellular
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destination.159-160 Laboratory-based experimentation that bears in mind the tenants of clinical
viability could start a wave of increased nanodrug efficacy with profound clinical implications.
The simple fact that liposomal architectures are comprised of naturally occurring biological
molecules is one of the most attractive features of liposomal theranostics. Latent lipid mechanisms
allow lipidic nanoparticles to cross the blood-brain barrier (BBB).161 Solubility issues with drugs
like Paclitaxel were formally solved with harmful adjuvants but can now be overcome with
harmless liposomes.162 Liposomes are also being used to solve multi-drug resistance in cancers,163
as novel immunotherapies164 and as potent inhibitors capable of acute actions that avoid unwanted
systemic side effects.165 Additionally, liposomes are now approved for use as viral vaccines,
analgesics, antifungals and a photodynamic therapy to treat macular degeneration.159
At least 15 liposomal nanodrug formulations have been FDA approved, with many more in
clinical trials.159 Commercially available LDSs are able to deliver their cargo through temporal
degradation after collecting at target sites.7 Cholesterol is a ubiquitous component of LDS
formulations, investigations into the roles of the lipid constituents of LDS architectures have
focused on tuning stability and circulation time to enhance passive targeting. Such work has honed
in on PG,166 SM,167 or PE168 and other natural fats such as tricaprylin169 and lecithin,170 which have
all found roles as structural components in FDA approved nanodrugs. In this way, tailoring
liposomal components has led commercially available liposomal drugs such as extended-release
morphine.171 Most of the liposomal nanodrugs mentioned thus far were created decade(s) ago.
There is a disconnect between lab-based nanotechnologies and clinical applicability that has kept
the vast majority of actively targeted and/or triggered-release nanodrugs from making it to market,
despite great promise.172 As previously mentioned, we will return to detailed discussions of active
targeting (chapter 3) and triggered release (chapter 4).
To improve localization of liposome nanocarriers we conjugated targeting groups to liposomal
surfaces.144 We have also shown that by simply incorporating DAG and/or PS into liposomal
architectures we can potentiate and fine-tune the targeted cell-association of PEGylated liposomes
to different tissue types (Chapter 3). To improve delivery, we have shown that release of cargo can
be triggered with light150 and that vesicle fusion can be promoted through click chemistry (Chapter
4).148 Click chemistry is often utilized for many aspects of our projects, beyond the promotion of
vesicle fusion discussed in Chapter 4. Click is used in the synthesis of lipid probes, the
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modification of liposomal membranes and the enrichment of labeled proteins. Click chemistry is
central to the experimentation described herein and will be reviewed next.

Click chemistry
Click chemistry describes a set of bioorthogonal reactions commonly applied in synthetic and
bio-organic chemistry. The term ‘click’ was adopted by Barry Sharpless and others to describe a
set of facile cyclization reactions that progress efficiently at ambient temperatures. Click reactions
have marked utility for derivatization or conjugation of biomolecules. The essence of click
chemistry is its bioorthoganality, i.e. the tolerance of all other biological functional groups that
allows for selective reactivity of only azides or alkynes (or tetrazines and cyclooctenes) in complex
mixtures.173-177 Click reactions include copper-catalyzed azide-alkyne cycloaddition (CuAAC),
copper-free strain-promoted azide-alkyne cycloaddition (SPAAC) and tetrazine/trans-cyclooctene
inverse electron demand Diels-Alder (IEDDA) cycloaddition. In the Best lab, we have used click
reactions extensively, particularly CuAAC and SPAAC.
The Best lab often also uses click synthetically as single steps in the engineering of functional
lipids.97, 148, 178-179 More examples of click chemistry used to engineer functional synthetic lipids
will be seen in Chapter 2. Recently, we have begun applying click for the chemical modification
of liposomal surfaces to increase efficacy in liposomal theranostics. Such modifications include
the clicking of an azido cell-penetrating peptide (CPP), such as octa-arginine 2 in Figure 1.12, to
a lipid anchor such as the commercially available Alkynyl-PE 1. This work was done in
development of a CPP-targeted liposomal gene-silencing drug for treating vascular injury.144
Ultimately,

post-conjugation

yielded

better

encapsulation

efficiency

than

the

pre-

modification/self-assembly strategy in Figure 1.12. Liposomal theranostics are introduced later in
this chapter and the concept of targeting LDSs will be reviewed in Chapter 3.
Click chemistry has also been applied for faster delivery of toxic cargo in LDSs. Click kinetics
are much greater than those of typical non-covalent targeting strategies.180 Click-based delivery
systems can localize isotopic labels to target cites (pre-modified with click partners) more quickly
and thus avoid temporal degradation and content-leakage leading to poor imaging resolution
and/or side-effects.181 An exemplary strategy for pre-modifying target sites is the pH low insertion
peptide (pHLIP).182 pHLIPs may be functionalized with tetrazine before being sent to insert at the
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Figure 1.12: Click chemistry used to create a functional liposomal nanocarrier. Azido octaarginine 2 is clicked to dibenzyl cyclooctyne lipid 1 thus enabling the formation of CPPdecorated liposomes. This work was done to aid Trey Fisher and the lab of Dr. Deidre Mountain
as they developed a targeted nanodrug with greater cell association and delivery properties.

target cites with lower pH (such as tumors), followed by administration of a liposomal imaging
agent targeted by the trans-cyclooctene IEDDA click partner.183-185
Preforming liposomes decorated with clickable headgroups to enable immobilization or
functionalization of intact vesicles has been widely explored.7 Use of liposomal CuAAC,186-191
SPAAC,192-193 and Staudinger ligations194 have resulted in reviews devoted to methodology that
allows for click-functionalized liposomes that maintain membrane integrity.195-196 Liposomal
theranostics have benefited extensively from these efforts. Liposomal doxorubicin has been
modified with a HSV-1 peptide (gH625) through conjugation of a clickable gH625 analog190 and
branched neurotensin peptides, for active targeting purposes.197 To create anticoagulant LDSs,
CuAAC and the Staudinger ligation have been employed to decorate liposomes with
thombomodulin.198 Click is a powerful tool for customizing LDSs as it affords elegant options for
creating lipid anchored molecules, such as CPPs that can then be formed into liposomes—this
strategy is outlined in Figure 1.12. Conversely, liposomes can be pre-formed with less bulky
clickable groups such that intact liposomes may have their extraliposomal surface modified after
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formation. This strategy is called post-conjugation. The use of CPPs (which imbue liposomes with
fusogenic properties) and other active targeting strategies are reviewed at the beginning of Chapter
3.
Click chemistry has also been applied for the fluorescence based investigation of lipid rafts and
was used recently to expose protein-protein interactions that play a previously unappreciated role
in the mesoscale compartmentalization of our cellular membranes.199 A staggering amount of
progress has been made on several scientific fronts thanks to click chemistry. Click reactions are
among the most powerful tools at the disposal of chemical biologists. Another set of tools
fundamental to the types of experimentation reviewed next and described in Chapter 2 are a set of
photoreactive compounds commonly called photoaffinity tags. Click and photoaffinity tags
converge to enable a robust form of chemical biology known as activity-based protein profiling
(ABPP), which will be introduced next along with a discussion of photoaffinity tags.

Activity-based protein profiling (ABPP)
Activity-based proteomics uses molecular probes to identify related classes of enzymes based
on conserved catalytic sites with affinities for probe architectures.200 In this way, probe molecules
tag, enrich and isolate proteins based on enzymatic activity qualified by affinity for specific probe
architypes. The ABPP revolution was made possible by bifunctional probes that can A) covalently
capture associated proteins and B) chemically bridge labeled probe-protein complexes to reporter
molecules such as dyes or biotin.174 Covalent capture makes use of photoactivatable crosslinking
moieties and enrichment uses bioorthogonal click handles that react exclusively with reporter
molecules. ABPP probes are typically soluble in the aqueous media of cellular environments.
Using ABPP, chemical biologists may uncover new pathways that lead to cancer,201 identify and
characterize new members of protein families, and catalog virtually any proteome based on
conserved recognition sites and protein function.
“Affinity” is used instead of “activity” to describe the adaptation of traditional ABPP to label
proteins based on docking interactions during translocation. It is the preference of proteins for
certain membrane composition that enable our work, rather than enzymatic activities. Thus, AfBPP
is a more appropriate title for experimentation aimed at cataloging PMPs based on membrane
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affinities. Our liposomal AfBPP platforms will be presented in Chapter 2.

Photoaffinity tags
Soluble bifunctional probes are often applied to the identification and characterization of
biological targets based on their affinities and functions. Bifunctional, in this case, refers to their
ability to capture protein targets with a photoaffinity tag and be subsequently enriched (usually via
click chemistry) for visualization and/or identification. A clickable probe is useful insofar as the
probe can first covalently capture target compounds prior to click enrichment. The major
advancement in this realm is the photoaffinity tag. Photoaffinity tags burst onto the chemical
biology scene as a means for ligands to capture and thereby facilitate the identification of protein
receptors.202 Such technologies are extremely valuable for drug discovery203 and the study of
various protein receptors. Clickable, photoactive probes provide platforms for biological mapping
ranging from phospholipase activities,204 PIPn binding proteins,96 and global profiling of cellular
dysfunctions such as cancer.205 Such techniques epitomize ABPP.
Two common photocrosslinking tags are the diazirine and benzophenone groups shown in
Figure 1.13 with their mechanisms. A diazirine consists of nitrogen-nitrogen double bonds
constrained within a three-membered ring with an additional sp3 hybridized carbon atom tethered
to the probe backbone. UV excitation promotes the escape of a far more stable diatomic N2
molecule, leaving a nucleophilic carbene in its wake. The carbene will react to covalently insert
into any nearby C-H, N-H or O-H bond—including water—thus the carbene is short-lived and will
be quenched if there are no peptides nearby. Benzophenone, on the other hand, goes through a
radical reaction, as seen in Figure 1.13. The diphenylketyl radical intermediate in this case can
relax back into the ketone if upon initial excitation there are no hydrogen bonds nearby for it to
propagate its radical insertion mechanism with.
Naturally, background labeling is a major concern when employing photocrosslinking groups.
There is a demand for global identification of background labeling due to the latent natural
affinities of diazirines and especially benzophenones. Benzophenones have been applied widely
across science, medicine and industry for nearly 50 years, often in sunscreens, and have been
studied for their pharmacokinetics, allergic and photoalergic interactions.206-207 Happily, efforts
are already underway to create inventories of background protein hits for benzophenones,
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Figure 1.13: Two common photoaffinity groups with their crosslinking mechanisms. A
diazirine photoaffinity tag is shown above and a benzophenone photoaffinity tag is shown
below.

diazirines and other crosslinking groups such as aryl azides.208

Bifunctional lipid probes
Lipid scaffolds have been synthesized into clickable photoaffinity probes that operate in similar
fashions to the hydrophilic bifunctional molecular probes first used in traditional ABPP. DAG is
an intuitive architecture for synthetic intermediaries to access several bifunctional probes
corresponding to natural lipids. Previous members of our research group have engineered and
made use of an azido DAG species to access several bifunctional lipid probes and the bifunctional
DAG version of said probe maintained affinity for PKC, thus demonstrating the efficacy of such
strategies.178 Indeed, the Best lab has advanced the field of bifunctional lipid probes on many
fronts. The inositol phosphates have been studied in this manner209 as well as phosphatidic acid179
and phospholipids in general.195 Ultimately, the use of crosslinking, clickable lipid probes has
become an established means to label lipophilic proteins.210
Single-tail lipids have been studied in virtually the same way and fatty acid protein affinities have
been investigated extensively using bifunctional probes.211-212 A bifunctional probe corresponding
to sphingosine, which could be thought of as lyso-sphingomyelin, was recently developed to probe
sphingolipid cellular regulation.213 Even more recently, a photocrosslinking clickable lipid probe
was used to identify the active site residues in paraoxinase 1 (PON1), a protein with antioxidant
and anti-atherosclerosis properties.214 Lipid probes such as these provide universal platforms for
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Figure 1.14: Examples of recently-used synthetic lipid probes. A bifunctional fatty acid
200
probe (A) used by Haberkant and coworkers for labeling proteins is shown, as well as
monofunctional (B) and bifunctional (C) PC-based probes employed by Gubbens and
199
coworkers. Click tags are red, photocrosslinking groups are blue.

chemical proteomics in terms of protein ligandability, which has in turn revealed a marked
correspondence between the lipid affinities of proteins and the active sites of drugs and/or
inhibitors.215 Lipid probes have already shed light on the mechanisms of many potent drugs and
are concurrently uncovering new avenues for advanced therapies for many diseases.
To date, glycerolipid A(f)BPP has chiefly employed probes based on PC216-217 or sometimes
PE218 as the parent architectures and liposomal iterations have been limited to the labeling of
integral membrane proteins with latent bilayer affinities. Isolating proteins from complex mixtures
based on affinities for different lipid headgroups—presented in a membrane context—is an
attractive method for uncovering important new protein and/or lipid cellular functions. Probes that
seek to identify affinity for PC are unremarkable in their specificity and/or ability to uncover new
biological interactions. In assays sought to confirm affinity for a recent PC probe, results with a
known PC binding partner were negative, suggesting that the probe labeled membrane proteins
indiscriminately.217
Synthetic organic chemistry is not the only means by which bifunctional lipid probes may be
engineered. For example, probes have been generated by feeding an unnatural alkyne-containing
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choline to cells along with a synthetic fatty acid bearing a diazirine group so that the cells
themselves generate a clickable, photo-crosslinking phospholipid probe to be used in proteomic
mapping.217 Despite this progress, the use of lipidic probes maintains many challenges that inhibit
their applicability. Many lipids, particularly two-tail species, struggle to go into solution in
aqueous media. Solvation effects and unwanted self-assembly phenomena such as critical micelle
concentration (CMC) hinder the operation of lipid probes. Furthermore, lipid probes will maintain
universal non-specific affinities for any greasy protein binding pockets and thus produce unwanted
interactions when studying headgroup affinities of lipid species. A key avenue for advancing the
utility of bifunctional lipid probes is the employment of liposomes as platforms for such
technology.

Liposomal chemical biology
The concept of recreating the membrane context to more accurately characterize the lipidomic
and proteomic behaviors therein is at least two decades old, but as it stands today liposomal
chemical biology is still an expanding field. Studying membrane enzymes using proteoliposomes
(bilayer vesicles created from the lipid-enriched fractions of cellular extracts) is known to be an
advantageous biomimetic strategy and narrowing the liposomal contents to just phospholipids
seems to have the same effect as proteoliposomes in Escherichia coli.219 Liposomes present
solutions for shuttling lipid probes into cellular environments or presenting lipid probes to complex
mixtures of proteins in cell extracts. Anchoring lipid probes into liposomal membranes may also
diminish non-specific hydrophobic interactions by burying the fatty acid tails of lipid probes into
the membrane, although lipophilic proteins will of course insert themselves in the same context,
and amphiphilic molecules may partition themselves into hydrophilic areas if they do not pack
well into bilayers. Such are the nuances of concepts such as lipid rafting and part of the reason
complex liposomal presentation of bifunctional ABPP probes is rare.
Liposomes can also create a more biomimetic environment in which to screen protein affinities,
particularly when experimentation involves introducing lipidic probes to cell extracts.
Incorporating liposomes into complex experimental protocols creates challenges regarding the
increased lipid content that can interfere with ex vivo cellular delivery of probes and the gel
electrophoresis and mass spectrometry (MS) that culminates both ex vivo and in vitro protein
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profiling assays. Liposomal administration of probes to cell extracts however, is particularly
intriguing as it recreates some of the biological context lost upon cell lysis, and could advance
extract-based chemical biology. Considerable optimization is required to harness liposomes as
platforms for the chemical investigation of protein-lipid binding interactions and such nuances are
discussed in Chapter 2.
Surface plasmon resonance (SPR) has been used to characterized liposomes 220 and similar
technologies have previously made use of immobilized liposomes using various attachment
strategies although avidin-biotin is most common.221 Plasmon resonant liposomes have themselves
been created by coating liposomes in gold such that they are responsive to near-infrared to
stimulate release of biological molecules.222 Liposomes have also been deposited on polydopamine
surfaces by forming amine-catechol conjugates to create nanofiltration technologies with potential
application to water purification.223 Studies such as these move away from traditional chemical
biology and begin to blur the lines between biomedical and chemical engineering, surface science
and other disciplines. The wide applicability of liposomes illustrates their versatility and positions
them at the interfaces of several scientific fields, including analytical chemistry. For example, MSbased investigations of tissue samples, such as time of flight secondary ion mass spec, can be aided
by liposomes to identify the presence and characterize the interplay of biological molecules
characteristic of AD or other diseases.224
Non-vesicle lipid microarrays are common are common alternatives to ABPP using lipid probes
to investigate lipid-protein interactions.225-227 Lipid arrays are accurate ways to measure some
lipid-protein interactions, although they lack the curvature and dynamics to be truly biomimetic.
Liposomal microwell or microarray protein profiling overcomes this obstacle and has been
performed by immobilizing liposomes on avidin plates using biotinylated vesicles.228-229
Microarray liposomal applications have been developed further to become quantitative and are
extremely convenient in their ability to provide high-throughput analyses of complex lipid
interactions.230 Advanced microarray technologies that make use of fluorescent liposomes to
characterize protein-membrane binding interactions dependent on signaling lipid content, often
PIPn species, are now extremely robust and versatile.231 Microwells with sizes correspondent to
diameters of avidin-secured biotinylated liposomes have also been used to immobilize vesicles
and enable membrane-based assays.232
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Many techniques have emerged in which liposomes are the stationary phase in column
chromatography and such techniques have been applied to drug discovery and molecular
detection.233-234 These techniques are often referred to as immobilized liposome chromatography
(ILC) or immobilized artificial membranes (IAM). Immobilization can make use of various
covalent attachment strategies to silica and other column media, or they are often immobilized
through biotin-avidin interactions. Fluorescent molecules may be incorporated into liposomes that
are immobilized on columns in order to gauge membrane perturbation of drugs, peptides or other
molecules.235 Yet another emerging nanotechnology involving liposomes is the creation of
stabilized polymeric vesicles that make use of photo-induced cyclization reactions of tricosidinoyl
lipid tails and such technologies have already been applied to the study of PIP n species.236 Future
applications of IAM or ILC may involve polymeric liposomes or could potentially use size
exclusion chromatography for the liposomal enrichment of membrane-captured proteins, as
described in more detail in the ‘Future work’ section at the end of Chapter 2.
Liposomes have been applied in a somewhat similar fashion to the liposomal AfBPP detailed
in the next chapter. Multifunctional probes have been incorporated into liposomes to label integral
membrane proteins to confirm their ability to crosslink and be derivitized.216 Much of this
experimentation has been done by incorporating probes into the mitochondrial membranes of yeast
extracts.
We have adopted some strategies and protocols from these works and are grateful for the
headway made by other research groups. Our studies differ in probe design and application; they
also have a different end goal, which is the specific detection of PMPs with specific and selective
signaling lipid affinities. Figure 1.15 illustrates some of the liposomal chemical biology that will
be discussed in the Chapter 2, where a generic lipid probe allows us to capture and identify proteins
dependent on their natural signaling lipid affinities. The background protein hits of
photocrosslinking groups is an obvious concern, as evidenced by aforementioned recent
experimentation that catalogs such protein-phototag affinities.208 This liposomal protein profiling
approach outlined in Figure 1.15 controls for this by employing liposomes with only the probe
(and PC) to identify non-specific (or PC-only) interactions.
Here, we present a novel platform whereby lipid probes are formed into liposomes with
crosslinking groups displayed at the membrane interface. Specific lipid probes may be employed.
43

Figure 1.15: A lipomimetic affinity-based protein profiling strategy. A photoactive (hook)
and clickable (N3) lipid probe is applied liposomally to label proteins with a fluorescent tag for
imaging or to a biotin tag for purification. This strategy identifies proteins attracted to natural
chase lipids (red dots, PS in this cartoon) by incorporating a ‘generic’ lipid probe into liposomal
treatments at a constant percentage while varying the chase lipid.

Or, a nonspecific lipid probes (or ‘generic’ probes) may be incorporated at a fixed percentage into
liposomes with varying signaling lipid contents. Efficacy was confirmed early on using known
protein-lipid binding interactions and the protocol was also applied to characterize the membrane
affinities of the HIV capsid protein CA.
Probe liposomes were also mixed with complex mixtures of proteins and achieved selective
labeling of low molecular weight proteins from the membrane fraction of lysed cell extracts. The
location of our photoaffinity tag and the membrane composition-dependent labeling suggest that
some of our hits may be PMPs. To our knowledge, similar liposomal strategies that afford tight
control of membrane composition while investigating complex protein mixtures has not been
previously reported, until now.
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CHAPTER

2:

LIPOSOMAL

AFFINITY-BASED

PROTEIN

PROFILING (AFBPP)
2.1: Introduction
Lipomimetic and lipospecific AfBPP
This chapter describes the development of protocols to incorporate lipid probes into liposomes
to identify proteins that are recruited to the membrane surface preferentially based on membrane
composition or probe architecture. Probe liposomes may be incubated with cell extracts for the
discovery of protein-lipid binding interactions in a complex mixture of proteins. Probe liposomes
may also be incubated with enriched lysates or isolated proteins to characterize the membrane
binding behavior of specific proteins. Probes may be generic, allowing natural lipids to be screened
at incremental percentages by treatment liposomes with a fixed percentage of a non-specific probe.
This lipomimetic approach requires less synthesis and more accurately recreates the natural ligandbinding of proteins to membranes.

Lipid-specific probes may also be used and, although this

lipospecific approach is more demanding synthetically, this allows us to compare changes to probe
architectures among PA and DAG-specific probes, as well the results of lipomimetic studies with
generic probes (GPs). Specifically, the lipospecific approach hones in on the role of lipid
headgroups in the role of recruiting PMPs.
Once we have captured and labeled proteins with a fluorophore, analysis involves separation
by sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and fluorescence
imaging where proteins preferentially recruited to our liposomal surfaces will fluoresce more
intensely due to increased probe labeling (based on variations in lipospecific probes, or natural
lipid content in the lipomimetic approach). In this way, we have pursued two distinct strategies for
the labeling of lipid binding proteins.
The lipospecific approach utilizes a probe analog of the natural lipid containing functional tags
introduced within the structure. A lipospecific experiment is outlined in Figure 2.1 on the next
page, where the hydroxyl group on the probe molecule indicates a probe engineered to be
analogous to DAG. The lipomimetic approach relies on natural lipids to recruit proteins to the
membrane where they are then labeled by generic probes with no analogous natural headgroup. A
lipomimetic experiment with PS as the chase lipid is depicted in Figure 1.15 at the end of the
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previous chapter.
The lipospecific strategy is theoretically more precise when envisioning the immediacy of the
photocrosslinking event. Nonetheless, any tailoring of a natural lipid scaffold will exert changes
on headgroup presentation. This becomes clear when considering how close the headgroups of
DAG and many phospholipids are held to their glycerol backbone, as well as the location of some
binding domains within folded protein structures. These considerations lead to the evolution of
probes generated by the Best Lab from benzophenone-based to diazirine-based functional lipids.
The lipomimetic strategy makes use of nonspecific GPs that are not meant to bear any similarity
to lipids of interest. In this approach, proteins are recruited by natural lipids and captured by nearby
generic probes embedded in the same membranes. This approach has considerable logistical
advantages and is more biomimetic because it uses natural chase lipids. It is theoretically less
precise and the use of control liposomes that lack the chase lipid is crucial. Additionally, the
lipospecific approach has the potential to discover binding domains while the lipomimetic does
not.
In the lipospecific case, probes are used where the natural headgroup is retained at the sn-3
position in addition to the bifunctional headgroup attached to the sn-1 position (Figure 2.2,
structures 1 and 2). Alternatively, lipid probes may have only the photocrosslinking group attached

Figure 2.1: Lipospecific experimental design. In this cartoon the lipid-specific probe
corresponds to DAG, the fishhook represents the photoaffinity tag and the azide is the click
handle used to enrich (triazole ring is linkage product of enrichment with an alkyne-reporter).
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to the headgroup with clickable tails inserted at the end of the lipid tails (structures 3 and 4, Figure
2.2). In the lipomimetic case, non-specific probes (Figure 2.3, compounds 5, 6, 7, 8) are used to
study the labeling trends of natural lipids without the need to synthesize lipid-specific probes for
each lipid of interest, also known as the ‘chase lipid’.
Applying this liposomal AfBPP platform to cell extracts is attractive as a translatable
technology that is more cost and time-effective and can be more easily recreated lab to lab than ex
vivo work. For similar reasons, we are especially excited about the lipomimetic approach.
However, it is important to note that turning the entire liposome into a probe will impart a degree
of background labeling. This is accounted for by control samples using liposomes that lack the
chase lipid. As we add in chase lipids such as DAG, PA, PS, or any combination thereof, we
observe changes in labeling. Changes in labeling can be considered putative data and may be
compared to results of lipospecific assays and, potentially, mass spectrometry data using this same
experimental platform. Of course, these studies may also be applied in live cells and work has
already begun to optimize such experimentation.

Figure 2.2: Two different lipid-specific probe architectures. Lipospecific probes with a
bifunctional alkyne/benzophenone headgroup (1, 2) or with clickable azide-tails and a diazirine
headgroup (3, 4) corresponding to DAG (1, 3) or PA (2, 4).
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Figure 2.3: Generic probes for lipomimetic studies. Structures are given for probes with
bifunctional alkyne/benzophenone headgroups (5, 6) or clickable azide-tails with a diazirine
headgroup (7). Syntheses by Adam Carr.

I was responsible for optimizing conditions for liposome formation, incubation,
photocrosslinking, click derivatization, gel electrophoresis and fluorescence imaging of separated
proteins—as detailed later in this chapter. I also synthesized a key intermediate (Figure 2.4) for
lipid-specific probes 1 and 2 in Figure 2.2, as well as a simple single azide-tail benzophenone
probe used in optimization studies (Figure 2.5).

Probe design
To achieve our goal of capturing and enriching PMPs, we designed bifunctional lipids that
maintained amphiphilic phospholipid tendencies to form spherical bilayer membranes i.e.
liposomes. The probes’ synthetic alterations allow them to be activated by UV light to covalently
bind nearby proteins, and be enriched by click chemistry to label or identify captured proteins. The
first photoaffinity tag we tried was benzophenone, which is represented by the fishhook seen in
Figures 1.14 and 2.1. We have more recently added probes bearing a diazirine photoaffinity groups
as the ‘fishhook.’ Various combinations of azide and alkyne click handles and reporters have been
experimented with; currently, we employ azide-tail probes such as 3, 4, and 7.
Once we have captured and labeled proteins with a fluorophore, analysis involves separation
by SDS-PAGE and fluorescence imaging where proteins preferentially recruited to our liposomal
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Figure 2.4: Synthesis of para-methoxy benzyl (PMB) protected azido DAG analog 15. 15
was used by Adam Carr to finish convergent syntheses of four lipid-specific probes (two with
amide-linked bifunctional headgroups (not shown) and two with triazole linkages (1 & 2))
corresponding to DAG and PA. Synthetic details are in section 2.3, spectra are in Appendix 1.

surfaces will fluoresce more intensely due to increased probe labeling based on variations in
lipospecific probes (or natural lipid content in the lipomimetic approach).
Best group member Adam Carr was chiefly responsible for synthesis of the probes. My
contributions to the synthetic end of this endeavor can be found in Figures 2.4 and 2.5. The
synthetic strategy is outlined here, procedural details and synthetic data can be found in Section
2.3: Materials and methods with corresponding spectra contained in Appendix 1. Following the
scheme in Figure 2.4: synthesis of key intermediate 15 began with acetal protection of the vicinal
diol on diethyl-L-tartrate 9 using cyclopentenone to form acetal 10. Ester reduction using lithium
aluminum hydride (LiAlH4) formed diol 11. A mono-tosylation technique using silver oxide
(Ag2O), finely crushed potassium iodide (KI) and tosyl chloride (TsCl) created the primary leaving
group requisite of a nucleophilic azide introduction to form the azido alcohol 12 using sodium
azide (NaN3).
Sodium hydride (NaH) was used to deprotonate the primary alcohol of 12 so that it may be
protected through reaction with para-methoxybenzyl chloride (PMBCl). The acetal protecting
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group was removed using para-toluenesulfonic acid (p-TsOH). NaH and a catalytic amount of
tetrabutylammonium iodide (TBAI) were used to install lipid tails, introduced as
bromohexadecane. From here, Best Lab member Adam Carr completed the synthesis by reducing
the azide to an amine and conjugating to a bifunctional headgroup. These probes performed poorly
in labeling experiments and are not shown. Mr. Carr also clicked the azido group to an alkynal
bifunctional headgroup to form the triazole linkages shown in the final probe structures 1 and 2.
Mr. Carr’s removal of the PMB protecting group using 2,3-dichloro-5,6-dicyano-1,4benzoquinone (DDQ), not shown, completed the synthesis.
Mr. Carr’s twin-azide tail synthetic probes require significant time and cost to produce. As such,
a simple probe molecule that was cheaper and less demanding to construct was devised and used
in test experiments to optimizing the protocol for azide-tail probes. Synthesis of single azide-tail
probe 8, shown in Figure 2.5, commenced with the conversion of bromoundecanol 16 into azido
alcohol 17.
A Finklestein-esque reaction began next by mesylating the alcohol of 18 using mesyl chloride
(MsCl) in the presence of pyridine. An iodo nucleophile was than introduced to the mesylated

Figure 2.5: Facile synthesis of single azide-tail generic probe 8. Probe 8 was used in the
optimization of lipomimetic conditions for azide-tail probe experiments to conserve twin-azide
tail diazirine probes. The synthesis is detailed in section 2.3 and corresponding spectra are in
Appendix 1.
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carbon, creating iodo-azide 19. The iodo leaving group proved to be significantly more susceptible
to attack from the benzophenoxide nucleophile, which was prepared from benzophenol and
potassium bicarbonate (K2CO3) and introduced with TBAI to create the lipophilic clickable
photoaffinity probe 8. MS characterization of azido (N3) compounds typically gives a mass ion
peak less the weight of two nitrogen atoms due to ionization of N2. Thus, an orbitrap MS with nonfragmentation mode was used to confirm our azide withstood this reaction scheme to be introduced
as click tails to probe architectures. Instrument details and characterization data are presented in
Methods and Appendix 1.

Labeling studies
Thorough procedural details are presented later, followed by a discussion of experimentation to
determine optimum liposomal labeling conditions in Section 2.3: Materials, methods and
optimization. The current optimized protocol can be found in Figure 2.6. Several gel results follow
an earlier protocol that involved additional steps (Protocol B, Figure 2.7). Variations in the
protocols are addressed here as we outline the procedures of our liposomal AfBPP. Experimental
results from the updated protocol will appear with ‘Protocol A’ in the Figure legend. Experimental
results that follow the original protocol will appear with ‘Protocol B’ in the Figure legend.
The principal difference in Protocol B experiments was that more lipid content was used and
probes were incorporated at lower percentages than are specified by Protocol A (4% instead of 8%
for lipomimetic studies). Another key difference was that Protocol B samples were treated with 28 μL of 20% SDS detergent solution pre-click to accommodate the extra lipid content, as discussed
in Section 2.3.
The click reagents for Protocol B were added separately in the order they are given in Figure
2.7. For Protocol A, a click mix was made using the same ingredients. Details for click enrichment
are discussed in Methods, where Figure 2.20 tabulates concentrations and volumetric ratios of the
click reagents for the Protocol A click mix. For alkynyl probes, the click reporter was Alexa-488
azide. For azido probes, the click reporter was Cy-3 alkyne or Alexa-488 alkyne for experiments
done at The Scripps Research Institute (TSRI), which is noted in the text and Figure legends.
Protocol B also employed a solvent wash/precipitation to remove excess lipid content before
gel loading. Any studies that follow Protocol A do not use the solvent wash/precipitation and all
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Make
Liposomes

•4 mM [lipid] w/ *4% benzophenone-based generic probes,
6-12% probe required when probes are lipid-specific
•3 mM or less [lipid] with *8% diazirine-based probes

•40 μL extracts ~2 mg/mL
•10-20 μL of liposomes
Incubation •10-20 μL of buffer, mix, sit in dark for 1hr
•Long Range UV light (~350nm)
•Keep samples cold (not frozen)
Irradiation •10 min.

Click

•Add 6 μL of click mix** per sample
•Pipette to mix, sit or mix gently ~1 hr in the dark.

Figure 2.6: Outline of Protocol A for liposomal protein profiling. *% probe refers to molar
percentage based on total molar lipid content. **click mix is 3:1:1:1, ligand:CuSO4:TCEP:azide
or alkyne reporter (Figure 2.8)

studies that follow Protocol B do. After the wash/precipitation the pellet was sometimes
challenging to solvate in loading buffer. If this was the case, the pellets were briefly sonicated in
loading buffer using a sonic probe with a perforated tip set to 20% power with 3 x 1s bursts. All
experiments following Protocol B heated samples in loading buffer at 100 °C for 2 minutes before
loading into gels, some experiments do not use sonication before heating and this is noted in Figure
legends. Studies that follow Protocol A do not use any heat/sonication before loading.
Protocol B also added CaCl2 to a final concentration of 1 mM to ensure there was ample cationic
calcium to bridge certain DAG-binding proteins to anionic phospholipid cofactors. Protocol B also
added protease inhibitor before incubation to minimize protein degradation during heated
incubation. Updated Protocol A no longer uses heat and does not require addition of protease
inhibitor. The Figure legends and Figures themselves will detail any other changes to the
experimental procedures followed for that experiment.
The size of liposomes was also optimized and vesicles with 400-600 nm diameters afforded
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Figure 2.7: Protocol B volumes and reagents for liposomal protein profiling. Details of the
original protocol that was later optimized into Protocol A. Key changes were the reduction of
lipid content to 10-20 μL of 3 mM liposomes, the redaction of CaCl2 and protease inhibitor, as
well as the removal of the SDS treatment.

the best results. Protocol A uses these larger vesicles and multiple means of preparation are
discussed in Section 2.3. Protocol B used 100-200 nm vesicles and the preparation of liposomes
in this size range is also discussed in detail in section 2.3, along with cell lysate preparation and
all other experimental protocols for the labeling studies presented herein.

Controls
Controls have been implemented to verify that labeling depended on the probe being present in
the membrane and to verify probe photocrosslinking functionality. During proof of concept
experiments, and in later experiments, liposomes that resembled study groups but lacked the probe
molecules in their bilayer constituents were used to test for background labeling due to nonspecific
protein-dye interactions. Experimental groups that don’t receive irradiation are also employed to
make sure the photosensitive crosslinking moieties are functioning.
For lipospecific studies, the generic probes serve as controls to weed out protein hits that are
not specific to the headgroups of lipid-specific probes. For lipomimetic studies, probe liposomes
that only contain bulk lipids and/or cofactors serve as controls to isolate protein hits that are
dependent on chase lipid presence in the membrane. The complexity of our experimental platform
means many variables could skew our results, particularly when using the generic probes. To
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Figure 2.8: A PS-Annexin lipomimetic proof of concept experiment. Liposomes with 6%
of GP 5 (Figure 2.3) are used to screen Annexin V affinity as a function of PS content. Protocol
B. No sonication.

ensure the accuracy of our lipomimetic approach we conducted competition studies where noprobe liposomes with or without the chase lipid were pre-incubated with extracts before
performing our normal labeling experiment. Competition liposomes with the chase lipid should
compete for the protein more effectively than competition liposomes that lack the chase lipid, and
thus competition-based reduction of intensity will be lipid-specific for bands with chase lipiddependent labeling.

2.2: Results
Validation using known protein targets
We began with proof-of-concept assays (Figures 2.8, 2.9) to test if our protocol could illustrate the
known affinity that Annexin V protein has for PS. Protocol B was applied to these studies and
Figure 2.10 contains the volumes and concentration of incubation materials and click reagents.
We observed predictable labeling that was dependent on PS content alongside reasonable
background labeling to zwitterionic PC with equal probe content (6% of 5). This preliminary study
was early support for the validity of our lipomimetic platform.
No-probe liposomes were tested as well (CO, C4, C8, Figure 2.9) during proof-of-concept
studies to be sure that labeling depended on the functionality of our probes. Gels were stained with
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Figure 2.9: A lipomimetic proof of concept SDS-PAGE experiment. GP 5 was used at 4% to
screen Annexin V affinity as a function of PS content. Fluorescence intensity is quantified (to
the left) for PO, P4 and P8 samples. No-probe controls confirm probe functionality and
coomassie-stained gels confirm equitable protein content. Protocol B, no sonication

Coomassie blue to be sure we had equitable protein content in each lane and that increased
fluorescence was not attributed to increased protein retention. Quantification, such as can be seen
in Figure 2.9, used imageJ software and suggested labeling in the case of PS-Annexin V might
have a threshold-type increase when PS composes most of the membrane. Most importantly, the
results in Figures 2.8 and 2.9 show that labeling is dependent on both our probe and the presence
of target lipids. We built upon this proof-of-concept study by screening the HIV capsid protein
CA, of which significantly less is known than Annexin V, with our lipomimetic assay.
CA protein was generously prepared by members of Dr. Francisco Barrera’s research group,
prepared under the supervision of Dr. Daiane Alves (T24 human cancer cell extracts were also
prepared by Dr. Alves as described in section 2.3). It has been established that CA requires
interaction with lipid membranes to fold properly237 and self-assemble into capsid structures, with
specific affinity for anionic lipids such as PA.238 We tested CA in the same manner as Annexin V
experiments, the details for which are presented in Figure 2.10 and generally follow Protocol B.
Again, lipomimetic studies with CA suggested that our assay worked to qualify the lipid
affinities of proteins, as can be seen in Figure 2.11. When PA is present in the membrane without
probe 5, or when probe 5 is present in the membrane without PA, minimal background labeling is
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Figure 2.10: Volumes of incubation ingredients and click reagents for lipomimetic studies
in isolated proteins

observed. When we combine our probe and our chase lipid, however, CA is recruited to the
membrane by PA where it may then be labeled by nonspecific probe 5. Additional results from
lipomimetic assays with CA and Annexin-V are presented in section 2.3.b: Additional
experimental data.

DAG-based labeling in lipomimetic studies using generic probe 7
The lipomimetic approach with diazirine probe 7 achieved selective labeling that depends on
the percent of DAG incorporated into the liposomes. This work was aided by Kenneth Lum of the
Cravatt lab at TSRI. Our work at TSRI was the culmination of numerous experiments to optimize
our protocol. DAG-specific proteins were visualized by fluorescent SDS-PAGE experiment
(Figure 2.12) in which we screened soluble membrane fractions of human embryonic kidney cells
293 (Hek) lysates. All liposomes, including controls, contain 10% PS as a binding cofactor for
DAG. A few bands representing ~20 kDa proteins are labeled intensely by membrane-bound probe
7 when there is 16% natural DAG in the membrane. These DAG-specific bands vary in intensity
when DAG concentration drops to 8% and continue to do so at or below 4% DAG, all but

Figure 2.11: Fluorescent image of a lipomimetic PA study screening the HIV-1 capsid
protein CA. CA protein binds to liposomes preferentially in the presence of PA. Concentrations
of natural PA and 5 are indicated, and the remainder of the liposomes are composed of PC.
Protocol B, no sonication
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Figure 2.12: A lipomimetic DAG study in Hek cell extracts with DAG-specific protein
labeling. Fluorescent image of experimentation performed at TSRI. UV+ samples shown in
duplicate. Natural DAG preferentially recruited low kDa proteins from the soluble fraction of
Hek extracts. Probe 7 present at 8% in the liposomal membranes. Entire gel images can be
found under Experimental data. Protocol A.

disappearing at 0% DAG. Controls that lacked UV irradiation showed that the labeling depended
on photoactivation of the diazirine group, the no-DAG control in the far-left lane of Figure 2.12
shows that labeling was not due to nonspecific dye interactions in irradiated samples.
We proceeded to see if DAG probe 3 (Figure 2.2) would label similar bands to non-specific
probe 7 when DAG was present in the membrane. DAG probe 3 was also subjected to competitor
liposomes that contained no probe. Competition liposomes with DAG competed away labeling
more readily than competition liposomes without DAG, as can be seen in Figure 2.13. Figure 2.13
also shows the reproducibility of the selective labeling as lipomimetic treatment groups elevate
their DAG content. Again, all liposomes including the competition samples contain 10% PS. These
studies were also performed at TSRI and entire gel images are presented in the Experimental data
section.
Lipomimetic labeling with other chase lipids
The lipomimetic approach used to investigate DAG has demonstrated specificity in complex
mixtures of proteins only with diazirine-based probe 7. Lipomimetic results using benzophenone
crosslinking non-specific probes, such as 5 or 6, are promising but inconsistent. Increases in
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Figure 2.13: A lipomimetic and competitive lipospecific DAG study in Hek cell extracts
with DAG-specific protein labeling. Fluorescent image of an experiment performed at TSRI
in Hek cell lysates. The lipomimetic trend observed in Figure 2.12 is replicated here. Results of
the lipospecific competition study suggest some of the proteins labeled by our DAG probe are
attracted to natural DAG as well. Full gel study, in duplicate, is included in section 2.3.b.
Protocol A

labeling are either indiscriminate or the bands are not well enough resolved for this assay to be
quantitative using these particular probes. However, we may draw the qualitative conclusion that
signaling lipids such as DAG, PS or PA generally increase protein recruitment to liposomal
membranes.
Figure 2.14, for example, shows an early lipomimetic SDS-PAGE experiment where the
increase in labeling observed with the addition of PA was nearly proteome-wide when screening
t24 human cancer cell extracts. A PIP3 lipid was also used to screen t24 extracts, as seen in Figure
2.15, and in this case the labeling was dose-dependent and maxed out at only 2% PIP3, which is
consistent with PIP3’s presence at very low abundancies in natural membranes. In general, when
choosing percentages at which to screen different chase lipids, we considered their natural
abundance in addition to their tolerable percentages in terms of forming stable bilayers. Replicates
of the study represented in Figure 2.14 were also clicked to a biotin for identification via mass
spectrometry (MS). However, sample preparation was made challenging by the increased lipid
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Figure 2.14: A lipomimetic PA study in t24 cancer cell extracts. Fluorescent image shown
of study in duplicate. 4% of probe 5 used in all liposomes/lanes, PA as indicated, and the
remainder of the liposomes comprised of PC. The increase in labeling is indiscriminate and
appears threshold-based, Extracts are from t24 human cancer cells. Protocol B, no sonication

content in our system and protein hits were below significant levels as a result. The current state
of experiments that culminate in MS is discussed in Section 2.4: Future Work.

Lipospecific studies with diazirine DAG probe 3
Figure 2.16 shows selective labeling with diazirine DAG probe 3 when compared with GP 7,
which has a similar architecture. benzophenone-based DAG probes have thus far proven
unsuccessful—or inconsistent—at labeling proteins in a liposomal context. We have observed a
~175 kDa protein that was selectively labeled by 3 but not by corresponding generic probe 7, as
can be seen in Figure 2.16 where a narrow band fluoresces near the top of the gel only in the lanes
where T24 extracts were treated with DAG probe 3. Probe 20, which is a crosslinking only probe
described later in ‘Future work’ was included in this experiment, which used size exclusion
columns (SECs) to purify samples after crosslinking but before click enrichment.
SECs selectively enrich large molecules or vesicles by trapping small molecules and salts in the
pores of the column media: Sephadex™ beads. Size-exclusion based liposomal protein extraction
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Figure 2.15: A lipomimetic PIP3 study in t24 extracts. Fluorescent image shown of study in
duplicate. 4% of probe 5 used in all lanes, PIP3 lipid as indicated with the remainder PC.
Quantification of intensity of the darker band was done using imageJ software and error bars
are standard error based on the two replicates shown. Protocol B, no sonication

(SELPE) isolates membrane-bound proteins via their dramatically increased size when tethered
to liposomes following photocrosslinking. When applying the lipomimetic or lipospecific platorm,
SELPE experiments may selectively enrich DAG-binding proteins by trapping them on to large
vesicles and carrying them through the SEC when natural DAG or DAG probes are used (Figure
2.16). SDS-PAGE followed by staining could test for preferential enrichment based on the
presence of photoaffinity tags and chase lipids, potentially eliminating the need for click
enrichment and fluorescent imaging. SELPE is a nascent platform, mentioned here to qualify
Figure 2.16, and will be touched on again in future work. The experimental results in Figure 2.16
represent an early attempt to test SEC for its potential use in our unique liposomal chemical biology
platforms. Interestingly, the band labeled by DAG probe 3 in Figure 2.16 was not labeled by PA
probe 4. We repeated this study with 4 and results are presented on the next page in Figure 2.17.
This time, the SEC step was taken out to be sure that the regular protocol could produce the same
result. Labeling by 3 was faint, but the same band was again labeled, which was definitively
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Figure 2.16: A lipospecific DAG experiment in T24 cancer cell extracts using size exclusion
column enrichment (SEC) pre-click. Fluorescent image of a lipospecific DAG experiment in
T24 extracts is hown. A crosslinking only probe was also screened and samples were enriched
via SEC pre-click. No-UV controls show zero background for the band of interest (175 kDa).
Protocol A, SEC details can be found in section 2.4: Future Work

not present in the lanes treated with the other probes. The experiment in Figure 2.17 also made use
of competition liposomes with PA, DAG or only PC (all competitor liposomes contain 10% PS)
to see if probe-specific bands could be competed off by the corresponding natural lipid. Some
DAG probe-specific labeling was also observed in the low kDa area where selective lipomimetic
labeling was observed in Hek cell lysates (Figure 2.12). Ultimately, the labeling in Figure 2.17 is
too faint to draw any conclusions from the competition assay. Nevertheless, the same high kDa
band labeled by 3 but not 7 is again observed. It bears repeating that at this point we continued to
observe labeling increases that were protein specific rather than proteome-wide when employing
Protocol A. Moreover, the labeling was repeatable with or without the SELPE addendum. Thus,
SELPE remains a promising avenue for future work using our liposomal protein labeling
platforms.
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Lipospecific studies with PA probes
Amide-linked versions (instead of triazole) of probes 1 and 2 were synthesized but showed no
labeling (see section 2.3.b). PA probe 2, Figure 2.2, required incorporation at 15% or more of the
liposomal membrane to label selectively over generic probe controls in yeast extracts. Labeling
was faint and we were unable to confirm that it was PA-specific. In T24 extracts, labeling was
non-existent until we also added natural PA to the membrane as can be seen in Figure 2.18 (next
page). In this case, we observed a less intense proteome-wide increase in labeling, similar to
lipomimetic studies that used PA as the chase lipid with a much lower percentage of generic probe
5. Treatment liposomes demanded incorporation of probes at high percentages to bring about
labeling when screening extracts of the yeast cell line saccharomyces cerevisiae. Figure 2.19 (page
after next) demonstrates this where 20% incorporation of a PA probe into treatment liposomes
brought about labeling of an entirely different band (band 1) than seen in the lipomimetic PA
experiment ran on the same gel that only labeled band 2.

Figure 2.17: A competitive lipospecific DAG/PA experiment. Fluorescent image of a study
in t24 extracts using PA probe (P) 4, DAG probe (D) 3 and generic probe (G) 7. Low kDa
proteins are labeled by 3 in a similar region to those labeled in lipomimetic DAG experiments
(Figure 2.10) and a high kDa protein is labeled by 3 (5th lane from right).
62

Figure 2.18: A lipospecific PA study in t24 extracts. Fluorescent and stained images of a study
using 15% of PA probe 2. Liposomes have gradient amounts of PA and the remainder is PC.
The stained gel shows equitable protein content in all lanes. Protocol B, no sonication.
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Figure 2.19: A lipospecific PA study in yeast cell extracts. S. cerevisiae yeast extracts are
screened, image is a fluorescent scan of the study in duplicate. This study also tests a
lipospecific PA probe (2) with a similar architecture to the lipomimetic generic probe 5.
Liposomes with 5 and PA label more intensely than probe only liposomes. The PA specific
probe, however, labeled a solitary separate protein with no overlapping background. All
liposomes contain 10% PS and the remainder is PC. Protocol B, no sonication
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Conclusion
We have developed a robust platform for discovering protein-lipid interactions in a biomimetic
membrane context. Assays that make use of large clickable benzophenone crosslinking
headgroups can qualify the proteomic impact of DAG content, as well as other signaling lipids,
but lack precision. Probes that make use of smaller diazirine crosslinking headgroups with discreet
clickable tails are capable of more precise identification of protein-lipid binding interactions.
Lipomimetic experiments have isolated low kDa proteins that appear to be labeled as a function
of natural DAG content in the liposomes. Lipospecific experiments have isolated a high kDa
protein band that selectively binds liposomes incorporating a DAG-based probe. The lipomimetic
DAG studies represented in Figure 2.12 were repeated at TSRI with the clicking of a biotin-alkyne
instead of a fluorophore-alkyne. These samples were then enriched via avidin chromatography,
followed by digestion and MS—all performed by Kenneth Lum according to previously reported
protocols.215 Preliminary results are promising and we are currently awaiting more thorough
analysis by Mr. Lum to determine if our lipomimetic studies identified known and/or novel DAGbinding PMPs. These MS studies are addressed in more detail in Section 2.4: Future work.

2.3: Materials, methods and optimization
Solvents and reagents were purchased from Sigma-Aldrich, Acros Organic or Fisher Scientific and
used as received. Dry solvents were obtained using an Innovative Technology, Inc. Pure Solv
delivery system and stored on molecular sieves. Column chromatography was done on 230-400
mesh silica gel from Sorbent Technologies. Characterization by nuclear magnetic resonance
(NMR) was performed on Varian Mercury 300 MHz or Varian VNMRS 500 MHz spectrometers.
High resolution mass spectrometry (HRMS) characterization was done on either a JEOL DART
AccuTOF spectrometer (HRMS-DART) or an Exactive Quadrupole-Orbitrap spectrometer
(HRMS- Orbi).

Synthesis of key intermediate 15 (Figure 2.4)
Syntheses of compounds 10, 11, and 12 were adapted from a previously reported procedure,178
which used an acetonide protecting group in place of the cyclopentyl acetal used here.
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Diethyl (2R,3R)-1,4-dioxaspiro[4.4]nonane-2,3-dicarboxylate (10)
Diethyl-L-tartrate (8.08 mL, 39.2 mmol) was added to 150 mL of toluene while stirring in a ﬂamedried round-bottom ﬂask, followed by cyclopentanone (16.59 mL, 196 mmol) and then paratoluenesulfonic acid (p-TSOH, 744 mg, 4.32 mmol). The reaction mixture was heated to 135 °C
under reflux with a Dean-Stark trap. After cooling to room temperature (rt), sodium carbonate (659
mg, 7.82 mmol) was added and stirring was continued for 10 min. Next, magnesium sulfate
(MgSO4) was added until no clumping was observed (~100 mg) followed by another 5 minutes of
mixing. The solution was ﬁltered, concentrated by rotary evaporation and then left under vacuum
overnight and reduced to diol 11 without further purification. To confirm the formation of 10, the
crude was solvated in dichloromethane (DCM) for column chromatography on silica gel using 020% ethyl acetate (EtOAc) in hexanes (hex). 10 is collected as a yellow oil. 1H NMR (300 MHz
CDCl3) δ 4.67 (s, 2H), 4.22 (q, J = 7.1 Hz, 4H), 2.01-1.74 (m, 4H), 1.74-1.61 (m, 4H), 1.26 (t, J =
7.1 Hz, 6H).

13

C NMR (126 MHz CDCl3) δ 169.63, 123.31, 76.99, 61.84, 36.58, 23.44, 14.10.

HRMS-DART: [M+H]+ calculated for C13H20O6: 272.1260, found: 272.1285

((2S,3S)-1,4-Dioxaspiro[4.4]nonane-2,3-diyl)dimethanol (11)
Lithium aluminum hydride (4.460g, 117.6 mmol) was added to 0 °C anhydrous tetrahydrofuran
(THF, 100 mL) with stirring in a ﬂame-dried, three-neck round bottom ﬂask. The suspension was
kept in a dry N2 atmosphere. Crude diester 10 (10.2 g, ~39.2 mmol) was dissolved in 100 mL of
anhydrous THF and added dropwise to the reaction over 30 min. The reaction mixture was stirred
at 0 °C for 2 h, then at room temperature for 2 h, before cooling back to 0 °C. The reaction mixture
was then quenched carefully with 5 mL water, 5 mL of 10% NaOH, and 15 mL more of water.
Stirring continued for 30 min while the quenched mixture warmed to rt. To dry the reaction,
anhydrous MgSO4 was added with stirring until clumping was no longer observed. The mixture
was ﬁltered to remove particulates and then concentrated by rotary evaporation. The crude was
solvated in DCM for column chromatography with silica gel packed with hex and the following
eluents: 50/50 EtOAc/hex, 75/25 EtOAc/hex, 100% EtOAc, 10% methanol (MeOH) in EtOAc.
Compound 11 was isolated as a clear oil (3.833g, 53% yield over two steps). 1H NMR (500 MHz
CDCl3) δ 3.89-3.84 (m, 2H), 3.71-3.66 (m, 4H), 3.36 (br.s, 2H), 1.84-1.71 (m, 4H), 1.70-1.557 (m,
4H). 13C NMR (126 MHz CDCl3) δ 119.31, 78.34, 62.42, 37.25, 23.37. HRMS-DART: [M+H]+
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calculated for C9H16O4: 189.1048, found: 189.1079

((2S,3S)-3-(Azidomethyl)-1,4-dioxaspiro[4.4]nonan-2-yl)methanol (12)
Diol 11 (3.8332g, 20.4 mmol) was solvated in 100 mL of anhydrous DCM. While stirring, silver
(I) oxide (Ag2O, 7.09 g, 30.6 mmol), tosyl chloride (4.28 g, 22.44 mmol), and finely crushed
potassium iodide (.339 g, 2.04 mmol) were added in succession to create a mono-tosylated
intermediate. The reaction was stirred at rt for 2 h and then filtered through a silica plug using
DCM to be concentrated on rotary evaporator. The concentrated filtrate was dissolved in
anhydrous dimethylformamide (DMF, 100 mL) and, with stirring, sodium azide (NaN3, 3.32 g,
51.07 mmol) was added. The reaction was stirred at 85 °C overnight and then cooled to rt, extracted
with EtOAc, dried with MgSO4, and then concentrated under rotary evaporation. Crude 12 was
resolvated in CHCl3, washed 4 x with 100 mL water and 1 x with 100 mL brine before being dried
with MgSO4, concentrated by rotary evaporation and then resolvated in DCM for flash
chromatography on silica gel packed with hex and eluted with 50/50 EtOAc/hex. Compound 12
was collected as an impure yellow oil and used without further purification. Beforehand, 1H NMR
was used to confirm that diastereotopic glyceroprotons emerge and resolve as doublets of doublets,
and MS further confirmed the presence of our target compound: 1H NMR (300 MHz CDCl3) δ
4.07-3.98 (m, 1H), 3.96-3.89 (m, 1H), 3.78 (dd, J = 3.9 Hz, 8.1 Hz, 1H), 3.65 dd, J = 3.8 Hz, 7.3
Hz, 1H), 3.51 (dd, J = 4.6 Hz, 8.8 Hz 1H), 3.35 (dd, J = 4.6 Hz, 7.8 Hz, 1H), 2.09 (br. s, 1H), 1.911.76 (m, 4H), 1.76-1.60 (m, 4H). HRMS-DART: [M-N2+H] + calculated for C9H15N3O3:
186.1052, found: 186.1085

(2S,3S)-2-(Azidomethyl)-3-(((4-methoxybenzyl)oxy)methyl)-1,4-dioxaspiro[4.4]nonane (13)
Crude 12 (4.28g, 20.07 mmols) was stirred in 100 mL of 0 °C anhydrous DMF under N2. Sodium
hydride (NaH, .9633g, 40.14 mmol) was added carefully. The solution was stirred at 0 °C for 1.5
h, exchanging the atmosphere for N2 several times while H2 gas escaped. Para-methoxybenzyl
(PMB) chloride (6.286g, 40.14 mmol) was added and the reaction progressed at rt for 3.5 h. The
mixture was quenched with 5 mL of methanol. The solvent was removed by rotary evaporation
and the concentrated crude was then solvated with EtOAc (250 mL) and washed with 100 mL of
ammonium chloride, 100 mL of brine, and then 150 mL of water. The organic layer was dried by
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MgSO4, filtered and concentrated to yield the crude product 13. Some impurities were removed
by column chromatography on silica gel pecked with hex and gradient EtOAc/hex elutions up to
75% EtOAc. Impure 13 was used for the next reaction without further purification. Before moving
on,

13

C NMR and MS were used to confirm successful PMB protection.

13

C NMR (126 MHz

CDCl3) δ 159.29, 129.32, 119.89, 113.81, 77.90, 76.59, 73.23, 71.43, 69.93, 55.26, 52.30, 37.31,
23.45. HRMS-DART: [M-N2+H]+ calculated for C17H23N3O4: 306.1627, found: 306.1656

(2S,3S)-1-Azido-4-((4-methoxybenzyl)oxy)butane-2,3-diol (14)
Impure 13 was re-dissolved in 20 mL of MeOH, followed by the addition of 2 g of p-TSOH (10%
w/v) and mixing for 24 h. The reaction mixture was concentrated by rotary evaporation, solvated
in 150 mL of EtOAc and washed with 150 mL of water (x 2) and 100 mL of brine (x 1). The
organic layer was dried by MgSO4, filtered and concentrated to yield crude 14. Pure product was
isolated as a colorless oil by column chromatography on silica gel packed with hex and eluted with
60-80% EtOAc/hexanes (1.77 g, 32% over 3 steps). 1H NMR (300 MHz CDCl3) δ 7.21 (d, J = 8.6
Hz, 2H), 6.83 (d, J = 8.7 Hz, 2H), 4.40 (s, 2H), 4.00 (br. s, 2H) 3.88-3.76 (m, 2H), 3.73 (s, 3H),
3.62-3.54 (m, 1H) 3.53-3.44 (m, 1H), 3.41 (d, J = 4.9 Hz, 2H).

13

C NMR (126 MHz CDCl3) δ

159.23, 129.88, 129.48, 113.80, 73.02, 71.22, 70.92, 63.88, 55.20. HRMS-DART: [M-N2+H]+
calculated for C12H17N3O4: 240.1158, found: 240.1189

1-(((2S,3S)-4-Azido-2,3-bis(hexadecyloxy)butoxy)methyl)-4-methoxybenzene (15)
Diol 14 (59.9 mg, 0.224 mmol) was mixed in 20 mL of dry DMF at 0 °C under N2 atmosphere.
While stirring, 40 mg of NaH (1.67 mmol) was added slowly. The solution was stirred at 0 °C for
1.5 h, exchanging the atmosphere for N2 several times while H2 gas escaped. 1-bromohexadecane
(.24 mL) was added along with 80 mg of TBAI and the reaction was stirred at rt over night before
being quenched with 2 mL of MeOH and then extracted with 100 mL of EtOAc. The organic
solution was washed with water and brine, dried by MgSO4, filtered and concentrated by rotary
evaporation. The crude was solvated in DCM for Column chromatography on silica gel packed
with hex and eluted with 0-10% EtOAc/hex to yield the pure product as a white powder (109.1
mg, 68%). 1H NMR (300 MHz CDCl3) δ 7.25 (d, J = 8.3 Hz, 2H), 6.88 (d, J = 8.3 Hz, 2H), 4.46
(s, 2H), 3.81 (s, 3H) 3.66-3.60 (m, 2H), 3.60-3.55 (m, 2H), 3.55-3.51 (m, 2H) 3.51-3.48 (m, 1H),
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3.47-3.43 (m, 1H), 3.37-3.29 (m, 2H), 1.61-1.52 (m, 4H), 1.36-1.21 (m, 52H), 0.88 (t, J = 6.4 Hz,
6H).

13

C NMR (126 MHz CDCl3) δ 159.23, 130.17, 129.26, 113.75, 78.97, 78.51, 73.07, 71.84,

71.44, 68.70, 55.23, 51.29, 31.91, 30.08, 29.69, 29.67, 29.64, 29.62, 29.49, 29.35, 26.10, 26.06,
22.67, 14.10. HRMS-DART: [M-N2+H]+ calculated for C44H81N3O4: 688.6243, found: 688.6275

Synthesis of single azide-tail benzophenone probe 8 (Figure 2.5)
11-Azidoundecan-1-ol (17)
The starting material, 11-bromoundecanol (3 g, 11.94 mmol) was added to a flame dried round
bottom flask and then taken up in 60 mL of dry DMF and stirred under argon gas while NaN3 was
added (1.553 g, 4.396 mmol). The reaction mixture was stirred for 3 h at 85°C. After cooling to
room temperature, the reaction was diluted with DCM, washed with water, brine, and then 0.1 M
HCl. The organic layer was collected and then dried with MgSO4, filtered and concentrated by
rotary evaporation to yield the pure product as a clear oil (2.7588 g, 92%). 1H NMR (300 MHz
CDCl3) δ 3.64 (t, J = 6.6 Hz, 2H), 3.39 (t, J = 6.9 Hz, 2H), 1.90-1.79 (m, 2H), 1.61-1.52 (m, 2H),
1.45-1.24 (m, 14H). 13C NMR (126 MHz CDCl3) δ 62.95, 51.45, 32.64, 29.51, 29.41, 29.37, 29.10,
28.79, 26.67, 25.7.

11-Azidoundecyl methanesulfonate (18)
Starting material 17 (1.6617 g, 6.6164 mmol) was added to a flame dried round bottom flask and
then taken up in 20 mL of dry DCM and stirred under N2 gas at 0 °C. Pyridine was added (1.08
mL, 13.233 mmol) while mixing, followed by mesyl chloride (512 uL, 6.6164 mmol). The reaction
mixture was stirred overnight at rt before washing with 20 mL of water and 1 mL of saturated
ammonium chloride and extracting with DCM. The organic layer was concentrated by rotary
evaporation and cleaned by flash chromatography using silica gel packed with hex and 10% EtOAc
in hex as the eluent. The product was collected as a slightly impure yellow oil and used for the
next reaction without further purification. 1H NMR (300 MHz CDCl3) δ 4.21 (t, J = 6.6 Hz, 2H),
3.25 (t, J = 7.9 Hz, 2H), 2.99 (s, 3H), 1.78-1.68 (m, 2H), 1.63-1.53 (m, 2H), 1.43-1.24 (m, 14H)
HRMS-Orbi: [M+H]+ calculated for C12H25N3O3S: 292.1694, found: 292.196
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1-Azido-11-iodoundecane (19)
Starting material 18 (194.2 mg, 0.6664 mmol) was added to a flame dried round bottom flask and
then taken up in 15 mL of dry THF and stirred under argon gas while sodium iodide (NaI, 119.9
mg, 0.7997 mmol) was added. The reaction was refluxed at 60 °C overnight. After cooling to rt,
the reaction was extracted with 8 mL of 6% sodium sulfate (NaSO4), followed by 3 mL of NaSO4.
20 mL of hex were added and the mixture was washed again with 10% NaSO4 (5 mL) before the
organic layer was collected and dried with MgSO4 followed by filtration and concentration by
rotary evaporation. Impurities were left behind by reverse trituration where hexanes were gently
swirled over the dried crude product to selectively solvate and remove pure 19 as a clear oil (162.1
mg, 75% from 17). 1H NMR (300 MHz CDCl3) δ 3.25 (t, J = 6.9 Hz, 2H), 3.22 (t, J = 7.0 Hz, 2H),
1.87-1.76 (m, 2H), 1.65-1.54 (m, 2H), 1.44-1.21 (m, 14H). 13C NMR (126 MHz CDCl3) δ 51.41,
33.53, 30.47, 29.39, 29.34, 29.11, 28.82, 28.50, 26.69, 7.28. HRMS-DART: [M-N2+H]+
calculated for C11H22IN3: 296.0797, found: 296.0794

(4-((11-Azidoundecyl)oxy)phenyl)(phenyl)methanone (8)
p-Hydroxybenzophenol (3.1 mg, 0.02 mmol) was added to a flame dried flask under argon
atmosphere. 1 mL of dry DMSO was added followed by potassium bicarbonate (K2CO3, 5.0 mg,
0.02 mmol) and mixing for 5 min. TBAI (6.0 mg, 0.02 mmol) was added followed by mixing for
20 min. Compound 19 (6.0 mg, 0.02 mmol) was added next and the reaction was mixed at rt under
argon for 4 h. The solvent was then removed by rotary evaporation and the crude was resolvated
in 35% EtOAc/hex and purified by column chromatography using silica gel packed with hex and
eluted with a gradient solvent system of 10% to 35% EtOAc/hex. Compound 8 was isolated as a
white resin (4.3 mg, 71%). 1H NMR (300 MHz CDCl3) δ 7.81(d, J = 8.9 Hz, 2H), 7.75 (d, J = 7.0
Hz, 2H), 7.56 (t, J = 7.4 Hz, 1H), 7.47 (t, J = 7.7 Hz, 1H), 6.95 (d, J = 8.9 Hz, 2H), 4.03 (t, J = 6.6
Hz, 2H), 3.26 (t, J = 7.0 Hz, 2H), 1.85-1.78 (m, 2H), 1.63-1.58 (m, 2H), 1.51-1.44 (m, 2H), 1.401.27 (m, 12H).

13

C NMR (126 MHz CDCl3) δ 195.56, 162.84, 138.34, 132.54, 131.80, 129.88,

129.69, 128.14, 113.98, 68.25, 51.47, 29.68, 29.48, 29.43, 29.31, 29.12, 29.10, 28.82, 26.69, 25.97.
HRMS-Orbi: [M+H]+ calculated for C24H31N3O2: 394.2416, found: 394.25
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General procedures for liposomal AfBPP
Liposome preparation
All lipids, apart from our synthetic probes, came from Avanti polar lipids. An Avestin lipofastmini extrusion system was used for most Protocol B studies. We also tested T&T scientific
Nanosizers™ and Avanti mini-extruders, the pros and cons of each are discussed herein. Detailed
procedural guidelines for liposome formation are followed by a discussion of liposome preparation
techniques.
The first step of liposome formation is the formation of lipid films. Stock solutions of bulk
lipids, probe lipids, chase lipid and occasionally membrane binding cofactors (cholesterol or other
chase lipids) in choloroform (CHCl3) and/or methanol MeOH are combined. For our bulk lipid,
PC, we used Egg-PC (mixed isomers). The DAG species we used was 1,2-dipalmitoyl-sn-glycerol.
The PS and PA we used in our studies were batches of mixed isomers from porcine brain tissue
and eggs, respectively. Below are the types of liposomes that would be formed for a lipomimetic
experiment using a generic probe with DAG as the chase lipid.
● Control liposomes: 8% probe, 10% PS, 10% cholesterol and 72% PC (no DAG)
● Three sets of study liposomes: 4, 8 or 16% DAG (8% probe, 10% PS and 10% cholesterol in
all) with 68, 64, and 56% PC respectively
To form such liposomes, stock solutions in CHCl3 of PC (12.7 mM), PS (10 mM), DAG (5
mM) and a non-specific probe (5 mM) were formed in 1 dram glass vials, stored at -20 to -80 °C
and used cold. A spreadsheet calculator (Figure 2.20) was created that outputs the volumes to be
added from each stock solution to create each batch of liposomes. The spreadsheet takes stock
concentrations, membrane composition by molar percentages, total desired moles of lipid, and
final concentration of lipid molecules in solution to formulate both volumes of organic lipid stock
solutions to be added to form lipid films, and the volume of aqueous media to be used for hydration.
Following the example spreadsheet in Figure 2.20, the second column from the left has the
amounts of stock solutions that would be combined to form lipid films for this particular liposomal
treatment group.
Aliquots of each stock solution are added using pipet tips approved for use with non-fluorinated
organic solvents, the solution is mixed thoroughly and then the solvent is removed by rotary
evaporation. Solvent may be removed under a stream of nitrogen, however the added mixing by.
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Figure 2.20: A spreadsheet to output stock solution volumes for lipid film formation. The
spreadsheet in this example has been modified to also output effective concentrations during
treatment (tx).

rotary evaporation helps to insure homogenized films are formed. Samples are kept away from UV
light as much as possible to avoid premature excitation of crosslinking species. Once visible CHCl3
is gone, residual solvent is removed under vacuum for at least 1 h or up to 24 hHydration in
phosphate buffered saline (PBS), is done by adding the specified volume (100 μL in the example
in Figure 2.20) directly to the vial and vortexing thoroughly. Next, heating and mixing at 60 °C
for 40 min (or 40 °C for 1 h) allows for the formation of giant multilamellar vesicles (GMVs).
Freezing at least once at this point to disrupt multilamellarity is always done. If sonicating to size
the liposomes, one freeze is sufficient. The number of freeze-thaw cycles should be adjusted for
desired size, as discussed shortly. For freeze thaw cycles, a dry ice/acetone bath in a Dewar flask
and a water bath set to 40-60 °C are used. The samples are cycled back and forth using adapters
that allow for pressure change to avoid cracking of the glass vials without splashing of acetone or
water when moving samples between baths. To freeze-thaw up to 7 samples at once using separate
vial adapters for each, I fabricated a rudimentary device using 1 dram vial lids and a metal-capped
mason jar. Lids were screwed to the metal cap and holes were drilled through the lids and cap.
This device works well but must have empty vials placed on any of the vial lids not occupied by
sample to be sure that acetone or water does not splash into the mason jar and drip into samples
during freeze-thaw cycles.
When sonicating using liposomal formulations such as those described in the example on the
previous page, DLS data has suggested that 1 minute of bath sonication yields 800 nM vesicles
with wide polydispersity indices (PDIs). 3 to 5 min of sonication yields 600 to 400 nM vesicles
respectively with consistent results and PDIs around 0.2. It should be noted that the samples were
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always frozen directly before sonication to avoid over-heating in the sonic bath. Experimentation
to test results of sonication should be done for each instrument and repeated periodically.
Extrusion is done after the last thaw, samples have been kept frozen for up to a week after the
final thaw before extrusion. Using disposable 3D printed Nanosizer™ extruders from T&T
Scientific, as few as one extrusion gives fantastic results when analyzing by DLS. Using traditional
extrusion techniques, such as the Lipofast mini extruder from Avestin there is a tradeoff between
the PDI, which gets better with more extrusion, and the functional size of the vesicles, which
deviates as the disposable filter warps with each pass through the extruder. I find that with the
Avesti Lipofast-mini extrusion system 7-11 passes is optimal depending on the concentration of
the sample and the filter size. With the Avanti Mini-extruder, I find that up to 19 passes is fine
with no diminishing returns in terms of size consistency. This may be due to their added filter
supports, which prevent warping of the disposable carbon filters. Liposomes are stored cold, but
not frozen, and used within 48 hours after extrusion.
For Protocol B, hydration was followed by 10 freeze-thaw cycles to form unilamellar liposomes
around 150nm in diameter, and finished by extrusion to ensure uniform diameters of between
samples. Protocol A uses liposomes in the ~500nm diameter range formed as described above by
one freeze-thaw followed bath sonication for 5 minutes. For sonication, DLS data began to indicate
giant vesicles in the 3-4 µm range in varying amounts between samples. This was attributed to the
waning vitality of the sonic bath at our disposal and we returned to freeze-thaw and extrusion.
Protocol A now uses 2 freeze-thaws followed by extrusion to 800nm using the Avestin extruder
system which produces uniform vesicles around 600 nm in diameter.

Preparing cell lysates
Human embryonic kidney cells 293 (Hek) lysates were prepared at TSRI by Kenneth Lum and
normalized to 2 mg/mL protein content. T24 cell lysates were prepared from human bladder cancer
tissue cultures by Daiane Santana Alves of the Barrera research group at the University of
Tennessee and were also used at 2 mg/mL protein content. Cell lysates were stored at -80 °C until
use. Previously reported methods for preparation of human cell lysates239 were used and are
outlined below.
Cells are grown to 80% confluency in appropriate media including 10% fetal calf serum (FCS).
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After harvesting and sonicating the cells, Dounce homogenization in phosphate buffer is followed
by 45 min of centrifugation at 1000,000 x g. The supernatant then contains the soluble fraction
where the proteome should include the PMP targets of our liposomal AfBPP. If protease inhibitors
are used they must be ethylenediaminetetraacetic acid (EDTA)-free to prevent chelation of copper,
which undermines click reporting down the line.
Saccharomyces cerevisiae yeast cell lysates were prepared in house using a procedure adapted
from previously reported protocols.240 Dounce homogenizers are not used and we instead use 1
mL of glass beads for lysis of ~1g cell pellets in 3 mL of lysis buffer (50 mM potassium phosphate
dibasic, 0.5 mM Na2SO3 and 1 tablet of EDTA-free protease inhibitor (Pierce™ mini-tablet) per
10 mL of lysis buffer). After adding the glass beads, samples are vortexed for 30 seconds followed
by 30 seconds on ice (x8) and then centrifuged for 3 min at 2500 rpm. The supernatant is then
aliquoted out and normalized to 2 mg/mL [protein] by running a Bradford content assay and
diluting with 1x PBS.

General incubation procedure
In a clear 96-well plate, 10 μL of 4 °C liposomes are first added (followed by other incubation
ingredients if following Protocol B). Cell extracts (~2 mg/mL) or proteins (~150 μg/mL) also at 4
°C, are added next followed by pipetting up and down to mix. If buffer is added last (Protocol A)
then mixing is done after addition 1x PBS. The plate is covered and for Protocol A the samples sit
in the dark for 1 h, for Protocol B the samples shake gently at 37 °C for 45 min. For competition
assays, competitor liposomes (or buffer, for controls) are added first and incubated for half the
duration, then treatment liposomes are added for the second half of incubation.

Photocrosslinking
After incubation, the samples are placed on ice and irradiated under long-range UV light (365
nm) for 10 min. Protocol A uses a Rayonet with two 8 watt UV lamps or, for experiments at TSRI
(noted in text and Figures), a Stratagene, UV Stratalinker™ 1800 Crosslinker with 4 x 8-watt UV
bulbs. Protocol B used a 4 watt benchtop UV lamp at 365 nm. Early studies began with 1 h of
irradiation on ice. Based on consultation with experts Natalie Sadler and Aaron Wright at Pacific
Northwest National Lab (PNNL), we determined this was unnecessarily long and likely
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Reagent

Concentration

Mix Ratio

Ligand

1.7 mM

3

CuSO4

50 mM

1

Click Reporter

5 mM

1

TCEP

50 mM

1

Figure 2.21: Optimal click reagent concentrations and corresponding volumetric ratios.
To determine the volume of click mix to add to each sample, use a final ligand concentration
of 50-100 uM.

deleterious. We shortened our incubation time to 10 minutes and increased protein retention with
no decrease in labeling.

Click enrichment
After photocrosslinking, Protocol A samples are enriched with a click mix given in Figure 2.21.
According to Protocol A, 6 μL should be added which gives us a final ligand concentration of 60
μM. A 100 μM final ligand concentration can also be used, and the slightly lower volume was
chosen as part of our efforts to reduce background labeling by dye molecules. Samples are mixed
and then sit at room temperature for at least one hour, after which they are stored at 4 °C until they
are ready to be separated by SDS-PAGE.
For Protocol B, click is preceded by an SDS treatment, which is described in the optimization
discussion shortly. After the SDS treatment, click proceeds as directed by Figure 2.7. Reagents are
added in the order they appear in Figure 2.7: TCEP, click ligand, CuSO4, click reporter (azide or
alkyne) and the samples are mixed at room temperature for at least 1 hour. Once the click reaction
is done, Protocol B proceeds to the solvent wash/precipitation. Solvent wash/precipitation and the
gel-loading of the resultant pellets are also detailed in the upcoming optimization section. As
mentioned, solvating the pellets in loading buffers was difficult at times and Protocol B made use
of tip sonication to get the pellets into loading buffer solution, as needed. Experiments that did not
sonicate the pellets are noted in their Figure legends. Tip sonication, when used, was done at 20%
power with two 1 s bursts. Sample occasionally shot up the sides of the tubes, when this happened
all samples were briefly centrifuged at low speed to move the liquid back to the bottom of the
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tubes.

Gel loading/running
Clicked Protocol A samples proceed directly to gel loading by adding 30 μL of 4x gel loading
buffer. Our 4X loading buffer is traditional for an SDS-PAGE experiment and the ingredients are
as follows: 4 mL 100% glycerol, 2.4 mL 1M Tris/HCl pH 6.8, 0.8 g SDS, 4 mg bromophenol blue,
0.5 mL beta-mercaptoethanol, 3.1 mL H2O. After adding buffer, samples are mixed and then sat
at room temperature for at least 10 minutes (no heating). If there is need to delay gel running it is
preferable to chill the samples rather than freeze to prevent protein precipitation.
Any SDS-PAGE system capable of separating proteins between 200 and 10 kDa will work well
to culminate our experiments. We have used multiple systems with success and find gradient gels
are ideal but fixed percentages at or near 10% also work well. Homemade extra-large 10%
polyacrylamide gels were used for experiments at TSRI and loading was done by Presently, we
are using Invitrogen™ Novex™ 8-16% Tris-Glycine Midi Protein Gels.

Fluorescent imaging and staining
Our imaging needs were met by a Typhoon fluorescent imager (General Electric) located in the
University of Tennessee genomics hub headed by Sujata Argarwal. The Typhoon settings depend
on the reporter dye being used, namely excitation/emission settings. The photo-multiplication tube
(PMT) was left at 600 nm by default but adjusted as needed (lowered to account for excess
intensity or raised if labeling was faint). A pixel size of 100 microns gave sufficient resolution
when the sensitivity was set to normal. A multipurpose Biorad gel-doc station with a light table
was used to capture pictures of stained gels. Experiments at TSRI made use of a similar Biorad
Chemidoc® documentation station with fluorescent capabilities.
Staining was always done using Pageblue protein staining solution (coomassie) by soaking gels
overnight and then destaining overnight in pure water followed by several rinses. Coomassie stain
was recycled and used three times before discarding. Image editing for clarity was minimal and
always linear. Stained gel images were occasionally obtained using free-standing light tables and
mobile phone cameras. However, all stained images presented here were taken on the
aformentioned Biorad gel-doc station.
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Optimizing labeling studies
A major challenge in liposomal AfBPP is finding an appropriate amount of lipid content such
that we may introduce our probes in a membrane context without interfering with the in-gel
imaging that culminates our experiments. We began with 200 μL of 5.5 mM [lipid] content
incubated with 100 μL of cell extracts. Coomassie staining revealed early on that proteins were
not entering the gels and we attributed this to two possible causes. Either the lipids were hogging
the SDS such that not enough remained to surround our proteins and impart the requisite charge
for gel movement. Or, intact liposomes with covalently trapped proteins were too large to enter
the gel. Large blobs of fluorescence as well as stained protein content were observed at the top of
the gels to evidence this theory. After more experimentation, we settled on 40 μL of liposomes for
treatment. We also found that using 40 μL of 2 mg/mL cell extracts gave us ample protein signal
as judged by stained gels.

SDS treatment
An SDS treatment step was introduced to disrupt the membranes before the click reaction and
to ensure the lipid content was occupied with SDS to allow for proper solvation of proteins in gel
loading buffers following the click reaction. This allowed proteins to enter the gel, as confirmed
by staining, but excess SDS was likely killing the click reaction and no labeling was observed. We
optimized the amount of SDS and found 5-10 μL of a 20% w/v solution of SDS allowed click
reporting and protein separation in gel (total SDS not to exceed 1.5% w/v). This SDS treatment
helped keep protein content consistent in gel experiments when using 40 μL of 5 mM [lipid]
liposomes to label proteins. When using this volume/concentration of liposomes, it was possible
to label proteins with a little as 2% probe in the membrane.
After adding 20% w/v SDS solution, samples are heated to 70 °C for 10 minutes, followed by
thorough mixing and sitting in a sonic bath for another 10 minutes. Samples proceed directly to
click. The SDS treatment step enabled some early success with our Protocol And was still a part
of our experimental procedures for some of the gel experiment results already presented, as noted
in the Figure legends, including experimentation with Annexin V and CA proteins. Studies
appearing in the additional experimental data later in this chapter made use of the SDS treatment.
Problems with consistency and repeatability remained so we sought advice from the Cravatt lab
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at TSRI, as previously mentioned, and decided to increase probe concentration in the membrane
to 8% and decrease the volume/concentration of liposomes drastically. This allowed us to go back
to no SDS treatment given the significant reduction in overall lipid content. We had previously
tested probe concentrations this high and knew we could form stable liposomes and label proteins
intensely if not selectively. The concurrent reduction in the abundance of liposomes was predicted
to afford more selectivity to our system by decreasing the amount of non-specific labeling. We
discovered that 10 μL of 3 mM liposomes with 8% probe could allow for consistent labeling with
trends that were DAG-dependent in lipomimetic studies. The volumes and concentrations we
chose for optimal Protocol A are far from arbitrary. Rather, they were chosen based off
observations of all previous liposomal AfBPP studies and manipulated to match the final probe
concentration of successful non-liposomal ABPP experiments reported by the Cravatt group.215

Other incubation ingredients
For Protocol B we added CaCl2 to a total of 1 mM (not counting calcium content of PBS or cell
extracts.) Early successes came when the added CaCl2 was a part of our experimental procedures.
However, when we removed the added calcium, we observed no change in labeling. Calcium
content of the extracts and/or PBS buffer was sufficient for our studies but future studies based
around varied labeling based on ionic concentration would be interesting. Our system often
incorporates anionic phospholipids such as PA or PS, so there was a risk of creating fusion between
vesicles if calcium content was too high.241 We now rely on the calcium present in our PBS buffer
and cell extracts to support any C1-DAG interactions in both lipomimetic and lipospecific
experiments where DAG is the chase lipid.
Protocol B also used protease inhibitor (Pierce™ mini-tablets, EDTA free) to prevent protein
degradation while liposomes and cell extracts incubated at 37 °C. Now that we incubate at room
temperature we do not use protease inhibitor. Protease inhibitor, incidentally, may also have
interfered with click reporting during early experiments that used cell extracts with EDTAcontaining buffers. Natalie Sadler and Aaron Wright brought this to our attention through
collaboration at PNNL, and we are grateful for The Wright Group’s expert advice during the
inception of this protocol. Presently, the incubation that has proven most successful is that which
appears in Figure 2.6.
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Click enrichment
Click reactions to enrich tagged proteins with dye molecules is another aspect of this protocol
that underwent significant changes during optimization of these experiments. Initially, we were
adding each reagent individually in the following order: tris (2-carboxyethyl) phosphine (TCEP)
was added first followed by the CuSO4, the click ligand and finally the azide or alkyne reporter.
TCEP has two purposes. It reduces the copper II present in copper sulfate (CuSO4) to copper (I)
and also reduces disulfide bonds in proteins allowing them to unfold. It is possible that when we
were clicking in this order the TCEP was being used by the proteins and not available in sufficient
quantities to reduce the copper to its catalytic form.
Presently, we make a click mix where the ligand, which is tris(benzyltriazolylmethyl)amine
(TBTA, Figure 2.22) predominates the volumetric ratio at ½ of the mix, as can be seen in Figure
2.8. In our system, it is particularly important to use an organic soluble probe in a 4:1 ratio of
tetrabutyl alcohol (tBuOH) and dimethylsulfoxide (DMSO). The amount of the click mix to add
to each sample is calculated based on a final ligand concentration of 100 uM. This ensures there
is enough organic media to help solvate the lipid material, freeing the lipidic click tag for reaction
with the reporter, which is also in organic media (DMSO). This was confirmed by switching to an
aqueous click ligand, tris(3-hydroxypropyltriazolylmethyl)amine (THPTA), which was unable to
catalyze the click reaction and we observed a general decrease in labeling when using THPTA in
water, presumably due to an inefficient click reaction.

Figure 2.22: Structures of click ligands. Left, tris(benzyltriazolylmethyl)-amine
(TBTA). Right, tris (3-hydroxypropyl-triazolylmethyl) amine. (THPTA)
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After the click mix is added, the samples are mixed and then sit in darkness for at least one
hour. It is possible to delay moving to the gel running portion of the experimental procedure by
chilling the samples or quenching with gel loading buffer. If the samples are to be chilled, they
should not be frozen as this may cause labeled proteins to crash out of solution as the complex of
protein with lipid probe and clicked dye is highly organic and the media is still predominantly
aqueous. Best results are achieved by running immediately after clicking. If delay is necessary,
better results are observed when samples are stored cold but not frozen between click and gel
running. The simplification of the click portion of our protocol mirrors the general theme of our
optimization efforts to circle back to the least complicated iteration of the protocol.

Precipitation/wash
A solvent wash/protein precipitation was used for all experiments that followed Protocol B. It
allowed us to accomplish two goals: concentrate the protein content of our samples to amplify the
signal of labeled PMPs, and remove lipid content allowing the SDS to do its job and usher protein
content into PAGE for separation. Ultimately, the wash/precipitation proved unnecessary when
only 10-20 μL of 3 mM [lipid] treatment liposomes are added to 40 μL of 2 mg/mL [protein] cell
extracts with an additional 30-20 μL of PBS so that total protein concentration is 1 mg/mL and
lipid concentration is below .75 mM with final click concentrations are based off of 50-100 µM
ligand.
During optimization, however, the solvent wash and precipitation allowed us to clean up the
samples, reduce background and produce less noisy gel images. The procedure generally included
the addition of methanol, followed by vortex and light centrifugation, then chloroform followed
by vortex and light centrifugation, and then water followed by vortex and longer centrifugation
followed by removal of the upper phase. Another methanol wash and supernatant removal ended
this clean up step. A step-by-step description of the solvent wash/precipitation with more details
is as follows:
-

add 200 µL MeOH, vortex, centrifuge at 9000XG for 30 sec

-

add 150 µL CHCl3, vortex, centrifuge at 9000XG for 30 sec

-

Add 200 µL pure H20, vortex, centrifuge for 3 min at 9000XG

-

Remove upper phase, careful not to disturb interphase/bottom phase (leave the chunky
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stuff in the middle alone, even if it means you don’t get all of the upper phase out.)
-

Optional: repeat this water wash

-

Add 250 µL MeOH, vortex, centrifuge for 3 min at 9000XG

-

Remove supernatant, don’t disturb pellet

-

Optional: Add 150 µL MeOH, vortex, centrifuge

-

Remove supernatant, don’t disturb pellet, you should be able to use a smaller pipet tip
to remove the supernatant at this point (20-200, set) making it easier to leave the pellet
unperturbed

-

Let samples sit until solvent dries off (anywhere from 20 minutes to 2 hours, in the
back of a hood), if you are in a hurry you can dry under a gentle nitrogen stream for
~10 minutes. Be careful not to blow the pellet out of the eppie, this is easy to do, it is
safer to dry passively.)

Of the two optional steps above, the extra wash with water appeared, at first, to be the more
effective at reducing background labeling. However, upon staining gel studies that employ an extra
aqueous sample cleaning, we discovered unequal protein lane to lane. Figure 2.23, on the following
page, depicts a lipomimetic study that employed a second water wash. The gel image is clean and
we do see increased labeling at higher concentrations of natural DAG and PA, but the stained gel
shows inequitable protein content between samples.
While the solvent wash was in place we felt it necessary to stain every gel experiment to be sure
labeling was a product of preferential recruitment of proteins to the membrane and not preferential
enrichment after click. We still use gel staining to confirm equitable protein content with each new
experiment but as there is no longer experimental variation with propensity to vary protein total
concentration there is no longer any variation between lanes of stained gels. As such, we have
moved on to rely more on no-UV controls to ensure experimental accuracy and UV (-) controls
are used in each replicate of every study.
Volumetric ratios of solvents and water were changed experimentally to see if we could retain
the wash/precipitation without the inconsistencies. The volumes/ratios given above demonstrated
the most promising results, however selectivity of the resultant gel experiments was not achieved
until we decreased the lipid content and removed the wash/precipitation step from our
experimental protocol. This simplification proved instrumental to allowing us to achieve
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Figure 2.23: A lipomimetic study performed using single tail benzophenone probe 8 with
the solvent wash/precipitation step with an extra water wash and top phase removal.
Selective labeling appears when chase-lipids are added, however this experiment should protein
inequities as evidenced by the control lanes to the right in the stained gel image (right). Protocol
A.
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reproducible selective labeling in lipospecific and lipomimetic studies, as presented earlier.
There are a few viable explanations as to why the wash/precipitation was ineffective. In
principal, it is a delicate task to clean up our samples using any type of solvent wash without
introducing intervening variables. This is because crosslinking indubitably introduces variable
lipophilicity to labeled proteins and the added lipid character of labeled proteins may have caused
labeled proteins—depending on the number of crosslinked probe molecules—to favor the organic
layer during the solvent wash.

Gel loading procedure for Protocol B
The gel loading was also more complicated when our system employed the solvent
wash/precipitation and reduced samples to a pellet. With the optimized system, there is no
sonication or heating necessary before gel loading. Beforehand, solvating the dried pellets in
loading buffer was sometimes challenging so sonication and heating were employed to ensure
consistent protein loading. The general procedure with gel loading buffer ingredients is as follows:
-

Add 25 µL of buffer 1 (4 % SDS, 50 mM triethanolamine, pH 7.4, 150 mM NaCl),
15µL of buffer 2 (50 % glycerol, 250 mM tris/HCl, pH 6.8, 10 % SDS, 0.03 % bromo
phenol blue), 2 µL of B-mercaptoethanol, vortex thoroughly, centrifuge
lightly/quickly.

-

Three 1s bursts with a probe sonicater on 20% power

-

Heat at 100°C for 2 minutes, gently shake down to room temp and then load into gel

2.3.b: Additional experimental data
As it stands, this project has demonstrated that gel-based liposomal AfBPP is a viable strategy
for qualifying lipid-protein interactions. We have shown that bifunctional lipidic ABPP probes
may be presented liposomaly, but by doing discovered that the introduction of liposomes by
Protocol B necessitates augmentation of mass spec protocols. We were unable to identify labeled
proteins by click-derivatization with biotin for pull down mass spectrometry experiments to
identify proteins when using Protocol B. Protocol A experiments that culminate in biotin reporting
and mass spectrometry to quantify our protein hits will be useful not only for the raw information
83

provided but also to confirm the repeatability of our liposomal AfBPP platform. Along the way,
we have observed interesting SDS-PAGE results in addition to those already presented, some of
which are presented in this section.

Lipospecific DAG probe results
We found that probe architectures with triazole linkages, such as lipid-specific probes 1 and 2
performed better than probes with amide linkages to the glycerol backbone. However,
corresponding generic probes 5 and 6 perform significantly better than their lipid-specific
counterparts with bifunctional headgroups. The click reaction that resulted in the triazole linkage
also eliminated the need for an additional synthetic step to reduce the azide at that position before
conjugating to a carboxylic acid As alluded to earlier, we observed no labeling when probes 1 and
2 were linked to their bifunctional headgroups by an amide bond, as can be seen in Figure 2.24,
compound 1a. DAG probe 1a was unable to label proteins even at 16% incorporation into the
membrane, as can be seen in Figure 2.25. While the triazole-linked iterations of these probes
showed labeling promise, they did not inspire confidence in their biomimetic capabilities. In
retrospect, the bifunctional headgroup is very large, which may impede upon the probe’s ability to
naturally qualify lipid-specific protein-headgroup interactions.
Additionally, DAG probe 1 showed faint labeling and required incorporation at high
percentages to bring the labeling up to appreciable levels, as can be seen in Figure 2.26. The
incorporation of PA along with 1 did indeed potentiate labeling (1 alone showed extremely faint
labeling without the incorporation of PA). The increase in fluorescence was indiscriminate, like
the results of lipomimetic PA studies with generic ester lipid probe 5 (Figure 2.15) and lipospecific
studies with PA probe 2 (Figure 2.19). This suggested to us that while 1 was capable of labeling
proteins it was relatively nonspecific and had little to do with the hydroxyl headgroup meant to
imitate natural DAG.

Lipomimetic DAG and PA studies using benzophenone probe 5
Much of the optimization efforts were with early probes that made use of benzophenone
crosslinking headgroups, with click tags also included in the headgroups. Problems with
nonspecific labeling, as discussed already, continued to undermine the utility of ester/ether linked
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Figure 2.24: A gel experiment comparing lipospecific use of an amide-linked bifunctional
DAG probe with a lipomimetic DAG study. We were hopeful that DAG probe 1a with an
amide linked bifunctional headgroup could selectively label proteins in a lipospecific manner.
As can be seen, the amide linked DAG probed was unable to crosslink and enrich PMPs.
Protocol B.
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Figure 2.25: Fluorescent image of a lipospecific study using amide-linked DAG probe 1a.
PA was used as an anionic binding cofactor. No labeling was observed. Protocol B.

benzophenone probe 5 even when we went back and applied optimal experimental conditions, as
can be seen by the gel study represented in Figure 2.26.

Lipomimetic studies comparing the lipid affinities of HIV capsid protein (CA)
CA self-assembly is crucial for integrity of the HIV virus.242 Recent AFM experiments have
suggested that protein-lipid interactions between the capsid proteins and the viral envelope control
the assembly of CA,237 while earlier studies had already suggested CA has affinity for anionic
lipids such as PA and PS.238 In Figure 2.27 we have one of our early CA studies using PS before
we implemented the SDS treatment step. Uneven protein loading lane to lane can be observed in
the stained gel image. Least protein content is present in the lane with treatment liposomes
containing the most PS (P8), despite this the labeling by these liposomes was most intense.
We optimized CA studies using PA. PA is cheaper than PS and exerts its effects at lower natural
percentages than PS, therefore PA was a logical choice for a chase lipid in optimization studies.
We began with 2 μL of SDS during the SDS treatment, by the time we increased it to 6 μL we
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Figure 2.26: Fluorescent image of a lipomimetic study using GP 5. This study was in
duplicate with 5 at 2, 4 and 8 % of the membrane (no chase lipid) and at 2 and 4 % with chase
lipids (DAG or PA at 15%). Results are like those from Protocol B studies where labeling does
occur but seems to be indiscriminate, bands are broad and difficult to define and introduction
of anionic chase lipids (i.e. PA) lead to lane-darkening. Experimentation performed at TSRI.
Protocol A.
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Figure 2.27: Lipomimetic PS study of CA protein. A pre-optimized Protocol B experiment is
shown with generic probe 5 to screen CA affinities. P8 (80% PS) intensity is significantly higher
despite less protein entering the gel as can be seen in the coomassie-stained images to the right
of the fluorescent images. Protocol B. No sonication.

were pleased to have fixed the uneven protein loading observed in Figure 2.27.
CA demonstrated a much more predictable and repeatable affinity for PA (Figure 2.28) than it
did for PS, which was confirmed when we repeated our CA studies with PS under more optimal
conditions (Figure 2.29). Because PA is more anionic than PS, this is easily reconciled with what
was previously understood about the HIV viral capsid.238
It was suspected that CA’s affinity for PA and PS was due to electrostatics. To test this, we
screened CA for DAG affinity, as DAG carries no charge at physiological pH. Indeed, as seen in
Figure 2.30, DAG did not seem to increase or decrease CA’s affinity for liposomes incorporated
with natural DAG. This can be justified not only by electrostatics, but also by the different cone
angles of PA and DAG, given that PA-binding proteins have demonstrated curvature dependent
membrane docking.9 Lipid-specific perturbations to membrane geometries are a crucial natural
phenomena in terms of lipid signaling and lipid-dependent vesicular communications in biological
contexts. The lipomimetic approach likely produces protein hits that vary not only because of the
headgroups present, but also because of membrane topography and shape.
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Figure 2.28: Lipomimetic PA study of CA protein. HIV capsid protein CA is recruited to
liposomal membranes more intensely as PA composition rises from 0 to 16%. Florescent band
intensity was measured using imageJ software and error bars are standard error for the two
replicates shown. Protocol B. No sonication
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Figure 2.29: A lipomimetic PS study with CA protein. In the fluorescent image (left),
replicates to the right indicate CA affinity for PS while replicates to the left show inconsistent
PS-recruitment of CA to the membrane. Protocol B. No sonication
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Figure 2.30: A lipomimetic DAG study with CA protein. As can be seen in the fluorescent
image on the left, DAG had no effect on CA recruitment, a significant departure from the results
of PS and PA experiments screening CA affinity. Protocol B. No sonication
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2.4: Future work
Our initial goal was to discover new protein-lipid binding interactions. As such, liposomal
AfBPP culminating with MS to identify selectively labeled bands will be the ultimate application
of our platform. Protocol A experiments that finished with biotin click reporting at TSRI and
passed to Kenneth Lum for avidin-based purification and analysis by MS. These studies generated
data with enough protein hits to warrant analysis. Pending Mr. Lum’s analysis, replicate MS
studies will commence to complete this project. During the MS studies at TSRI, we aliquot a
portion of the sample and click to a fluorophore to separate by SDS-PAGE. Figure 2.32 contains
the fluorescent gel image representative of the MS data being processed at TSRI. Liposomal
samples went up to 8% DAG, based on previous data (Figure 2.12) suggesting this biologicallyrelevant DAG concentration was sufficient to bring about lipid-specific labeling. Probes are
incorporated at 8%, including DAG probe 3, which can be seen in the left lane labeling roughly
the same bands as corresponding generic probe 7. This suggests the lipospecific studies in these
Hek cell lysates are not nearly as effective as the lipomimetic study. In Figure 2.31, ‘H’ indicates
heavy cells that are isotopically labeled so that labeled proteins in UV-positive samples may be
distinguished from light cells (‘L’) used for the UV-negative samples. The use of H and L cells
creates resolution on the MS chromatograph that insures only probe-specific labeling is identified.
Best Group member Adam Carr also tested his probes administered non-liposomally in
corresponding MS experiments with aliquots also represented in the fluorescent gel image in
Figure 2.31. To get his probes into solution, Mr. Carr required probe-specific combinations of
DMSO, alcohols and water. Interestingly, the ionically-charged PA probe 4 did not label nearly as
intensely as DAG probe 3, and 3 exhibited significantly more labeling than in the background lane
of generic probe 7. This result differs from the liposomal application of these lipid-specific probes,
implying that free-probe administration is indeed a much different experimental platform. The
membrane-context and consistency of probe solvation-conditions is an attractive feature of the
liposomal application, however the use of these probes non-liposomally can also be considered an
avenue for future work. During our time at TSRI, Mr. Carr and Mr. Lum had success feeding freeprobes to live cells. However, I observed no labeling in tandem liposomal live cell AfBPP studies.
Our current perspective is that protein discovery in cell lysates is the ideal application of the
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Figure 2.31: Fluorescently labeled aliquots from MS studies at TSRI. Liposomal treatments
are indicated, as well as heavy (H) and light (L) cells. Dark smear due to over-abundant signal
in the 8% DAG lipomimetic lane. Protocol A.
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liposomal platform, however optimizing conditions for live-cell studies is yet another potential
direction of liposomal AfBPP.
In regards to liposomal AfBPP MS experiments that followed Protocol B. Natalie Sadler at
PNNL did the avidin purification for these samples and reported solvation issues that translated to
too few protein hits, rendering the data insignificant. We reasoned this was a result of either excess
lipid content or residual detergent from the SDS-treatment. Either way, this was something we
overcame by switching to Protocol A, which raises probe concentration slightly to lower total lipid
content considerably.
We have relied on the expertise and instrument-access of other labs for the mass spec portion
of this project. Using heavy and light cells in biotin pull-down experiments helps to avoid false
positives, but it also limits the capacity for this platform to be high-throughput. Currently, we are
adding a step after the photocrosslinking where samples are passed through a size exclusion
column (SEC) so that only proteins bound to the membrane are carried through. SEC makes use
of polymeric dextran gels called sephadex that elute vesicles immediately, fractionates
macromolecules, and traps small molecules in the column media. Fractionation depends on the
size of the sephadex gel media, which ranges from g-10 to g-200 with larger numbers representing
larger pore sizes and retention or fractionation of larger molecules.

SELPE
SEC-based liposomal protein extraction (SELPE) was conceived to create meaningful data from
MS instruments at our immediate disposal. SELPE allows us to isolate resolved protein fractions
unique to each liposomal treatment type. If successful, this will expedite protein discovery by
illuminating avidin purification and allowing more accessible instruments to analyze our samples.
Theoretically, crosslinked proteins are bound because they adhere to a stable membrane surface,
thus the crosslinking reaction should not result in additional membrane perturbation. Before the
disruption of the liposomes (by adding the highly organic click mixture in Protocol A or the SDS
treatment in Protocol B), the labeled proteins are a part of the larger liposomal superstructure.
Thus, they may be separated by size from non-bound proteins. SEC is an established means to
separate liposomes from smaller aqueous components of the extraliposomal matrix, which we have
used prevoiusly.148 Isolated SEC fractions are desalted and free of click-reactants and non-labeled
94

proteins. If proteins are indeed recruited to the membrane based on liposomal treatment type, then
we may digest these fractions directly and test them by mass spec to see which proteins are
selectively enriched (based on the protein content in background fractions). In lipomimetic studies,
this would be done by subtracting protein hits of generic probe-only liposomes from the protein
hits from probe liposomes with chase lipids. For lipospecific studies, this would involve
subtracting the protein hits from generic probe-only liposomes from lipid-specific probe
liposomes. An aliquot of tested fractions is saved for click-enrichment and visualization in gel. For
SELPE applications, visualization may use clickable probes and fluorophores, or non-clickable
(crosslinking only) probes and gel staining since SELPE relies on inequitable protein content to
qualify labeling.
Figure 2.16 shows successful Protocol A application of SELPE using sephadex g-200 beads
swelled in 1x PBS and pre-treated with PC-only liposomes to prevent liposome retention. During
this trail run liposomes were formed to 600 nm using 1 freeze-thaw and sonication. Since then, we
have experimented with 10 and 5 freeze thaws and in both instances the labeling disappears. DLS
confirmed that these liposomes were 150 nm and 300 nm respectively, and thus liposomal-protein
complexes were not large enough to elute through the relatively large sephadex 200 medium.
SELPE conditions are still under optimization, more experimentation with larger liposomes and
smaller sephadex beads will determine how best to apply this promising addendum to our
liposomal AfBPP. To aid in SELPE development, crosslinking-only probe 20 was synthesized via
the facile scheme presented in Figure 2.32.

Figure 2.32: Synthesis of crosslinking-only benzophenone lipid 20. This simple functional
lipid is being used to optimize SELPE conditions. Data not shown.
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Our first SELPE studies made use of 20 to liposomally screen t24 human carcinoma cell extracts
and protein content of fractions was determined by Bradford assay. Figure 2.33 has an example of
one such optimization study, where the amount of protein eluted in fraction 2 was amplified by
the presence of crosslinking lipid 20. This study used g-70 medium and SUVs created by
sonicating for 20 minutes. Later fractions from the study in Figure 2.33 began to fractionate
proteins too large to be retained on the the g-70 media, demonstrating the ability of liposomes to
usher through captured membrane proteins before the sephadex gel begins to separate proteins
based on inherent size.
We will continue to optimize SELPE as it is envisioned to be an elegant extension of the
liposomal protein profiling platform presented herein. As such, SELPE may one day be applied to
any of the other possible applications of our platform. Such applications include the study of other
signaling lipids or combinations thereof, as well as the anchoring of peptides, carbohydrates or
other molecules on our liposomes to screen protein interactions and/or gauge the feasibility of LDS
targeting moieties.

Discussion
As it stands, this liposomal AfBPP platform could translate well to biochemical investigations
of molecular membrane partitioning, the study of biomedically engineered liposomes tailored to
clinical applications, or any other number of relevant studies geared at assessing bilayer behaviors
and interactions. Variations in natural membrane context will also be interesting to investigate by
the lipospecific approach to determine if more labeled bands are produced by DAG probe 3 with
the addition of binding cofactors other than PS, such as PA, SM, or additional calcium content. It
will also be interesting to see if GUVs label differently than the LUVs we have studied thus far.
Once confident MS protein hits are garnered via our collaboration with the Cravatt Lab at TSRI,
or by SELPE, the promise already demonstrated by this platform will grow considerably.
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Figure 2.33: SELPE data. Protein content from fractions 2 and 3 (F2, F3) from SECs
following incubation and crosslinking in T24 human cancer cells (H) using benzophenone
probe at 4% (BP) or 0% (C) of PC SUVs. G-70 media was used and swelled in 1x PBS
augmented with C liposomes to .5 mM [lipid]. Elution used 1x PBS through 2 mL of g-70 beads
in glass mini-columns with .8 cm diameters, collecting 100 μL fractions.
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CHAPTER 3: TARGETING NANODRUGS USING NATURAL
SIGNALING LIPIDS
3.1: Introduction
This project was made possible by a collaboration with the vascular research lab (VRL) of Dr.
Deidre Mountain at the University of Tennessee Graduate School of Medicine in Knoxville. The
principal aim of the experimentation described in this chapter is to specifically increase the cell
association and subsequent cargo delivery of an LDS using DAG and/or PS. Our collaboration
with the VRL began with development of a novel liposomal nanocarrier to treat the cyclic
degeneration of arterial tissue following vascular injury.144 The VRL’s original project was headed
by Trey Fisher and is described as background for this chapter’s titular project.
Figure 3.1 represents what we have gleaned from this project thus far, which is that DAG and/or
PS potentiate the cell association of a PEGylated lipoparticle (PLP) already functionalized with a
stearyl octa-arginine, (stearyl-R8) cell penetrating peptide (CPP). Cell association refers to the
retention of liposomes either by adhering to cell surfaces or entering the cells, such that treatment
liposomes are not washed away after incubation. Differential lipid expression is well-established
in cells and based on observations from work described in chapter 2, we posit that signaling lipids
present a simple solution to the complex problem of actively targeting LDSs. Nonetheless,
tailoring the natural signaling lipid content of liposomes to generate specificity and increase
delivery efficacy remains largely unexplored.
Some studies have broached this concept, such as experimentation with raft-like LDSs for HIV1 treatment.137 DAG and PS have both been widely studied for their ability to promote fusion
between vesicles.23, 241 Added fusogenic tendencies could be an ancillary benefit to incorporating
DAG and/or PS in LDS architectures. PS is envisioned to work electrostatically, given its negative
charge, while DAG is known to be a key factor in promoting vesicular communications that require
fission and fusion of smaller lipid vesicles sent intra/extracellularly or at synaptic gaps.20, 22, 69 At
the least, increased fusogenic behavior of liposomes with elevated DAG/PS content should be
considered a contributing variable to the cell association studies described herein. However,
increased fusogenic properties inherent to the liposomes cannot account for cell-type specific
trends in association. Lipid-protein and lipid-lipid interactions between liposomes and cell surfaces
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Figure 3.1: A schematic representation of how the addition of DAG and/or PS potentiates
the cellular association of an octa-arginine (R8) cell penetrating peptide (CPP)functionalized liposome. Gray membranes (bottom of image) represent cell surfaces.
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are the leading hypotheses to explicate the dose-dependent increases in association of DAG and/or
PS-containing liposomes that occur disparately between types of cells/LDS formulations.
Before delving more deeply in-to the experimental design and results of lipid modifications to
the R8-PLP, we will first present the requisite background. A brief review of active targeting will
be followed by a summary of the VRL’s previous work to develop the R8-PLP delivery system
before lipid modification.

Actively targeting nanocarriers to specific cell types
Active targeting involves rationally engineering nanocarriers to control cell preferences. LDSs
may display small molecules or peptides on their surfaces that home them to target tissues. This is
accomplished by exploiting abnormalities unique to diseased tissues, most commonly tumor
microdomains. Other target tissues with specific cellular affinities may be targeted, such as the
liver. For example, the asialoglycoprotein receptor is a glycoprotein found only on mammalian
hepatocytes that binds selectively to galactose residues, and this relationship has been exploited
by liver-targeted galactose-decorated nanoparticles.243 Carcinomas remain the most commonly
targeted types of diseased cells due to aberrant expression of certain cell surface receptors and
expression of modified proteins unique to cancerous cells.244 Active targeting molecules include
monoclonal antibodies, antibody fragments, single chain variable fragments, aptamers, proteins,
peptides, aptides, vitamins, carbohydrates, glycoproteins and other small molecules.7
Proteins are the most commonly used active targeting tools. For example, the cyclic arginineglycine-aspartic acid peptide (cRGD) is a commonly used targeting motif that increases
nanocarrier delivery to tumors.245 Breast cancer cells are among the most studied targets of
functionalized nanodrugs and significant research has gone into the active targeting of breast
cancers. A few examples include progesterone, HER2 antibodies and estrogen, which have all
been used to target cell surface receptors that are overexpressed or unique to breast cancer
tissues.246 Mucin-1 (MUC-1), a DAG-binding protein mentioned in chapter 1, is overexpressed in
breast cancers as well and can be targeted using a monoclonal antibody called hCTM01,247 as well
as other MUC-1 specific aptamers.248 Breast cancers also present abnormally high numbers of
estrogen receptors on their membrane surfaces, which may be targeted by tamoxifen.249 Tamoxifen
is closer in size to sterol hormone targeting groups (progesterone and estrogen) than it is to protein
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targeting molecules.
Sterol hormones used to target LDSs are technically examples of lipids used in active targeting.
This general distinction does not support the glycerophospholipid-based strategy we explore
herein, however, the ability of small molecules to impart selectivity to bilayer-based nanodelivery
does. Folic acid (FA) is a common example of a small molecule targeting entity,250 folate receptors
are overexpressed in many tumor types (including breast cancer) due to their need to grow
rapidly.251 Sigma-1 and Sigma-2 receptors, which may be targeted by anisamide (a small molecule
with affinity for sigma receptors),252 are overabundant on rapidly spreading cells such as metastatic
tumors.253 The success of relatively small targeting entities like anisamide and FA lends credence
to the hypothesis that if the headgroups of lipid constituents within LDS bilayers are varied, then
cell association of said LDSs will vary as well, dependent on cell type.
There are many other active targeting strategies, several of which have been inspired by the
integrin family of proteins;162, 250 αβ integrins are transmembrane glycoproteins observed in greater
abundance in the membranes of tumor cells. Tumor abnormalities are not the only means by which
we target cancer cells. The vasculature around target sites may also be targeted by LDSs. Eselectin, an adhesion molecule selectively expressed by inflamed or cancerous blood vessels, has
demonstrated promise as a target for controlling metastasis of cancer cells through
nanotherapies.254 Inflamed vasculature sites have also been targeted by a peptide recognized by
vascular cell adhesion molecule-1 (VCAM-1). VCAM-1 is an often-targeted receptor unique to
activated endothelial cells, which may be exploited to deliver drugs that inhibit endothelial cell
adhesion and function.255
PS is the lone example of a rationally selected natural lipid to build actively targeted liposomal
architectures. PS can be used to target liposomes to macrophages,256 which are drawn to PS when
flipped to outer-leaflets of apoptotic cells. Apart from this example, lipid signaling has not been
used to target LDSs, to our knowledge. Altering bilayer lipid profiles to selectively increase
ligandability to target cells is an intuitive strategy since many cell-surface proteins are associated
with specific arrays of lipids, as detailed in chapter 1. Historically, lipid profiles of LDSs are varied
only to maximize stability, increase circulation time and, in doing so, potentiate passive targeting.
Examples of successful deviations from traditional PC-vesicles include the inclusion of PG, PE
and the cationic lipid dioleoyloxypropyltrimethylammonium (DOTAP).159 DOTAP is essentially
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Figure 3.2: A cartoon depiction of active targeting. A liposome displays a targeting molecule
(blue) with preference for a cell surface receptor (red) overexpressed at the target cite.
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dioleoyl PC, without the phosphate group, but rather a cationic trimethyl ammonium at its sn-1
position. SM may also be exchanged for PC to create SM + cholesterol liposomes, termed
Optisomes®,257 which are well-established alternatives to PEG-PC liposomes for extended
circulation, evasion of the RES, and passive delivery of drug cargo.167 Other lipid add-ins to LDSs
include fatty glycerides such as triolein or tricaprylin, which afford opportunities to control LDS
stability for specific applications.170-171 PG, PE and triglycerides are similarly incorporated as
favorable structural components,166, 168 but not for their abilities to increase cellular association of
LDSs. To our knowledge, DAG species are unexplored as structural or functional components of
liposomal nanodrugs.
Active targeting, as defined here, refers to the exploitation of molecular relationships to add
specificity. Liposomal nanocarriers may also increase their efficacy in other ways. Modifications
to promote release will be discussed in chapter 4, along with fusogenic liposomes. LDSs can be
imbued with virus-like fusogenic capabilities by melding regular liposomes with viral particles,
creating nanodrugs that can target and fuse with tumor cells, increasing delivery efficacy.258 In
fact, the protein-driven mechanisms of viral adhesion and cellular entry were the impetuses for
CPP-use in nanocarriers. CPPs can be conceived as active targeting in some instances. However,
as active targeting has evolved to create unprecedented specificity, CPPs are not always
discriminate enough to be considered as such. Nonetheless, the viral-like cell-entry properties they
bestow upon LDSs provide a crucial advantage for emerging nanotherapies.

Cell penetrating peptides
Trans-activating transcriptional activator (TAT) was discovered in 1988 from HIV-1 and is the
original CPP.259 CPPs are cationic and small (40 or fewer amino acids) and are occasionally called
membrane translocating sequences, protein transduction domains, or Trojan peptides. Arginine
and lysine are the most common amino acid links in CPP chains.260 Arginine’s guanidinium moiety
is crucial to the ability of cationic CPPs to bore through the plasma membrane and drag their
nanocarriers into the cytoplasm.261 Extracellular alkalinity exposes deprotonated fatty acids on the
outer leaflet of cell membranes, which attract the guanidiniums. This ionic binding triggers bilayer
insertion, thereby creating a temporary toroidal pore. Peptide diffusion on the surface of the pore
ushers it to the acidic cytosolic matrix where protonation of fatty acids allows release of the CPP,
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and the vessel.261 This is but one possible mechanism of CPP entry and, although this mechanism
fits with the CPP used in the work described in this chapter, it should be noted that there are 1,000+
CPPs with a litany of possible cell entry mechanisms. Other entry mechanisms may center on the
nanodrug system or target cell, rather than the peptide itself.262, 263 Mechanisms aside, CPPs are
useful for allowing LDSs to cross membranes and achieve intracellular delivery with reduced
endosomal escape.
The research described in this chapter makes use of a cationic polyarginine CPP called octaarginine (R8) with a lipid anchor (stearic acid) for anchoring to our LDS membrane. Stearyl R8,
presented in Figure 3.3, has increased the efficacy of several nanotherapies in addition to the LDS
already reported by the VRL,144 discussed next. For instance, R8 has been applied to increase
delivery of a viral-like lipid/polymer hybrid genetic nanotherapy to mammalian neurons.264
Because polyarginine CPPs are not discriminate, much research has gone into finding out ways to
increase the selectivity of CPP-guided nanocarriers.265

An R8-LDS for treating vascular disease through gene silencing
The VRL has developed a novel genetic nanotechnology for the attenuation of peripheral
vascular disease (PVD) through RNA interference (RNAi).144 Endovascular interventions are
widely employed and effective at treating PVD.266 However, intimal hyperplasia (IH) is a common
occurrence following these treatments and can induce restenosis (narrowing of the blood vessel),
which demands a follow-up endovascular intervention.267 Secondary endovascular interventions

Figure 3.3: A stearyl octa-arginine (R8) CPP
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have significantly lower rates of success and higher mortality risks.268 There are more than 200
million PVD cases worldwide269 and this number increases as populations continue to age.
Increasing efficacy of the principal endovascular interventions and developing non-invasive
treatments of IH would improve quality of life for millions of patients and substantially lower
healthcare costs.
Dysfunctional vascular smooth muscle cells and endothelial cells (VSMCs and VECs) are at
the root of IH. Specifically, over-active VSMCs proliferate and cause restenosis while indolent
VECs exhibit delayed recovery at the site of injury. To treat IH, the VRL chose short-interfacing
RNA (siRNA) due to its therapeutic promise as a gene-silencing agent capable of switching off
the cyclic degeneration of vascular tissue when delivered by a nanocarrier.270 RNAi using siRNA
affords the opportunity to silence specific genes, effecting a phenotypic response that ameliorates
pathological cellular behavior such as unchecked growth and cyclic inflammation by ‘turning off’
responsible upregulated proteins.271 siRNA therapies have already been explored for the treatment
of vascular disease and show promise therein.272

Previously, the VRL investigated and

characterized cellular pathways to IH.273-274 Dr. Mountain’s team has studied the role of matrix
metalloproteases (MMPs) in the progression of IH275 and thus settled on siRNA cargo to silence
MMP-2 operation in VSMCs as the target for their genetic liposomal nanotherapy.
Using liposomes as the delivery mechanism for their genetic cargo was an obvious choice as
cationic liposomes (CLs) have had success in vitro shuttling siRNA to target sites to control gene
expression.276 The biocompatibility of CLs (which make use of cationic DOTAP lipids) is suspect,
however, and to advance the clinical viability of liposomal genetic therapies the VRL chose to test
natural PC-based vesicles functionalized with PEG camouflage and a lipid-anchored CPP. The
highly cationic octa-arginine CPP (R8) imbues the LDS with some of the same electrostatic
benefits of CLs while maintaining biocompatibility within the liposomal architecture. The R8
peptide is useful for increasing both adhesion and cellular uptake; it is an effective means to
potentiate passive targeting. R8 is not discriminate enough to be considered an active targeting
agent. Nonetheless, it does increase delivery efficacy substantially.144 There is ample literature
precedent to suggest that siRNA gene silencing liposomes are a viable drug-delivery strategy. At
least four different liposomal siRNA-loaded liposomes have made it to clinical trials over the last
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few years.277 Stable nucleic acid lipid particles (SNALPS) commonly employ cationic and
fusogenic lipids as nanodrug components. Additionally, dual-functionalized nucleic aciddelivering liposomes have been reported that bear both a CPP and a targeting peptide with affinity
to a metalloprotease present in certain tumor types.278
Our research group has experience preparing and characterizing liposomes and because of this
we were approached by the VRL to help develop an experimental design that allowed them to
form a multifunctional PEGylated liposome that maintained high encapsulation efficiency of their
siRNA cargo. Mr. Fisher and Dr. Mountain’s lab quickly advanced the project independently and
our research group remained involved to consult on chemical aspects of their project and to
characterize membrane-derivatization products using matrix assisted laser desorption ionization
(MALDI).
The VRL compared CLs, PEG-only DOPC/cholesterol liposomes (PLP), and PLPs formed with
the stearyl-R8 CPP (R8-PLP). Their work showed that the R8 CPP increased cell association
steadily and dramatically at 10%. Additionally, R8 addition to PLP increased encapsulation
efficiency (EE) of siRNA such that it was the same as CLs. CLs demonstrated significant
cytotoxicity while the R8-PLP and PLP did not.
The R8-PLP delivered siRNA and achieved transfection. Significant silencing was observed of
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as determined by qualitative polymerase
chain reaction (qPCR). GAPDH, known as a quintessential cytosolic glycolytic protein, has come
under scrutiny for its aberrant expression in certain tumors and is suspected to aid in the
proliferation of atherosclerotic plaques.279 Ultimately, Dr. Mountain’s team developed a promising
new genetic nanotherapy using PC liposomes. The VRL’s next goal is to actively target their
liposomes such that siRNA may be selectively targeted to VSMCs with the potential to usher other
therapeutic cargo to VECs.
Many small peptides are capable of targeting liposomes to specific cell types, as exemplified in
Figure 3.2 and discussed in the introduction. This strategy is being pursued by the VRL and has
the potential for potent specificity, although it presents many challenges. The R8-PLP, for
example, already comes equipped with 10% PE-anchored PEG and 10% stearyl-R8 peptide (the
remaining 80% is composed of a 7:3 mixture of DOPC and Cholesterol). Liposomal modifications
that include PEG or peptide headgroups can lead to lateral dispersion on the membrane surface,
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which creates bilayer instability. 20% of total lipid content is already on the high-end of literature
precedent of PEG/lipopeptide content for stable liposomal nanocarriers. To go beyond this could
compromise morphology, consistency and encapsulation efficiency. Another option is to decrease
the R8/PEG content to accommodate additional lipopeptides for active targeting, however this
could decrease circulation time and/or functionality. Additionally, peptide-peptide interactions
between the R8 and potential targeting moieties could jeopardize the system.
Therefore, we were curious to see if lipids such as DAG and/or PS could be used to potentiate
the activity of the R8-PLP. DAG and PS have been formed into stable membranes as high 25%23
and they do not present bulky headgroups that aggravate the membrane with lateral dispersion
forces. The body uses lysosomes and lipidic vesicles to communicate and shuttle cargo both
intercellularly and intracellularly and DAG is crucial to these operations.33, 51 Moreover, tight
control of signaling lipid abundance seems to be crucial for smooth muscle cell function,45, 123 and
there is evidence to suggest that cell-specific proteomes will have preference for certain membrane
compositions.12,
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By taking cues from biology, this strategy aims to make the LDS more

attractive to the target cells.

Experimental design
To test the hypothesis that signaling lipids can be incorporated into LDS architectures to increase
the efficacy of liposomal theranostics, we devised a three-tiered project as outlined in Figure 3.4.
The propensity of DAG and/or PS to increase the association of an R8-PLP to either VSMCs or
VECs was tested first at gradient percentages of individual lipids at 5, 10, 15 and 20% of LDS
membranes. Based on these results, we devised combinatorial LDS formulations that screened for
optimal DAG content when PS content was fixed at 10% PS among all lipid-modified LDS
treatment groups. Prior to combinatorial cell association studies, we tested these mixed lipid LDS
architectures for their ability to efficiently encapsulate siRNA. Finally, qualitative polymerase
chain reaction experiments will assess gene-silencing to quantify delivery of siRNA by DAG/PSmodified LDSs.
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Cell-Association
DAG and PS effects
screened independently
first, followed by
combination studies
Vascular smooth muscle
cells (SMC) and
endothelial cells (EC) both
tested to investigate
selectivity

Encapsulation Efficiency
Encapsulation of genesilencing siRNA cargo
tested along with
consistency of size and
charge.
Liposome formulations
based on most promising
cell association studies

qPCR
Qualitative polymerase
chain reactions are
used to assess delivery
of cargo to growing
cells by measuring
gene-knockdown.

Figure 3.4: Experimental design to test the ability of DAG and/or PS to increase delivery
efficacy of an CPP liposomal nanocarrier (R8-PLP)

Controls
For the first round of cell association studies—before combining DAG and PS into one
liposomes—we included PLP controls which neither had the R8 CPP nor any DAG/PS content.
This was done as an additional confirmation that our results were consistent with the VRL’s
previously reported data suggesting the R8 increased cell association when present at 10% of total
membrane composition. Figure 3.4 presents flow chart for studying the effects of liposome
composition on delivery. Figure3.5 has the molecular structures of all lipids used. Data were
charted as fold increases above liposomes containing R8-stearate but lacking DAG/PS. Each assay
used not only a new batch of cells but also a fresh batch of liposomes to control for variations in
liposome preparation, if present. Negative controls were employed upon treatment whereby cells
received starvation media only (no liposomes). Controls which had signaling lipids but lacked the
R8 peptide were also used to check if the lipids could increase cell association without the presence
of the CPP. Additionally, the VRL has adopted protocols to insure consistent liposomal
concentrations between treatment groups, as detailed in the Methods section.
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Figure 3.5: Structures of lipid constituents used for in LDS formulations. 1,2-Dioleoyl-snglycero-3-phosphocholine (DOPC) is our bulk lipid. Dipalmitoyl DAG and PEG-PE were used.
PS was derived naturally from porcine brain tissue and its most abundant form is shown with
one palmitic and one oleic tail. Rhodamine-PE (Rhod-PE) is dioleoyl. Stearyl-R8 is shown in
Figure 3.3.
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LDS formulations
Figure 3.5 contains all lipid structures used in these experiments. Liposomes were formed by
thin film hydration, ethanol injection and dialysis. Details of liposomal preparation and
characterization are described in Section 3.3, Methods, along with cell culture, association and
encapsulation efficiency assays, and other procedural details. Figure 3.6 contains a table of LDS
compositions tested in our first cell association assays. Combinatorial formulations are presented
in Figure 3.13 alongside the results from their experimentation.

3.2: Results
When natural DAG and/or PS were incorporated at incrementally higher percentages within the
architecture of an LDS with fixed R8, repeatable and dose-dependent responses of increased
association to VSMCs and VECs with trends unique to each lipid and cell type were observed.
DLS data confirm that our liposomes have consistent integrity at 37 °C when they are formed with
encapsulated siRNA cargo. DLS and zeta potential characterization for liposomal formulations are
presented later when discussing the results of our encapsulation studies, as these formulations
contain the genetic therapeutic cargo. siRNA is costly so to conserve resources the cell association
experiments presented first do not incorporate the cargo.
The fluorescent images of VSMCs in Figures 3.7 are consistent with the results of initial cell
association assays (Figures 3.8, 3.9). Encapsulation efficiency experiments proved that our
DAG/PS-modified LDSs retain their ability to secure genetic cargo for therapeutic applications
(Figure 3.12).
DAG-potentiated cell association to VSMCs
As % DAG increases from the R8-only treatment group to R8+20% DAG (D20), an exponential
increase in cell association is observed, as can be seen in Figure 3.8. These results were remarkably
consistent and suggest DAG incorporation into nanocarrier architectures is a worthwhile strategy
for potentiating cellular association. When LDS formulations with potent cell association are fed
to cells at higher molar treatment percentages, there is observable cell damage (data not shown),
which is why we treat with 0.1 mM [lipid] rather than the previously reported 0.2 mM [lipid] in
cell association experiments.144
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% PEG-2000-PE

% R8

% Rhod-PE

% DAG % PS

% PC/Chol (7:3)

PLP

10

0

0.1

0

0

89.9

R8

10

10

0.1

0

0

79.9

D5

10

10

0.1

5

0

74.9

D10

10

10

0.1

10

0

69.9

D15

10

10

0.1

15

0

64.9

D20

10

10

0.1

20

0

59.9

P5

10

10

0.1

0

5

74.9

P10

10

10

0.1

0

10

69.9

P15

10

10

0.1

0

15

64.9

P20

10

10

0.1

0

20

59.9

P20N

10

0

0.1

0

20

69.9

Figure 3.6: Lipid compositions of LDS formulations for initial cell association assays.
These treatment types were selected to incrementally screen the ability of DAG and PS to
increase the cell association of R8-PLPs.
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Figure 3.7: Fluorescent microscopy images showing increased cell association of liposomes
as signaling lipid content goes up. Refer to Figure 3.6 for detailed composition of each
treatment type.
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Cellular integrity is equitable between negative controls, which are treated with buffer only, and
liposomal treatment groups when treating with 0.1 mM [lipid]—as confirmed by bright field
microscopy. However, when we moved to combinatorial studies, as discussed later, we observed
morphological changes in cell membranes in treatment groups with very high associations. A
possible explanation could be that the increased uptake of DAG/PS LDSs leads to incorporation
of DAG and PS into the cell membranes, altering bilayer shape.

PS-potentiated cell association to VSMCs
As the percentage of PS increases from R8 only to 15% PS (P15) a linear increase in cell
association is observed (Figure 3.9). However, at 20% PS the cell association begins to drop back
down. The disparity of these results when compared with DAG treatment groups is intriguing, and
suggests that signaling lipids could present strategic opportunities to tune the associations of LDSs.
An additional control with 20% PS and no R8 (P20N) demonstrated occasional increases in cell
association between replicates, as can be seen by the large error bars for that treatment group.

DAG-potentiated Cell Association to VSMC
Fold Increase above R8

5
4
3
2
1
0
PLP

R8

D5
D10
Treatment type

D15

D20

Figure 3.8: Quantified cell association data from DAG-VSMC experiments. DAG content
increases cell association of R8-PLP liposomes in a repeatable, dose dependent manner that
appears exponential if R8 is treated as zero. Error bars are standard error based on at least 3
replicates.
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Figure 3.9: Quantified cell association data from PS-VSMC experiments. PS content
increases cell association of R8-PLP liposomes in a linear manner to 15% with diminished
returns at 20 %PS. Error bars are standard error based on at least 3 replicates.

Overall, the results of PS studies in VSMCs were less consistent than DAG studies. This may
imply different mechanisms of increased association between DAG and PS. In any case, the
consistency of DAG-promoted association is an attractive feature when considering the clinical
translatability of this strategy.

DAG-potentiated cell association to VEC
Results presented here are based on only two replicates thus far. Thus, it is too soon to
confidently ascertain quantifiable information from these studies. We can qualitatively state that
the DAG-potentiated cell association in VECs (Figure 3.10) is more like the threshold type trend
we observe up to 15% PS in VSMCs (Figure 3.9), rather than the consistent trend we observed in
VSMCs when treating with DAG (Figure 3.8). The changes in association are less consistent
between the first two VECs replicates than observed with VSMCs studies, however the
inconsistency does not belie the fact that VECs also have some clear sensitivity to DAG inclusion,
especially at 20% DAG.
The data so far suggest that DAG has positive effect on LDS association in both cell types.
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Figure 3.10: Quantified cell association data from DAG-VEC experiments. DAG content
induces a much different response than observed in VSMC. Error bars are standard error based
on 2 replicates.

Discriminate increases would be ideal for our applications, but the utility of DAG in nanodrug
architectures to provide universal increases in delivery efficacy is still a worthwhile discovery. If
the mechanisms of increased association do indeed vary between these cell types, DAG (at certain
percentages) could afford opportunities for active targeting. Ideally, DAG/PS will eventually
present opportunities to selectively usher gene silencing material to VSMCs to prevent restenosis,
while leaving VECs free to convalesce until they can return to healthy function. More studies are
needed in VECs to determine if DAG alone or DAG/PS can be used to selectively target one cell
type over the other.

PS-potentiated association to VEC
As can be seen in Figure 3.11, PS has already shown more consistency in its ability to potentiate
association of the R8-PLP to VEC, although only two replicates are presented. This is markedly
different than the response DAG elicits from VECs thus far. Moreover, it is disparate from the
response elicited by PS in VSMCs, especially the P20 sample that saw a decrease in association
when compared with the trend up to the P15 treatment group in VSMCs (Figure 3.9). In VEC,
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however, the P20 treatment group continues the steady increase observed as % PS increases
(Figure 3.11).
Here, the data again suggest that PS and DAG are capable of imbuing LDSs with tunable
targeting capabilities. In the case of vascular injury, the opportunity to stimulate languid VECs
while silencing MMP-2 in proliferating VSMCs could greatly increase the treatment efficacies of
IH following PVD interventions. Again, more studies are required, but there appear to be disparate
trends between DAG and PS as we move from VSMCs to VECs. However, the possibility has yet
to emerge where a PS-LDS could selectively target only one cell type while a DAG-LDS could
target the other. The differences we have observed thus far between cell types is in consistency;
we have yet to demonstrate the selectivity we aim to achieve. Nonetheless, the utility of these
lipids to increase treatment efficacies is already apparent, even at this early stage of
experimentation, and the results so far suggest that continued exploration of lipid-guided LDSs
could uncover formulations that can indeed target one cell type over the other with consistency.
Moreover, batch-to-batch consistency among LDS formulations is a major hurdle for establishing
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Figure 3.11: Quantified cell association data from PS-VEC experiments. Increases in
association appear more consistent than with PS treatments in VSMC, and more pronounced
than DAG treatments in VEC. Error bars are standard error based on 2 replicates.
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a clinically viable nanodrug. With this in mind, we have shown that PS is a more appropriate
targeting lipid for VECs, while DAG demonstrates more clinical potential for applications for
LDSs targeted to VSMCs.

Encapsulation efficiency of optimal DAG/PS liposomes
The demonstrable increases in association of our vesicles by adding DAG and/or PS was a
promising result at the outset of our project, however the R8-PLP must retain its ability to
encapsulate genetic cargo when the signaling lipids are added, if they are to be a clinically viable
active targeting strategy. Therefore, encapsulation efficiency studies were performed on the
following liposomal formulations: D10P10, D15P10, D20P10, D20, P10 and R8 (Figure 3.12).
The details of liposome composition are provided in Figure 3.13. When we moved on to
combinatorial cell association studies we incorporated a formulation with 20% DAG, 10% PS and
no stearyl-R8, termed DPN (Figure 3.13). Encapsulation efficiency was measured by including
siRNA cargo in the buffer used for ethanol injection during liposome formation, followed by
dialysis to remove unencapsulated siRNA. Then, liposomes were ruptured using detergent and
siRNA content was quantified. Detailed experimental procedures are included in Section 3.3:
Methods.

% siRNA encapsulated

Encapsulation Effeciency
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LDS formulation
Figure 3.12: Encapsulation efficiency results. Combinatorial formulations as well as D20
and P10 retain acceptable encapsulation efficiencies when compared with the R8-PLP (R8).
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As can be seen in Figure 3.12, we found that with PS constant at 10% there was no reduction
in encapsulation efficiency up to 10% DAG and minimal, inconsistent reductions at 15% and 20%
DAG. Moreover, the D10P10 liposomes encapsulated the siRNA more efficiently than the R8
liposomes while D20 and P10 had insignificant increases coupled with less consistent results.

DLS size and zeta potential studies of optimal DAG/PS formulations
Liposomes screened for encapsulation efficiency were also tested by DLS to measure average
size, polydispersity index (PDI) and zeta potential. Figure 3.14 shows that our liposomes have
consistent size profiles around 50-70 nm in diameter. Interestingly, 20% DAG appears to be more
tolerable when PS occupies 10% of the membrane as well. Sizes and PDI rise with the addition of
DAG and/or PS, diameter reliability is within tolerable ranges for such a complex LDS. Moving
forward, it may be worthwhile to lower the percent of PEG or R8 to decrease nonbilayer membrane
content, and test such formulations for cell association and encapsulation efficiency.

Combinatorial cell association studies in VSMCs using DAG and PS
Once we confirmed that our combinatorial DAG/PS LDS formulations encapsulated cargo well
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Figure 3.13: Combinatorial LDS treatment groups. All formulations except the DPN control
group and D5P10 were screened for encapsulation efficiency, size, and zeta potential before
moving on to combinatorial cell association assays
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Figure 3.14: Average diameter of DAG/PS LDS formulations. Error bars are standard error
from at least 3 replicates

and had acceptable zeta potentials and size consistencies, we moved on to test these formulations
using the same cell association procedure described previously. Figure 3.16 shows that the D5P10
formulation yields a remarkable increase in cell association above the R8 only formulation when
compared to previous cell association assays. Cell association drops with D10P10 but then
continues to go up and peak where we expected it to with the D20P10 formulation.
D5P10 liposomes have a PDI consistently below 0.2 (Figure 3.14), which is also an attractive
feature of this formulation. Furthermore, fluorescence microscopy demonstrated some cell damage
with combinatorial formulations high in DAG (Figure 3.17). Therefore, the D5P10 liposomes are
a very exciting treatment group to carry forward with to qPCR studies as we can achieve significant
increases by incorporating low percentages of our type 1 signaling lipid, DAG.

Future work: Cargo delivery profiles by qPCR & cytotoxicity assays
This project has not yet progressed to studying the ability of our formulations to deliver siRNA
cargo, achieve transfection, and silence MMP-2 activity in VSMC. These studies are imminent,
and we are excited to proceed with this project and present our findings so that liposomal nanodrug
architectures for various applications can begin to test the effect of incorporating signaling lipids.
Based on previous work by the VRL and correlations between cell association and gene
transfection, we anticipate that our novel LDS formulations will achieve significantly higher
deliver profiles than R8-only controls.
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Figure 3.15: Average PDI of DAG/PS liposome formulations. Error bars are standard error
based off at least 3 replicates.

Additional future work includes cytotoxicity assays to confirm that our LDSs do not kill cells.
Based on microscopy evidence, we are confident they will not. Cells are checked under a bight
field microscope consistently during growth and treatment and appear healthy. VECs will also
continue to be subjected to cell association assays with the initial LDS formulations in Figure 3.6,
and once that is complete they will be screened with the combinatorial formulations found in
Figure 3.13, just as VSMCs were.

Discussion
As alluded to previously, the idea that DAG and other signaling lipids could be used in
liposomal architectures to increase nanocarrier efficacy was conceived during the work described
in Chapter 2. The literature review in Chapter 1 lays out various roles that DAG plays in
pathological cells. This raises the possibility that DAG’s mechanism of increased cellular
association may involve active targeting of overly abundant proteins selectively expressed in the
injured human aortic cells that have been studied. However, more experimentation in a variety of
tissue types is required to confidently assert that the increased association we have observed is due
to intermolecular activity beyond DAG’s mechanical impact on supramolecular assemblages. If
DAG was found to have little or no impact on the cell association of LDSs when treating healthy
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Figure 3.16: Cell association data using combinatorial formulations of DAG/PS. Error bars
are standard error based on at least 3 replicates.

tissues from other parts of the body, this would support the notion that DAG’s protein affinities
were at play in the results we presented here. If the experimental trends presented above are indeed
due to membrane perturbations brought about by DAG’s type 1 lipid geometry, this project still
demonstrates that DAG, PS, and other signaling lipids present solutions to increasing the cellular
association of liposomal nanocarriers.

3.3: Methods
Liposome formation and characterization
Lipids (Figure 3.5) were purchased from Avanti Polar Lipids (Alabaster, AL), stearyl-R8 was
purchased from LifeTein LLC (Somerset, NJ). Lipids were combined as indicated in Figures 3.6
and 3.12 by dissolving in chloroform and mixing in 1 dram glass vials and then removing solvents
under a stream of nitrogen to create lipid films. Liposomes were then formed by ethanol injection
as previously reported.281 Lipid films were resuspended in 200 μL of pure molecular grade ethanol
and mixed for 30 minutes at 40 °C . Ethanolic lipid solutions were then injected dropwise into 10
nmM tris-HCl (pH 8) under constant vortexing. Liposomes were then purified from ethanol via
overnight dialysis in pure water at 4 °C using 1 mL 300 kD Float-A-Lyzer™ G2 dialysis devices
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Figure 3.17: Representative fluorescent images from combinatorial DAG/PS cell
association assays in VSMC
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(Spectrum labs, Rancho Dominguez, CA). A single pure water exchange midway through dialysis
ensured efficient purification from residual ethanol. After dialysis, the final volume was measured
and used to determine treatment volumes for cell association assays such that all samples received
equimolar lipid content. Liposomes were extruded to 100 nm using polycarbonate membranes
Nanosizers™ (T&T scientific, Knoxville, TN), stored at 4 °C and used within 48 hours.
Average size, PDI and zeta potential for of every LDS treatment type was measured in triplicate
by dynamic light scattering (DLS) and electrophoretic mobility on the Zetaizer Nano ZS
instrument (Malvern Instruments Ltd, Worchestershire, UK).

Cell culture
Cryopreserved 49-year-old male tissue samples were purchased from LifeLine Cell Technology
(Walkersville, MD) for culturing of human aortic smooth muscle cells (HASMCs). Cells were
grown in T75 flasks and then plated at 1.5 × 105 cells per well (6-well plate) for cell association
experiments. Cells were grown to ~80% confluency in VascuLife growth medium composed with
VascuLife Basal Medium and VascuLife smooth muscle cell supplement kit with gentamicin and
amphotericin (LifeLine Cell Technology). Incubation was performed at 37 °C under 5% CO2 with
95% humidity until cells reached ~80% confluency. Before liposomal treatment, cells were made
quiescent by treating overnight with Dulbecco's Modified Eagle Medium (DMEM, Thermofisher
Scientific) with gentamicin and amphotericin.

Measuring cell association
Lipid-dependent cell association was measured using a set of standard procedures previously
adapted by the VRL to confirm R8-dependent cell association. The assay involves the formation
of liposomes with 0.1% rhodamine-PE, 10% PEG and 10% R8 among positive controls with the
addition of signaling lipids accompanied by a reduction in PC/Chol content, as depicted in Figures
3.6 and 3.12. 80% confluent cells were treated with 0.1 mM [lipid] liposomes in DMEM. After 24
h treatment, cells were washed three times in PBS, lysed with 1 mL of 1% Triton X-100, and
centrifuged at 12,000 RPM for 5 min at 4 °C to remove debris. Cell lysates (200 μL) were plated
in triplicate in 96-well plates, carefully so as not to contaminate samples with debris. Fluorometric
analysis using a Glomax multi microplate reader by Promega with a 575 nm filter determined
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average fluorescence units for each sample, minus baseline fluorescence of nontreated controls
receiving no rhodamine source within each experimental replicate. Samples were normalized to
the R8-only liposomes to judge fold increase in association as a function of DAG/PS content.
Replicate studies always used fresh batches of liposomes. Fluorescence microscopy made use of
a Texas Red fluorescent filter at 400Χ with 400 ms exposure across all groups.

Measuring encapsulation efficiency
To encapsulate siRNA, liposomes were prepared precisely the same as described previously but
the tris buffer (used during EtOH injection) also contained 50 μg of siRNA (Thermofisher
Scientific, Waltham, MA) and 10 mM CaCl2. Dialysis also included an additional media exchange
(two total) to ensure that all unencapsulated siRNA was removed.
Retention of siRNA after ethanol injection, dialysis and extrusion was quantified using a QuantiT RiboGreen RNA Assay Kit (Thermofisher Scientific). 10 μL of liposomes were digested in 1%
Triton X-100 at 37 °C for 15 min to release siRNA from their aqueous cores. Samples were then
mixed 1:1 with RiboGreen reagent that labels siRNA with fluorescence, and emission was then
measured at 525 nm. A standard curve of siRNA in 1% Triton X-100 was created to qualify the
arbitrary fluorescence units of siRNA released from digested liposomes and thus determine siRNA
concentration. Encapsulation efficiency was then calculated for each LDS formulation as (μg
siRNA encapsulate/50 μg total siRNA) × 100.
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CHAPTER 4: USING SYNTHETIC LIPIDS TO ACHIEVE
LIPOSOMAL FUSION AND CARGO RELEASE

4.1: Introduction
Collectively, a few of the other projects I assisted with during my graduate career fall under the
umbrella of controlled—or ‘triggered’—release. Lipids engineered to respond to target cells or
external stimuli may be incorporated into LDS to create stimuli sensitive nanoparticles (SSNs).
SSN technology, a field the Best Lab strives to be at the forefront of, will be briefly reviewed in
this chapter’s introduction. The review in section 4.1 will include mention of two Best Lab
projects: a photoactivatable lipid trigger activated by UV light to stimulate liposomal release, and
promoting fusion between membranes via synthetic clickable lipids. Section 4.2 will detail how
we confirmed the mixing of aqueous contents as part of our investigation of click-promoted fusion.
Figure 4.1 shows the general strategy of how functional lipids can promote release of aqueous
cargo. Lipophilic cargo can also be encapsulated within bilayers and be selectively released in this

Figure 4.1: A cartoon of triggered release from SSNs. A synthetic lipid (yellow headgroup)
is shown reacting to a stimulus to perturb its membrane environment, allowing for release of
aqueous cargo (star shape).
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way. Just like the active targeting strategies reviewed earlier, very few SSNs make it to clinical
testing and as yet none have passed. Section 4.3 will discuss the future directions of SSNs,
including strategies that take cues from biology for more clinically viable triggered release
platforms.

Existing strategies for controlling liposomal release
Advances towards active targeting are for naught if liposomes succumb to cellular endocytic
pathways or if cargo is degraded lysosomaly prior to being released into the cytosol. To ensure
delivery of encapsulated drug, triggered release strategies have developed two distinct modes of
operation. Passive release makes use of unique cell pathologies at target cites, just like active
targeting. Active release involves engineering SSNs that respond to external stimuli to control
release. Both of these strategies are referred to as forms of ‘smart delivery’.7
Passive release liposomes are triggered to release their contents in the presence of abnormal
pH, temperature, oxidative conditions or other traits characteristic of target tissues, such as unusual
enzymatic activities at tumors. Aberrant enzymatic activity harnessed by passive release strategies
includes the matrix metalloproteases,282 which are the therapeutic targets addressed in the previous
chapter. Passive release stimuli are inherent to the target site, such as the lowered pH 283 and
increased redox potentials of tumors and inflamed tissue.284 Research to capitalize on these
intrinsic differences has created a plethora of responsive liposomes, including pH-sensitive
sheddable PEG coatings so that LDSs drop their camouflage upon reaching target cites with higher
acidity, increasing cellular uptake.285 However, intrinsic differences such as acidity are often
slight, making these strategies promising but challenging to actuate.
Active release platforms, on the other hand, respond to external stimuli. This affords more
control over the location of release. However, reaching the vessels with the stimulus can be
challenging once they have entered the body and accumulated at target sites. External stimuli for
active release include applied heat,286 ultrasound,287 light288 or electromagnetic fields.289
Demarcations between active release strategies are often blurred. For instance, inductive magnetic
heating290 or ultrasound291 can be used to achieve hyperthermic release. No matter the heating
mechanism (be it superparamagnetic, echogenic, or simply applied heat), SSNs exhibiting
hyperthermic release are called thermosensitive liposomes.
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A common thermosensitive strategy among SSN formulations involves tailoring liposomal
architectures with lyso lipids to lower their transition temperatures to heighten heat-sensitivity.292
Lysolipid thermally sensitive liposomes (LTSL) incorporate mixtures of monoacyl and diacyl PC
to create SSNs that respond to thermal ablation brought about by microwave, radiofrequency or
aforementioned heating mechanisms.293 Currently, a thermosensitive SSN, ThermoDox®, has
reached phase 3 clinical trials. ThermoDox® is a LTSL administered with radiofrequency ablation
to stimulate release, but it is also sensitized to microwave or ultrasound heating.294 ThermoDox®
is the only SSN currently under clinicial trials.159
Visudyne®, which was developed well over a decade ago, is a commercially available LDS that
delivers a photodynamic therapy (PDT), which in this case is a light-absorbing synthetic porphyrin
called verteporfin.295 Although IR light triggers the therapeutic agent in this case, the liposomes
(as a delivery vessel) are not being triggered to unload their cargo by the administered light. In
terms of commercially available SSNs that respond to light, there are technically still none. The
promise of light-mediated liposomal release technologies remains unrealized clinically. In general,
the dearth of commercially available SSNs highlights the need for developing more tools for
triggering liposomal release.159
The complex, interdisciplinary nature of SSN development can be a barrier towards their
implementation. Careful biophysical tuning of trigger molecules must coincide with rationally
chosen, well-vetted bilayer counterparts for biomedically engineered responsive LDSs. Moreover,
these endeavors often rely on inorganic, polymer, or synthetic organic chemistry to afford
nanodrug developers the tools they need to control liposomal release. As an example, we will
discuss a synthetic photoactivated lipid developed by the Best Lab.

A photocleavable PC-analog for controlled release of liposomal cargo
This was the principal project of former Best Lab member Dr. Andrew Bayer. I aided his
synthesis of an intermediate compound (full tail acid 4.6, Figure 4.2) used by Dr. Bayer to complete
his lipid nitrobenzyl PC trigger (NB-PC), which displayed promising release characteristics.150
The synthesis in Figure 4.2 was devised by Dr. Best and Dr. Bayer. They chose PC as the trigger
analog for its strong bilayer properties and formed stable bilayer vesicles with 100% NB-PC. Full
tail acid 4.6 was engineered to have a nitrobenzyl entity that is stimulated by UV light to undergo
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Figure 4.2: Synthesis of a photocleavable release trigger. NB-PC, synthesized by Andrew
Bayer of the Best Lab, was used to create an SSN triggered by UV light to release bilayer
cargo. NB-PC exemplifies how synthetic organic chemistry creates tools to break new ground
for LDS functionality.
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cleavage. By coupling 4.6 to LPC, Dr. Bayer created a PC analog that is triggered to turn itself
back into an LPC analog. LPC has strong non-bilayer tendencies. Thus, tail cleavage destabilizes
the membrane substantially, releasing bilayer cargo.
Cleavage of the full tail acid occurs as follows: the nitrobenzyl group absorbs a ~365 nm photon,
exciting the nitro oxygen proximal to its ortho-benzyl neighbor, and causing to react with the
benzylic carbon, promoting cleavage of the bond between the benzyl carbon and the amide-LPC
leaving group. The resultant cleaved tail exists as benzaldehyde with an ortho-nitroso (the paraN-hexyl-phenylamide at the bottom of the tail is unaffected.) Dr. Bayer found that the NB-PC
trigger began to promote release when it was incorporated at as low as 10% of PC vesicles, with
steady increases in release profiles as percent NB-PC went up. Importantly, release controlled by
exposure to UV light, with no background release observed in samples kept in the dark.
To access full tail acid 4.6, we began by capping the amine of 4-(aminomethyl)benzoic acid
(4.1) with trifluoraceticanhydride (TFAA) to create 4.2. We then nitrated the benzene ring using
standard electrophilic aromatic nitration conditions; the slow addition of sulfuric acid combined
with nitric acid created nitrobenzyl 4.3. The amine was freed from its trifluoro acetamide cap using
potassium bicarbonate, and then reprotected with a Boc group to form 4.4. We then coupled the
carboxylic acid to a hexylamine tail to form the bottom of our full tail acid as seen in compound
4.5. The top portion of the full tail acid 4.6 came in the form of an opened succinic anhydride
molecule by first removing the Boc group using trifluoracetic acid (TFA) and then treating with
potassium bicarbonate and succinic anhydride. Dr. Bayer finished the synthesis by coupling 4.6 to
LPC to create NB-PC trigger. Full experimental procedures and characterizations for the synthesis
of full tail acid 4.6 and NB-PC have been reported previously150 and are omitted from this
dissertation.
To measure release of membrane-bound cargo, the Best Lab utilized a nile red-based
fluorescence release assay. Nile red, Figure 4.3, is only fluorescent in aqueous solution when
solvated in a membrane context, and thus can be used to study membrane behavior. Nile red’s
utility is also born if its inherent similarity in structure to hydrophobic drug molecules such as
camptothecin (CPT), as can be seen in Figure 4.3. CPT is a chemotherapy commonly used in
development nanoparticle delivery of cancer drugs.296 The NB-PC photo-trigger demonstrated
highly predictable release properties based on reduction in Nile red signal, which was released
129

Figure 4.3: Structures of Nile red dye and the cancer drug Camptothecin are compared.
Nile red was used as a hydrophobic drug mimic to confirm the ability of NB-PC (Figure 4.2)
to promote release from SSNs upon exposure to UV light.

from the membrane only in response to UV light, only when NB-PC was incorporated into the
membrane.
Clearly, active release strategies have the potential to impart a degree of control beyond that of
passive targeting. While these two strategies strive to achieve similar goals, passive release is an
extension of active targeting and takes its cues from biological phenomena that enable release.
Active release hinges upon external, bioorthogonal stimuli that selectively motivate SSNs to expel
their contents. A related field of controlled release that draws inspiration from both passive and
active release platforms is liposomal fusion.

Inducing membrane fusion using clickable lipids
Ever since artificial membranes were first developed as functional nanoparticles, vesicle fusion
has been explored in relation to liposomal technologies. In biology, lipophilic SNARE proteins
dictate when and how membranes fuse.297 A variety of functional liposomes have emerged that
make use of complementary molecular interactions or electrostatics to promote vesicle
conglomeration, adhesion, and fusion.298 Significant research has gone into unraveling the degree
of fusion and multicompartmental vesicle formation that takes place given various fusion
strategies. However, for fusion technologies to develop clinically viable applications,
bioorthoganality is paramount. Here, we return yet again to click chemistry to discuss an offshoot
of active release where SPAAC can be used to spontaneously fuse liposomes respectively
decorated with clickable azide and alkyne moieties.
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Figure 4.4: STEM images of azido liposomes before and after incubation with cyclooctyne
liposomes.148 Image A shows ~100-200 nm liposomes bearing a lipid-anchored, concentric
circles within membranes indicate collapse of unilamellar vesicles under the stain used for
contrast, occasional aggregation was observed. Image B shows GMV formations only present
when azide and cyclooctyne liposomes are mixed. Aggregation and fusion are readily observed.
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Click chemistry, as discussed in Chapter 1, is a robust platform for the derivatization and
manipulation of liposomes. Dr. Best and former Best Lab member, Dr. Stuart Whitehead, devised
a scheme whereby fluorescent dilution experiments and electron microscopy were used to confirm
SPAAC-driven fusion between azido and cyclooctyne liposomes.148 Clickable liposomes were
formed using synthetic phospholipids with either azide or cyclooctyne moieties anchored to their
surfaces. Clickable liposomes where also pre-formed with lipidic dye molecules to enable Förster
Resonance Energy Transfer (FRET) assays for qualifying intermixing of sibling membranes.
Initially, I advised and aided in liposome formation, DLS and (scanning) transition electron
microscopy (STEM/TEM) to help probe for photographic evidence (Figure 4.4) of increased
vesicle aggregation/fusion in the presence of Dr. Whitehead’s clickable synthetic lipids.

4.2: Verifying mixing of aqueous cargo between fused liposomes
Dr. Whitehead’s FRET and STEM results evidenced fusion events that occurred only when
azido and cyclooctyne liposomes were incubated together. However, said experiments did not
preclude the possibility that inner leaflets were still intact and aqueous cargo was not being
delivered. If a pseudo-fusion event such as this was occurring, covalent linkages between clickable
liposome membranes would have resulted in multivesicular formations with discrete aqueous
compartments. Thus, the possibility remained that Dr. Whitehead’s synthetic clickable lipids had
achieved covalent conglomeration rather than full fusion. Conveniently, content mixing assays can
be performed that verify the rupture of aqueous liposomal cores.241
We suspected full fusion was occurring, as the STEM images in Figure 4.4 suggested the
presence of larger, non-spherical vesicles. Moreover, the four-tailed linked-lipid species formed
upon inter-vesicle click reactions would instantly create exponentially larger headgroups for each
reacting lipid. This would theoretically increase lateral dispersion immensely for each membrane,
destabilizing the bilayers and exposing inner-leaflets. We reasoned that if clickable groups on
inner-leaflets become exposed, the cascade of membrane dissociations would lead to amphiphilic
reorganization into fused vesicles with some degree of multilamellarity and/or multivesicularity.
These vesicles would likely be bilayer liposomes, since at least 50% of our formulations were
bilayer-forming PC, with mixed aqueous cargos. This mechanism could be justified by FRET and
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STEM, but not confirmed. Thus, we applied additional experimentation to test for internal
compartment disruption, which was necessary to be confident that click-promoted fusion could be
applied to the delivery of both hydrophobic and hydrophilic cargo.

The terbium-trichloride (TbCl3)-dipicolinic acid (DPA) content mixing assay
TbCl3 and DPA, Figure 4.5, have negligible inherent fluorescence on their own. When these two
compounds are mixed, however, an exponential increase in fluorescence is observed. In the study
group, clickable sibling liposomes were each filled with one of these dye partners and incubated
with another and then probed for changes in fluorescence as compared to control groups. Control
groups contained the appropriate dye partner but lacked the clickable lipids to promote fusion. If
our system was simply inducing aggregation and/or multivesicular conglomeration, control and
study groups would produce similar data. If, however, we were inducing fusion between our
clickable liposomes, a predictable and repeatable increase in fluorescence should be observed in
the study group that should be significantly higher than background leakage observed in the control
groups. Moreover, fluorescence would be increased in both samples in non-specific vesicle
leakage was occurring.

Results
We observed significantly greater increases in fluorescence intensity when liposomes displayed
their clickable lipids, as can be seen in Figure 4.6.148 This was attributed to fusion events that
resulted in the mixing of aqueous cargo to form the fluorescent Tb-DPA complex.

Figure 4.5: Structures of DPA and TbCl3
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Figure 4.6: Results of the DPA and TbCl3 content mixing assay.148 Fluorescent signal of the
terbium-DPA complex is detected at 489 nm to determine mixing of aqueous cargo. Change in
intensity is charted as a function of incubation time in minutes. A significant increase in the
mixing of aqueous cargo is observed in the study liposomes (46/46/8 PC/PE/cyclootyne lipid
encapsulating DPA + 46/46/8 PC/PE/azido lipid encapsulating TbCl3). Change in intensity of
control liposomes (54/46 PC/PE encapsulating DPA + 54/46 PC/PE encapsulating TbCl3) is due
to osmotic leakage of aqueous cargo. Error bars are standard error based on at least three
replicates.
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To achieve these results, we experimented with reverse phase evaporation (REV) liposome
formation to increase encapsulation efficiency of DPA and TbCl3. Ultimately, we settled upon
standard thin-film hydration followed by freeze-thaw and extrusion, finishing with SEC to remove
unencapsulated dye molecules. Various other parameters of the content mixing assay were
optimized to yield consistent fluorescent data that we could confidently attribute to mixed aqueous
cargo. Procedural details are presented next in Methods.

Methods
ODIBO lipid (OL, Figure 4.7) was synthesized by Dr. Whitehead148 and an azido lipid (AL,
Figure 4.7) was previously synthesized by the Best Lab.299 All other lipids were purchased from
Avanti Polar lipids. Solvents, reagents and other materials were purchased from Acros, Aldrich or
Fisher Scientific and used as received. Liposome extrusion was done with a LiposoFast-Basic
extruder (Avestin). Fluorescence experiments were done in a PerkinElmer LS-55 luminescence
spectrometer with a 100 μL microcuvette using a scan rate of 100 nm/min, a 5.0 nm excitation slit,
and a 7.5 nm emission slit. Excitation was at 278 nm, emission was measured using an average of
3 scans and maximum emission was observed at 489 nm. SEC protocols and content mixing assay
buffer ingredients were adapted from a previously reported protocol,241 as described below.

Figure 4.7: Synthetic clickable lipids used. Clickable lipids of the ODIBO (OL) and Azide
(AL) variety were immobilized in respective liposomes used to promote liposomal fusion
between click-sibling vesicles. Both lipids were synthesized by Dr. Whitehead148 and other
members of the Best Lab.299
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Liposomes were formed by making stock solutions from dry PC (65 mM), OL(1.3 mM), and
AL (1.3 mM) solvated in CHCl3. PE which was purchased in CHCl3 at 13.9 mM and used as is.
Lipid films of three different compositions were formed (‘O’, ‘A’, and ‘C’) by combining
appropriate volumes of stock solutions (with a total of 4 mM of lipids when rehydrated in 1 mL of
aqueous buffer) to make: O 46:46:8 (PC:PE:OL), A 46:46:8 (PC:PE:AL), C 54:46 (PC:PE). C
was made in duplicate. Film formation culminated with solvent removal using rotary evaporation
followed by sitting overnight under vacuum. Two distinct hydration buffers were formed and kept
away from light: buffer T contained 15 mM TbCl3 while buffer D contained 50 mM DPA. The
remainder of both buffers was comprised of 2 mM L-(–)-histidine and 2 mM N[Tris(hydroxymethyl)methyl]-2-aminoethanesulfonic acid sodium salt (TES). Hydration consisted
of adding 1 mL of buffer, vortexing thoroughly, heating for 1 h at 50 oC with intermittent vortexing.
Film O was hydrated in 1 mL buffer D to create study group OD. Film A was hydrated in buffer
T to create study group AT. One C film was hydrated in buffer T and the other in buffer D to
create CT and CD control groups. 10 freeze/thaw cycles to disrupt multilamellarity were done
after hydration. To ensure consistent diameters between samples, liposome solutions were
extruded 11 times using a 100 nm polycarbonate membrane. The final extrusion was followed
directly by SEC to remove unencapsulated dye molecules. 60 mL of SEC buffer was prepared with
ultrapure water using the following reagents: 2 mM TES (N-[tris(hydroxymethyl)methyl]-2aminoethanesulfonic acid), 2 mM histidine, 100 mM NaCl and 1 mM EDTA. SEC buffer was used
to swell 1.2 g of SephadexTM G-50 Medium (GE Healthcare) for 3 hours with occasional mixing.
The bead slurry was gravity packed into lass microcolumns with 8 mm diameters with 5 cm of the
swelled SephadexTM media. Each liposome type was eluded through its own column using SEC
buffer. 1 mL fractions were collected, kept 4 °C, and used directly or within 1 day. Liposomes
eluded in the second fractions, from which aliquots were taken for fluorescence studies. For the
study group: O (300 uL) were added first scanned alone, followed by A (300 uL), a brief mix, and
another scan applying heat. The cuvette was sealed and placed in a 40 °C water bath followed by
5 s of vortexing. Heating times between measurements were as follows: 30 s, 30 s, 2 min, 2 min,
5 min, 5 min, 10 min, 15 min, 20 min for a total of 1 hour. Control experiments were done in
precisely the same manner with CD added first and scanned alone in place of O, and CT added
subsequently.
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4.3: The future of triggered release
Active targeting and passive release demonstrate how developing nanoparticles can add
specificity to nanodrugs by tailoring targeting groups and trigger types to whatever tumor, disease
or infection is to be attacked. Our work in Chapter 3 demonstrates that rationally designed lipid
architectures may also add specificity to liposomal nanoparticles. To date, commercially available
LDSs are still lacking for many intuitive applications. Bacterial infections, for example, are good
targets for future nanodrugs. The EPR effect, which is responsible for the passive targeting that
makes nanodrugs more selective/effective than free drugs, can also be exploited for the
nanoparticular treatment of bacterial infections. A 2013 review on the matter suggested that not
only is increased vascular permeability a conserved trait of human bacterial pathogens, but sites
of infection exhibit EPR similarly to tumors and other neoplasms.300
Given the similarity in size between nanoparticles and infectious agents, it is a reasonable
assertion that EPR could also be applied to the obfuscation of bacteria in circulation, particularly
in their granular ‘cystic’ form. Furthermore, research has suggested that the cystic form of a certain
bacteria may be the source of pathogenesis of the bacteria that causes lyme disease.301-302 Given
that the fenestrations accompanying tumors also accompany bacterial infections, liposomal
antibiotics are an outstanding opportunity to advance antibacterial drugs.
Regarding triggered release, let us continue with the causal agent of Lyme disease, the
spirochete bacteria B. burgdorferi, as an example. The differential environments of spirochetes
and their hosts could be a tactical advantage of nanocarriers developed for spirochete hunting. A
manganese-based localization strategy in the form of a cationic recognition site with lipophilic
appendages is particularly intriguing for treating Lyme. Part of B. burgdorferi’s survivability
comes from its ability to function without iron.303 The bacteria’s outer membrane instead consists
of manganese (Mn2+) metalloproteins.304 An interesting caveat of metalloproteins that chelate and
fold about low-abundance cations such as Mn2+ is that the metals do not compete for the proteins,
but rather the proteins have their preference and compete with other molecules for the metals.305
In addition to Mn2+, dysregulation of metal cations is a conserved trait of many diseases.
Calcium overabundance is linked to Alzheimer’s disease,306-308 and many other serious
conditions309-310 including amyotrophic lateral sclerosis (ALS),311-314 ischemic stroke,315-318 and
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malaria.319-321 Potassium is another ion crucial to cellular function322 and potassium ion channel
proteins are the most diverse class of transmembrane ion transporters whose overexpression has
been conclusively linked to cancer, particularly metastasizing cells.323 Ion channels in general
make up a significant portion of drug targets.324 Zinc would be another interesting environmental
trigger for passive release. Overabundant zinc is lethal, and correlated to brain diseases and
injuries,325-329 several cancers,330-336 and Alzheimer’s disease.337-346 Moreover, zinc deprivation347349

and zinc sensors350-352 have been successfully tested to inhibit progression of diseased cells.

The metalloproteases targeted by the nanodrugs developed in Chapter 3 further evidence that
cation dysregulation is a promising future strategy for developing triggered release platforms. The
future of controlled liposomal release hinges upon our understanding of the pathologies we aim to
treat, and our ability to generate lipidic tools with which we may capitalize upon newly uncovered
pathological proclivities.
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EPILOGUE
To gain a more complete understanding of how the lipidomes and proteomes of our cells
interact, it can be advantageous to step back from a purely biophysical perspective. Lipid-protein
signaling operations are, ultimately, consequences of chemical proclivities and the contextual view
of these events incorporates an impossible number of variables that reform said chemical
proclivities based on environmental cofactors and membrane mechanics. This macroscopic
perspective is often lost among laboratory chemists and promising nanotechnologies developed
under their guise often lack clinical viability as a result.172 Conversely, I have observed a general
skepticism among clinicians when presented with promising new treatment strategies as a result
of the general dearth of novel therapies that progress to human clinical trials after testing in animal
models. This observation came through my work as a clinical intern at the Pat Summitt
Alzheimer’s Clinic, formerly known as the Cole Neuroscience Clinic. In between patient
interviews, my conversations with care providers would often range to science and discussions
about what excited medical doctors versus what excited research doctors. Lab-based therapeutic
development often isolates molecular protein interactions. When it doesn’t, it is usually limited to
cells growing in a dish or humanized animal models. What kills cancer cells in a dish rarely kills
tumors in humans and what reverses Alzheimer’s plaques in rodents rarely does so in humans.
The disparity between model systems is naturally the reason for this lack of translatability, but
fortunately scientists now have yet another means to control for these differences: the liposome. If
a cancer drug is too toxic to administer, liposomal drug delivery may be a solution. If a powerful
AD treatment fails to cross the BBB in humans, again a liposomal shuttling system could overcome
this hurdle. It is challenging to think of a drug that would not benefit from liposomal
administration. Liposomal delivery of common medications like ibuprofen and antibiotics could
have great impact. New applications of simple LDSs warrant as much investigation as
sophisticated multifunctional iterations of existing cancer nanodrugs. If chemists and biologists
thought more like physicians while developing nanodelivery systems, several more nanodrugs
would be FDA approved. On the other hand, if physicians thought more like lab scientists while
considering new treatment options for clinical trials, then they would be much more excited about
liposomal therapies.
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Liposomes, like other surface sciences and nanotechnologies, bridge fields like engineering,
biophysics, analytical and organic chemistry, chemical and cellular biology, and beyond.
Applications continue to arise and will ideally narrow the gap between clinicians and chemists.
Many scientific tools such as toxic reagents and expensive nonrenewable materials have
applicability despite themselves. Liposomes on the other hand are nontoxic, biodegradable, highly
tunable and enable technologies that may otherwise not exist. Liposomes have opened up new
doors in regenerative medicine,4 renewable energy,353 and many other fields.
Within this dissertation is a road map, of sorts, towards bringing LDSs closer to their vast
clinical applicability. Chapter 1 underscores the crucial role that low-abundance signaling lipids
such as DAG play in cellular pathologies, while Chapter 2 illustrates the utility of liposomes in
adding to the well of signaling lipid knowledge. Additionally, studies such as those described in
Chapter 2 could be used to characterize the affinities of target tissues and membranes of pathogenic
bacteria and viruses to better inform upon ideal liposomal formulations for nanoparticle-based
treatments. The potential to find simple, natural solutions to increasing LDS efficacy can be found
in lipids such as DAG and PS, as illustrated by the work in Chapter 3. Finally, Chapter 4 presented
cutting-edge technologies that creep closer to commercial availability with each passing year. The
rapid expanse of liposomes is accelerated not only by imaginative new technologies, but also by
investigations into the protein interactions and membrane characteristics of lipids like DAG.
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